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HIF-1 mediated upregulation of VEGF and VEGF-R
in systemic sclerosis (SSc): Imbalance with
angiostatic factors suggests VEGF as a novel
option for the treatment of ischemia in patients
with SSc
O Distler*, A Scheid†, A Del Rosso‡, J Rethage*, M Neidhart*,
RE Gay*, U Müller-Ladner§, M Gassmann†, M Matucci-Cerinic‡, 
S Gay*
*Ctr Exp Rheum, Zurich, Switzerland
†Inst Physiol Univ Zurich, Zurich, Switzerland
‡Dept Med Sect Rheum, Florence, Italy
§Dept Int Med I, Univ Hosp, Regensburg, Germany
Vascular changes are consistent early findings in patients with SSc
and often precede the development of fibrosis. Despite a signifi-
cant reduction in the capillary density, there is paradoxically no suf-
ficient angiogenesis in the skin of SSc patients. By using a pO2
histograph, we showed that low pO2 values are overt in involved
skin of patients with SSc. In vitro, real-time PCR revealed a
3.7-fold upregulation of the potent angiogenic growth factor VEGF
in SSc fibroblasts after hypoxic exposure compared to normoxic
controls. In situ hybridization for VEGF in skin biopsies of patients
with SSc showed an overexpression of VEGF mRNA by fibroblasts
and mononuclear infiltrates, whereas its expression was limited to
keratinocytes in healthy control biopsies. In contrast to the SSc
skin, HIF-1 alpha protein was found to be coexpressed with VEGF
in healthy skin samples, indicating that the constitutive VEGF syn-
thesis in the skin is driven by this transcription factor. Additionally,
we showed that the lack of angiogenesis in SSc is not due to a
reduced bioavailability of the overexpressed VEGF, since the
VEGF receptors Flk-1 and Flt-1 were found to be expressed on
endothelial cells of patients with SSc, but not in healthy controls,
and since SSc patients had severely elevated serum levels of
VEGF compared to healthy controls. Despite the enhanced levels
of VEGF, serum samples of SSc patients did not induce angiogen-
esis in the vivo chorion allantois membrane assay, indicating that
the proangiogenic effects of VEGF may be outweighed by angio-
static factors. The hypothesis that VEGF synthesis has to be above
an individual threshold in SSc patients to induce angiogenesis was
further strengthened by the finding that patients without fingertip
ulcers had significantly higher levels than patients with fingertip
ulcers. Interestingly, the angiostatic factor endostatin was elevated
in a subset of patients and thus may counteract directly the bio-
logic effects of VEGF in SSc patients. Serum levels of VEGF were
also correlated significantly with disease severity parameters
including antitopoisomerase antibodies. These results suggest that
therapeutic application of VEGF by either gene transfer or as a
recombinant protein might be a novel option in SSc.
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Comparison of the features of arthroscopic
synovial biopsies with biopsy samples obtained at
surgery
TJM Smeets*, MC Kraan*, E Barge†, MD Smith‡, PP Tak*
*Academic Medical Center, Amsterdam, The Netherlands
†Leiden University Medical Center, Leiden, The Netherlands
‡Repatriation General Hospital, Daw Park, SA, Australia
Objective: Most of the older descriptions of the synovial infiltrate
are based on examination of synovial tissue (ST) obtained at
surgery. However, ST from end-stage destructive rheumatoid
arthritis (RA) and arthroscopic biopsies obtained during active
inflammation could exhibit different characteristics. The aim of this
study was to define the cell infiltrate, the expression of proinflam-
matory cytokines, angiogenic factors, and matrix metallopro-
teinases in ST selected at arthroscopy compared with ST from
end-stage RA obtained at joint replacement.
Methods: Synovial biopsy specimens were obtained from the
actively inflamed knee joints of 11 RA patients with longstanding
RA by arthroscopy and compared with ST from 13 patients with
end stage, destructive RA requiring joint surgery. Use of medica-
tion was on average similar in the 2 groups. Immunohistologic
analysis was performed using monoclonal antibodies (mAb) to
detect T cells, plasma cells, macrophages, fibroblast-like synovio-
cytes (FLS), as well as the expression of IL-1β, IL-6, and TNF-α,
matrix metalloproteinase (MMP)-1, MMP-3, MMP-13, tissue
inhibitor of matrixmetalloproteinase (TIMP)-1, and vascular
endothelial growth factor (VEGF). The integrated optical density
was evaluated by computer-assisted image analysis.
Results: The expression of CD68+ macrophages was significantly
higher in ST selected at arthroscopy compared to samples
obtained at surgery, both in the intimal lining layer and in the sublin-
ing layer. The expression of CD3+ T cells also tended to be higher
in arthroscopic samples. There was no clear difference in the
expression of CD38+ plasma cells and CD55+ FLS. The expres-
sion for TNF-α, IL-6, MMP-1, MMP-3, MMP-13, TIMP-1, and VEGF
was on average higher in ST obtained at arthroscopy. The expres-
sion of IL-1β was on average higher in ST obtained at surgery.
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(Print ISSN 1465-9905; Online ISSN 1465-9913)Conclusion: Active arthritis activity is especially associated with
increased cell infiltration, expression of proinflammatory cytokines,
MMPs, and angiogenic growth factors in synovial biopsy samples
selected at arthroscopy. Increased expression of IL-1β in the syn-
ovium of patients with destructive RA requiring joint replacement
may well reflect the important role of IL-1β in cartilage and bone
destruction.
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Epstein-Barr virus load in rheumatoid arthritis
patients and normal controls: accurate
quantification using real time PCR
N Pieri-Balandraud*, D Reviron†, J Roudier*, C Roudier*
*INSERM, Marseille, France
†Etablissement Frantais du sang, Marseille, France
Objective: For twenty years the Epstein-Barr Virus (EBV) has been
suspected to contribute to the pathogenesis of rheumatoid arthritis
(RA). RA is strongly associated with shared epitope positive
HLA-DR alleles. EBV load has been extensively studied in RA
patients, using semi-quantitative PCR. Inconsistent results reflect
the lack of sensitivity and accuracy of this technique. We quantified
EBV in peripheral blood mononuclear cells by real time PCR, to
(1) determine whether EBV load is higher in RA patients compared
to controls and (2) test whether HLA-DR alleles influence EBV load
in RA patients and controls.
Methods: Fifty patients fulfulling the 1987 ACR criteria for RA
were studied. Most patients were treated with DMARDs including
methotrexate, leflunomide, etanercept or infliximab. Fifty healthy
controls were chosen from bone marrow donors at the Marseille
blood transfusion center. HLA-DR genotyping of patients and con-
trols was performed by PCR-SSP. Real time PCR was performed
using a Roche LightCycler. A 214bp fragment from the highly con-
served long Internal Repeat IR1 was amplified. IR1 is repeated
eleven times in the EBV genome, increasing the sensitivity of
detection. Two specific hybridization probes were used to recog-
nize adjacent internal sequences within the target. EBV-positive
Burkitt’s lymphoma cell line was used as an external standard.
Results: EBV load is expressed in EBV genome copy number per
microgramm of human genomic DNA. Preliminary results show a
higher EBV load in RA patients (0–60copies/µg) than in normal
controls (0–10copies/µg). We are currently testing the influence
of HLA-DR genotypes on EBV load in controls.
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Low levels of apoptosis and high FLIP expression
in early rheumatoid arthritis synovium
A-K Ulfgren*, A Anca Irinel Catrina*, LG Lollo Gršndal†,
SL Staffan Lindblad*, LK Lars Klareskog*
*Karolinska Institute, Stockholm, Sweden
†Red Cross Hospital, Stockholm, Sweden
Objectives: To define synovial apoptosis with respect to disease
duration, inflammatory cell type, FLIP (FLICE like inhibitory protein)
and cytokines expression in patients with rheumatoid arthritis (RA).
Methods: Synovial biopsy specimens from eleven patients with
longstanding RA (median disease duration 21 years) and eight
with early RA (median disease duration 5 months) have been inves-
tigated. We evaluated apoptosis (TUNEL method combined with
morphologic analysis), cell surface markers (CD3, CD68),
cytokines (IL-1α, IL-1β, TNF-α and IL-6) and FLIP expression.
Computer-assisted image analysis was used for quantification.
Results: Apoptosis level in RA synovium was significantly higher in
the group of patients with long standing RA than in the patients
with early RA (8.8% versus 0.6%, P=0.001), while number of
macrophages and FLIP expression were higher in the early as com-
pared with long standing RA group (16.2% versus 8.3%, P=0.02
and 31.1% versus 0.2%, P=0.001 respectively). All three markers
significantly correlate with disease duration (r=–0.7, P<0.001 for
FLIP, r=0.6, P=0.001 for apoptosis and r=–0.5, P<0.05 for
CD68). Cytokine expression and T cell scores were not signifi-
cantly different in early RA compared to longstanding RA. We did
not observe differences between corticosteroids treated versus
corticosteroids non-treated patients or between DMARD treated
versus non-treated patients.
Conclusions: Our findings suggest that RA synovial macrophages
are resistant to apoptosis in early RA and express high levels of
FLIP. During natural or drug modified disease progression the
apoptotic mechanism may be restored with a specific increase of
synovial apoptosis in patients with long standing arthritis.
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Intestinal anaerobic bacteria in early rheumatoid
arthritis (RA)
P Toivanen*, S Vartiainen*, J Jalava*, R Luukkainen†,
T Möttönen‡, E Eerola*, R Manninen*
*Turku University, Turku, Finland
†Satalinna Hospital, Harjavalta, Finland
‡TUCH, Div Rheum, Dept Med, Turku, Finland
Increasing attention has recently been paid to the normal intestinal
flora as a potential source of etiological agents in RA. Changes in
the intestinal flora, due to fasting or diet, have been shown to
reflect improvement of the patients when they are divided into high-
and low-responders. Previously, evidence has also been presented
that intestinal flora in the early RA is different from that of non-RA
controls, due primarily to anaerobic bacteria.
The present study was designed to compare the fecal microbiota
of the patients with early RA with the microbiota of the control
patients using 16S rRNA oligonucleotide probes, detecting a
variety of anaerobic bacteria in the normal intestinal flora. Fecal
samples of 25 early, disease modifying antirheumatic drugs, naive
RA patients and 23 control patients suffering from noninflammatory
pain were investigated. The contribution of five bacterial groups
was determined by using whole cell hybridization with seven fluo-
rescently labeled 16S rRNA-targeted oligonucleotide probes.
These probes cover one third to a half of the total bacteria in the
human intestine. Patients with early RA had significantly less bacte-
ria belonging to the Bacteroides, Prevotella and Porphyromonas
genera than the controls (4.7% vs. 9.5%, P=0.00005). The
finding was confirmed with a probe specific for bacteria of the
Bacteroides fragilis group (1.6% vs. 2.6%, P=0.02). The samples
of RA patients and the controls did not differ significantly when five
other oligonucleotide probes were applied. They were detecting
bacteria in the genera Atobium, Coriobacterium, Collinsella, Bifi-
dobacterium and Fusobacterium, and in the Eubacterium rectale-
Clostridium coccoides group. We conclude that the content of
anaerobic bacteria in the intestinal flora of the patients with early
RA is significantly different than that of the controls. The number of
bacteria belonging to the Bacteroides-Prevotella-Porphyromonas
group was, on average, in RA patients only half that of the controls.
If this finding can be confirmed, together with a recent suggestion
that certain Bacteroides species are required for fortification of the
barrier function in the intestinal epithelium, it adds further evidence
to the hypothesis that intestinal bacterial flora plays a role in the
etiopathogenesis of RA.
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Prevalence of antibodies against a Sindbis-related
(Pogosta) virus, a potential cause of chronic
arthritis
A Toivanen*, M Laine*, R Luukkainen†, J Oksi*, R Vainionpää*
*Turku University, Turku, Finland
†Satalinna Hospital, Harjavalta, Finland
A disease characterised by arthritis, rash and fever was described
in Northern Finland in 1974 and named, according to the region,
Pogosta disease. It closely resembles Ockelbo disease in Sweden,
and Karelian fever, occurring in Western Russia. When analysing
the clinical picture during an outbreak we found that 93% of the
patients had joint inflammation, 40% with polyarthritis. Rash was
seen in 88% of the patients, and 23% had fever. It has been sug-
gested that the disease is self-limiting, but in a follow-up study we
found that 50% of the patients suffered from chronic muscle and
joint pain at least 2.5 years after the initial symptoms. There have
been several outbreaks of Pogosta disease in Northern Karelia.
They seem to occur every seven years. It has been assumed that
Pogosta disease is locally restricted, as is described also for
Ockelbo disease and Karelian fever. All three diseases are attrib-
uted to Sindbis-related arboviruses, and the spreading vector
appears to be the late summer mosquitoes. Pogosta disease is
considered to affect mostly young adults and middle-aged people.
In an epidemiological study we analysed, using a semi-purified
Sindbis-virus as antigen, antibodies against Pogosta disease in
2250 serum samples. Four hundred sera were from healthy blood
donors and 1850 samples from patients who were suspected to
have some viral infection. The samples represented different parts
of Finland. Eleven percent were positive for IgG and 0.6% for IgM
class antibodies. The antibody prevalence was almost equally dis-
tributed throughout the country, highest in Western Finland (17%).
Of all samples with IgG class antibodies 25% were taken from
children below 10 years.
Three conclusions can be made: 1) Pogosta disease is more
common than was thought until now. 2) It is not only restricted to
Eastern Finland but is spread throughout the whole of Finland. 3) It
is also common in children, in contrast to an earlier belief.
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Production of IFN-α α by Natural IFN-α α Producing
Cells (NIPC), induced by apoptotic cells and
autoantibodies via Fcγ γRII, could be a pivotal event
in the etiopathogenesis of SLE
LR Rönnblom*, T Lövgren*, U Bsve*, GV Alm†
*Uppsala University, Uppsala, Sweden
†Immunology (V), BMC, Uppsala, Sweden
Background: Patients with SLE have an activated type I IFN
system, and serum IFN-α levels correlate to both disease activity
and severity. We have shown that SLE patients have an IFN-α
inducing factor (SLE-IIF) in serum, consisting of anti-DNA antibod-
ies and DNA in complex. The DNA could originate from apoptotic
cells that are present in increased numbers in SLE patients. We
recently demonstrated that IgG from SLE patients, but not normal
individuals, together with apoptotic cells stimulate NIPC to
produce IFN-α. In the present study we further characterized the
interferogenic cell material and the role of different FcR on NIPC
for the IFN-α response.
Methods: Apoptosis was induced in U937 cells by treatment with
UV light and cell supernatant was collected at different time points.
Normal PBMCs, costimulated with IFN-α, were cultured with the
apoptotic cell material together with purified IgG from SLE patients
or from normal individuals, and produced IFN-α was measured in
culture supernatants. In some experiments the SLE-IgG was
treated by papain or pepsin to obtain Fab and F(ab′)2 fragments,
respectively. The effect on the IFN-α response by antibodies to
CD16, CD32 (FcγRII), and CD64 as well as aggregated IgG was
also investigated.
Results: Apoptotic cells release IFN-α inducing material in a time-
dependent fashion and more than 1000U IFN-α/ml was produced
in the PBMC cultures, but only when the apoptotic cell material
was combined with intact SLE-IgG. Normal IgG, SLE-IgG Fab or
F(ab′)2 fragments together with apoptotic cell material where
unable to induce IFN-α production. Heat-aggregated IgG and anti-
CD32 antibodies inhibited the IFN-α response, whereas antibodies
to CD16 and CD64 had no effect on the IFN-α response.
Conclusion: NIPC are induced to IFN-α production via the FcγRII
by SLE autoantibodies and apoptotic cell material. This observa-
tion may explain the observed ongoing IFN-α production in SLE
patients and may be of importance for the understanding of the
pathogenesis of SLE.
8
Serum amyloid P component (SAP) binds to late
apoptotic cells and mediates their phagocytosis by
macrophages
M Bijl, G Horst, H Bootsma, PC Limburg, CGM Kallenberg
Academic Hospital Groningen, Groningen, The Netherlands
Background: Serum components, like serum amyloid P compo-
nent (SAP), together with membrane receptors on phagocytes play
essential roles in the phagocytosis of apoptotic cells. Disturbances
in one of these factors might reduce phagocytosis and induce
autoimmunity. SAP binds to apoptotic cells. SAP deficient mice
spontaneously develop autoimmunity. We evaluated SAP binding
to early and late apoptotic cells and whether this binding has func-
tional consequences for the phagocytosis of these cells.
Methods: Human peripheral blood monocytes were isolated and
cultured for 7 days to obtain monocyte derived macrophages.
Jurkat cells were irradiated with UVB to induce apoptosis. After
4 hours 40% of cells stained with annexin V, and were propidiu-
miodide negative (early apoptotic cells, EA). After 24 hours 65% of
cells were annexin V and propidiumiodide positive (late apoptotic
cells, LA). EA and LA cells were incubated with FITC labeled SAP
in the presence or absence of Ca2+ and subsequent binding was
measured by flowcytometry. Phagocytosis was performed by incu-
bation of macrophages for 30 minutes with EA or LA cells in the
presence of human serum (HS) and depicted as phagocytosis
index (PI, number of Jurkatt internalized by 100 macrophages).
Experiments were repeated with SAP depleted serum and after
reconstitution with different concentrations of SAP.
Results: Sixty percent of LA cells did bind SAP in the presence of
Ca2+, whereas the EA cells did not. SAP depletion of serum
resulted in a 50% decrease of PI for LA cells, and complete
restoration of PI could be demonstrated with SAP reconstitution
up to 100 µg/ml. SAP depletion had no effect on PI of EA cells.
Conclusion: SAP binds to late apoptotic cells and is involved in
the phagocytosis of these cells by human monocyte derived
macrophages. This might have consequences for diseases in
which phagocytosis of early apoptotic cells is decreased.
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Expression of syndecan-1 during development,
growth and cartilage degeneration in a transgenic
mouse model for osteoarthritis
L Pirilä*, H Salminen*, AM Säämänen*, J Kivinemi†,
YT Konttinen‡, E Vuorio*
*Turku University, Turku, Finland
†Biotie Therapies Ltd, Turku, Finland
‡Dept. of Anatomy and Medicine, Helsinki, Finland
Mice heterozygous for the Del1 transgene locus with short deletion
mutation in type II collagen gene develop degenerative changes in
the knee joints from the age of 3 months which progresses to an
end-stage OA by the age of 12–15 months. This study focuses on
expression and distribution in syndecan-1 during development of
osteoarthritic cartilage degeneration. Human samples from carti-
lage of osteoarthritic patients was studied for comparison. North-
ern analysis of total RNA extracted from knee joints of transgenic
Del1 mice and their nontransgenic controls was used to monitor
changes in syndecan-1 levels during development, growth, aging
and cartilage degeneration. Immunohistochemistry was used to
study the distribution of syndecan-1 in mouse and human samples.
Syndecan-1 was present in the knee joints during development,
growth and aging both in the control and Del1 mice, the mRNA
levels being highest in the aged and late osteoarthritic samples.
The most intensive immunostaining of syndecan-1 was seen in syn-
ovial tissue and adjacent of the defected areas of cartilage and
menisci. In addition, some individual cells or cell clusters in the
superficial zone of articular cartilage contained syndecan-1. In
human osteoarthritic cartilage, dedifferentiated syndecan-1 positive
cells were seen in corresponding locations to those in Del1 mice.
We demonstrated syndecan-1 for the first time in aging and
degenerating murine articular cartilage and synovial tissue. Synde-
can-1 is involved in phenotypic modulation of the articular chondro-
cytes and during osteophyte formation. In this Del1 mouse model,
proliferation plays a role forming characteristic chondrocyte clusters
near the surface, while apoptosis occurs primarily in the calcified
cartilage. These results suggest that syndecan-1 has a role in the
functional activity of the chondrocytes during the disease process.
Control of syndecan expression in articular cartilage could be an
attractive target for therapeutic interventions in the future.
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Osteoclasts are essential for TNF-mediated joint
destruction
KR Redlich*, S Hayer*, R Ricci†, JP David†, M Tohidast-Akrad*,
J Zwerina*, G Kollias‡, G Steiner*, JS Smolen*, E Wagner†,
G Schett*
*University of Vienna, Vienna, Austria
†Research Inst of Molecular Pathology, Vienna, Austria
‡Hellenic Pasteur Institute, Athens, Greece
Recent studies suggest that osteoclasts may contribute to bone
erosions in the joints of animal models of arthritis and human
rheumatoid arthritis. We therefore adressed the question, can
bone destruction occur in an osteoclast free model of arthritis? To
answer this question, c-Fos knockout mice (c-fos–/–) were
crossed with mice overexpressing human soluble TNF (huTNFtg).
C-fos–/– mice lack osteoclasts and are therefore osteopetrotic
since c-fos is essential for the signaling of osteoclast differentia-
tion. HuTNFtg mice develop a severe and destructive arthritis
through the signaling of huTNF via the p55 TNF receptor. The
resulting four groups of mice (wildtype, huTNFtg, c-fos–/– and
c-fos–/–/huTNFtg) were followed over 10 weeks and assessed for
joint inflammation and joint destruction. Clinical features of arthritis,
such as paw swelling and reduction in grip strength progressed
equally in both huTNFtg and c-fos–/–/huTNFtg mice. Clinical fea-
tures of arthritis were absent in c-fos–/– and wildtype mice. Quan-
titative histological evaluation of joint sections revealed no
difference between huTNFtg and c-fos–/–/huTNFtg mice in the
size of inflammatory synovial lesions. As previously described,
huTNFtg mice showed severe bone erosions in all joint compart-
ments. Bone resorption was characterized by the abundant pres-
ence of osteoclasts, as confirmed by cells positive staining for
TRAP and the calcitonin receptor. Furthermore, the number of
osteoclasts and the size of bone erosions were significant. In con-
trast, c-fos–/–/huTNFtg mice did not show any form of bone
destruction despite the presence of severe inflammatory changes.
C-fos–/–/huTNFtg mice were confirmed to lack osteoclasts by
negative TRAP staining and the presence of osteopetrosis. Con-
trols (c-fos–/– mice and wildtype mice) did not show histological
signs of inflammation or bone erosion. In conclusion, these data
clearly show that TNF-mediated bone erosion is triggered by
osteoclasts, and the absence of osteoclasts turns TNF-mediated
arthritis from destructive to non-destructive arthritis.
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Interaction of intimal fibroblasts with intracavitary
fibrin: a morphologic follow up in ovalbumin
arthritis
O Sánchez-Pernaute, R Largo, I Díez-Ortego, MA Alvarez-Soria,
E Calvo, M Lopez-Armada, G Herrero-Beaumont
Jiménez Díaz Foundation, Madrid, Spain
Background: An imbalance between haemostasia and fibrinolysis,
and subsequent fibrin generation within the rheumatoid joint could
have a role in disease perpetuation.
Objective: To study fibrin formation at the synovial space in a
model of rheumatoid arthritis, and its possible role in activating the
synovial cells from inside of the cavity.
Methods: Antigen arthritis was induced by injecting ovalbumin into
rabbits’ knees. We looked for the appearance of fibrin in the effu-
sion and at the inflamed tisues with immunohistochemistry, in a
sequential fashion (from 24 hour to 1 week after disease induc-
tion). Morphologic changes at the intimal synovial surface in
contact with fibrin matrices were studied over a long period of time
by several qualitative variables. Analysis of the variables was
carried out with Kruskall Wallis and Mann Whitney nonparametric
tests, and linear regression was performed using the least squares
method.
Results: Fibrin aggregates appeared from the initial stages of the
disease at the synovial effusion. Later on, they were localised on
the synovial surface. Differentiation of the aggregates from the
underlying synovial tissue was easy at the beginning, but then pro-
gressive changes were noted at the fibrin-tissue interface, ending
with the invasion of the aggregates by synovial cells and their
incorporation into the tissue. The process involved cross-linking of
fibrin matrices with fibronectin, and synoviocyte proliferation and
migration.
Conclusion:  Fibrin aggregates generated inside the joint cavity
may constitute a source of activation and acquisition of invasive-
ness of synovial fibroblasts, a process to explore between the per-
petuating mechanisms of rheumatoid arthritis.
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Vascular endothelial growth factor (VEGF)
expression in muscle tissue and the effect of
corticosteroid therapy in patients with poly- and
dermatomyositis
IE Lundberg
Karolinska Institutet, Stockholm, Sweden
Background: Previous studies on pathogenic mechanisms indi-
cate that the microvessels have a role in the disease mechanisms
in polymyositis (PM) and dermatomyositis (DM). A reduced number
of capillaries has been reported and this observation together with
the increased expression of interleukin-1 and TGF-β suggest that
there might be an hypoxic condition in the inflamed muscle tissue
that could explain some of the clinical symptoms.
Aim of study: To further test this hypothesis we investigated if vas-
cular endothelial growth factor (VEGF), which is upregulated by
hypoxia, is expressed in muscle tissue in patients with PM and DM.
A second aim was to investigate whether VEGF expression is
affected by corticosteroid therapy.
Patients and methods: Six patients with PM and 4 with DM were
investigated. A first muscle biopsy was taken at diagnosis and a
second after 3–6 months with corticosteroid therapy. VEGF
expression was investigated by immunohistochemistry using a
rabbit polyclonal IgG antibody. Both conventional microscopic
evaluation and computerised image analysis were used for evalua-
tion of VEGF expression.
Results: These are our preliminary data: First biopsy: with conven-
tional microscopic evaluation VEGF expression was observed in
the endothelial cells of the microvessels in 9/10 patients and in
larger vessels such as arterioles and venules in all patients. VEGF
was also expressed in muscle fibres in all, and in mononuclear
inflammatory cells in 3/10 patients. In the second biopsy, VEGF
expression was still present in endothelial cells of capillaries and
larger vessels as well as in muscle fibres, but with a seemingly
weaker expression in the endothelial cells of PM patients and an
increased expression in the DM patients. With computerised image
analysis the results were similar.
Conclusion: VEGF is expressed in endothelial cells of capillaries
and slightly larger vessels, in muscle fibres, and in occasional
inflammatory cells in muscle tissue from patients with poly- and
dermatomyositis. After corticosteroid therapy the expression
decreased in some patients and increased in other patients.
Whether or not the changed VEGF expression has any clinical sig-
nificance and correlates with changes in muscle function still
needs to be analysed.
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Etiology of a spontaneous autoimmune joint
disease in mice
J J Sinkora
Institute of Microbiology, Novy Hradek, Czech Republic
Aims: To reveal which microbes are capable of inducing Ankylos-
ing Enthesopathy (ANKENT), a spontaneous joint disease in sus-
ceptible mouse strains. Besides gender and age (young males
afflicted) and genes (B57B6 background with some H-2 haplo-
types being more effective), environmental factors (stress and
microflora) have also been suggested to play a role in ANKENT
onset. We have recently shown that ANKENT does not develop
under germfree (GF) conditions.
Materials and methods: To identify ANKENT-triggering bacteria
we transferred B10.BR ANKENT-prone mice into germfree condi-
tions. Individual colonies were then associated with selected
microbial cocktails. The incidence of ANKENT and immune system
development has been studied in these gnotobiotic colonies.
Results: When compared to GF and conventional (CV) males
(prevalence of 0 and ~20%, respectively), high incidence (~20%)
of ANKENT has been revealed in mice associated with a cocktail
of bacteria isolated from the intestine of an ANKENT-afflicted CV
male. In the cocktail, no strong pathogens and Enterobacteriae like
E. coli or Salmonella were present. The first ANKENT case has
also been observed in mice colonized with a more restricted cock-
tail containing two selected gram-positive microbial strains.
Surface phenotype of lymphocytes isolated from systemic lym-
phatic tissues, MALT and diseased joint were characterized. No
significant differences in lymphatic tissues were detected between
individual experimental groups. However, the prevalence of CD4+
cells among joint-infiltrating lymphocytes was recorded.
Discussion: The presence of viruses, eukaryotic micro-organisms
and noncultivable bacterial species (like segmented filamentous
bacteria) is not required for ANKENT incidence. Although the
autoimmune nature of the disease has not definitely been proven
yet, the existence of specific ANKENT-triggering microbes strongly
supports this hypothesis. The ANKENT-triggering agents are cur-
rently characterized by rRNA analysis.
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Investigation of serum cartilage oligomer protein
(COMP) levels in rheumatoid arthritis (RA)
M Brozik, L Hodinka, E Palkonyai, I Sznts, M Seszták,
Zs Schmidt, U Böhm, K Merétey
National Institute of Rheumatology, Budapest, Hungary
RA is a disease characterised by an inflammatory process in the
synovium and a degradation process of the joint cartilage. When
articular cartilage matrix is degraded by a disease process, protein
fragments are produced and some of them subsequently appear in
the blood circulation and can be used to monitor cartilage degra-
dation. COMP was first described by D. Heinegard as a noncol-
lagenous protein primarily found in articular cartilage. COMP levels
of serum and synovial fluids have been shown to have potential as
prognostic markers of osteoarthritis and RA progression as well.
For the detection of COMP mainly monoclonal antibody based
competition ELISA systems have been described. Recently on the
basis of the research group of D.Heinegard a two-site sandwich
ELISA test from AnaMar Medical AB has been available in wich
two monoclonal antibodies directed against separate antigenic
determinant of COMP molecule are applied.
Using the COMP ELISA test of ‘AnaMar’ we measured the serum
COMP levels of 47 patients who fulfilled the ACR criteria of RA. Dura-
tion of the disease varied between 3–6 years. CRP and RF levels
were also measured from the same sample. Patients were grouped by
clinical activity, radiological progression and also by RF and CRP pos-
itivity. Our results showed that there was no difference between the
serum COMP levels of seropositive and seronegative patients (11.4
vs. 10.71ng/ml). Serum COMP levels of clinically active patients
(11.7ng/ml) were higher than of patients with inactive disease
(10.5ng/ml) (P<0.08). The average COMP levels of the radiologi-
cally progressive group was higher (12.5ng/ml) than that of the non-
progressive ones (10.3) (P<0.06). Statistically the highest difference
was found between patients with elevated CRP (12.3ng/ml) and
those with normal CRP levels (8.8ng/ml) (P<0.03). Significant cor-
relation was also found between serum CRP and COMP levels
R:0.54 (P<0.003). These results confirm previous findings that the
serum COMP level reflects the actual degree of cartilage destruction
ongoing during the inflammatory process of arthritis, thus can be a
useful marker in predicting radiological progression and in monitoring
the effectiveness of the treatment of RA.
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Increased Fcγ γRII and III expression in synovium
and on monocyte derived macrophages of RA-
patients results in altered function after immune
complex stimulation
AB Blom, PLEM van Lent, TRDJ Radstake, AEM Holthuysen,
AW Slöetjes, RL Smeets, P Barrera, LAB Joosten, WB van den
Berg
University Medical Center St. Radboud, Nijmegen, The Netherlands
Introduction: Rheumatoid arthritis (RA) is characterized by exten-
sive deposition of immune complexes (ICs) in the synovium. These
ICs can communicate with resident macrophages and inflamma-
tory cells entering from the circulation using FcγReceptors (FcγRs).
Objective: To determine whether macrophages of RA patients
express different levels of FcγRs and whether this difference
results in altered production of inflammatory mediators after stimu-
lation with immune complexes.
Methods: Monocytes were isolated from blood of 10 RA-patients
and 10 healthy controls and cultured for 7 days with M-CSF to
obtain macrophages. Using FACS analysis, the expression of
FcγRI, II and III was determined. At day 7 cells were stimulated with
heat aggregated gamma globulins (HAGG) and 24 hours there-
after cytokine production was measured. In addition, immunohisto-
chemistry was performed on synovial biopsies of knee joints of
27 RA patients and 5 controls. FcγRI, II and III were detected, as
well as several inflammatory mediators.
Results: Macrophages derived from PBMC of RA patients showed
a significantly higher expression of FcγRII (45%) and FcγRIII (15%)
compared to controls. When RA cells were stimulated with HAGG,
we found higher TNFα production. Also, when matrix degrading
gelatinase/collagenase was detected, a significantly higher activity
of these enzymes was found in the supernatants of HAGG stimu-
lated RA macrophages vs. controls. Underlining these findings, we
found highly significant positive correlations between the expres-
sion of FcγRII and III and the degree of inflammation in the joint in
RA patients, but not for FcγRI. FcγRII and III expression was higher
(respectively 80% and 125%) in RA synovium compared to con-
trols. TNFα expression in the synovium was correlated with FcγRIII
expression (r=0.51). MMP-1 expression was strongly correlated
with FcγRI, II and III (respectively r=0.48, 0.60 and 0.62). FcγR
expressions also correlated well with other cytokines, for example,
IL-18 (positively: r=0.63) and IL-12 (negatively: r=–0.46).
Conclusion: Macrophages of RA patients express higher levels of
FcγRII and III, resulting in elevated production of TNFα, and
MMP-1. In addition, differences in FcγR expression in the synovium
may also lead to different cytokine patterns. These data suggest
that disturbed FcγR expression plays a role in RA pathology.
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IL-18 expression in synovial biopsies of patients
with active rheumatoid arthritis is associated with
enhanced levels of both IL-1 and TNFα α
LAB Joosten, P Barrera, E Lubberts, AB Blom, B Oppers-
Walgreen, LAM van den Bersselaa, WB van den Berg
UMC Nijmegen, Nijmegen, The Netherlands
Objective: The present study was performed to examine the
expression patterns of IL-18 in synovial biopsies of patients with
active RA. In addition, we determined whether expression of this
primary cytokine was related to expression of TNFα, IL-1β, IL-12,
IL-17, and adhesion molecules or cell markers.
Methods: Synovial knee biopsies were taken from 29 patients with
active RA and were immunohistochemically stained for TNFα,
IL-1β, IL-12, IL-17, and IL-18. Furthermore, ICAM-1, VCAM-1,
E-selectin, CD3, CD14, and CD68 were stained. Both paraffin and
cryo-sections were used for the detection of cytokines, adhesion
molecules or cell markers. Five biopsies per patient were analyzed.
Results: IL-18 staining was detectable in 80% of the RA patients
both in lining and sublining. TNFα was present in 50% of the RA-
patients, whereas IL-1β was seen in 90% of the patients. When
staining for TNFα was positive, variable location of TNFα was seen
in the synovial lining, sublining layer and endothelial cells. IL-1β
staining was consistent in all three compartments. IL-12 was pre-
dominantly expressed in the sublining in 59% of the RA patients,
whereas only 24% of the patients stained positive for IL-12 in the
lining. Of interest, IL-17 staining was obvious in 70% of the RA
patients, and only seen in the sublining layer. ICAM-1 and
E-selectin staining was only seen in the endothelial cells, whereas
VCAM-1 was noted in the synovial lining and endothelial cells.
IL-18 expression in the synovial lining was positively correlated with
both IL-1 (r=0.71, P<0.0001) and TNFα (r=0.68, P<0.0008). In
addition, IL-18 expression correlated with both microscopic inflam-
mation scores (r=0.78, P<0.0001) and macrophage marker
CD68 (r=0.64, P<0.0007) expression. Furthermore, IL-18 was
positively correlated with both acute phase markers ESR (r=0.61,
P<0.0004) and CRP (r=0.57, P>0.001).
Conclusion: Our results showed that IL-18 expression is associ-
ated with elevated levels of TNFα, IL-1β in synovial biopsies of
patients with active RA. In addition, synovial IL-18 expression cor-
relates with both acute phase markers ESR and CRP. These data
indicated that IL-18 is a primary proinflammatory cytokine in RA
that drives local IL-1/TNFα production and may be involved in
enhanced acute phase protein levels.
Gene regulation and genetics
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A gene in the telomeric HLA complex distinct from
HLA-A is involved in predisposition to juvenile
idiopathic arthritis (JIA)
A Smerdel*, BA Lie*, R Ploski†, BPC Koeleman‡, E Thorsby*, 
O Førre*, DE Undlien*
*Rikshospitalet University Hospital, Oslo, Norway
†Medical Academy, Warsaw, Poland
‡University Medical Center, Utrecht, The Netherlands
Objective: Juvenile idiopathic arthritis (JIA) is associated with par-
ticular alleles at three different Human Leukocyte Antigen (HLA)
loci: HLA-A, -DR/DQ and -DP. These associations are independent
of each other; i.e. they cannot be explained by the known linkage
disequilibrium (LD) between alleles at these loci. The purpose of
this study was to look for additional JIA susceptibility genes in the
HLA complex.
Methods: We investigated 102 Norwegian JIA patients and 270
healthy individuals, all carrying the DQ4-DR8 haplotype, by scan-
ning ~10Mb of DNA covering the HLA complex for microsatellite
polymorphisms. An expectation-maximization (EM) algorithm was
used to estimate haplotype frequencies, and the distribution of
microsatellite alleles on the high-risk DQ4-DR8 haplotype was
compared between patients and controls, to exclude effects sec-
ondary to LD with these susceptibility genes.
Arthritis Research    Vol 4 Suppl 1 Abstracts of the 22nd European Workshop for Rheumatology ResearchResults: Allele 5 at the microsatellite locus D6S265 (D6S265*5),
100kb centromeric of HLA-A, showed strong positive association
with disease (OR=4.7, Pc<10–6). Haplotype analysis demon-
strated that the D6S265*5 association was not caused by LD to
the gene encoding HLA-A*02, which has previously been
described also to be associated with JIA. Rather our data suggest
that a gene in LD with D6S265*5, but distinct from HLA-A*02, is
involved in predisposition to JIA.
Conclusion: We found that D6S265*5 could be a marker for an
additional susceptibility gene in JIA which is distinct from A*02,
adding to the risk provided by DQ4-DR8.
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Differential gene expression of proliferating
synovial fibroblasts in rheumatoid arthritis
KM Masuda*, R Masuda*, M Neidhart*, BR Simmen†,
BA Michel‡, U Müller-Ladner§, RE Gay*, S Gay*
*Center of Experimental Rheumatology, Zurich, Switzerland
†Schulthess Clinic, Zurich, Switzerland
‡Department of Rheumatology, Znrich, Switzerland
§University of Regensburg, Regensburg, Germany
Objective: The aim of this study was to investigate the expression
profile of rheumatoid arthritis synovial fibroblasts (RA-SF) during
proliferation, and to explore the molecular mechanisms of synovial
proliferation in RA.
Methods: Total RNA was extracted from 2 cultures of RA-SF, low-
density (LD) proliferating cells and high-density (HD) nonproliferat-
ing cells, respectively, and suppression subtractive hybridization
(SSH) was performed to compare differential gene expression of
these 2 cultures. Subtracted cDNA was subcloned, and nucleotide
sequences were analyzed to identify each clone. Differential
expression of distinct clones was confirmed by semiquantitative
RT-PCR. The expression and distribution of novel genes in synovial
tissues was examined by in situ hybridization.
Results: Forty-four clones were upregulated in LD cells, and 44
clones were upregulated in HD cells. Forty-six of the 88 clones
were identical to sequences that have previously been character-
ized. Twenty-nine clones were identical to cDNAs that have been
identified, but with unknown functions so far, and 13 clones did not
show any significant homology to sequences in the GenBank
(NCBI). Differential expression of distinct clones was confirmed by
RT-PCR. In situ hybridization showed that specific genes, such as
S100 calcium-binding protein A4, nuclear factor of activated
T cells 5, upstream of N-ras and F-box only protein 3, were also
expressed predominantly in synovial tissues from patients with RA
(3/7, 6/7, 5/7, 5/7, respectively), but not from normal individuals
(0/3, 0/3, 1/3, 1/3).
Conclusion: SSH was a useful approach to compare the expres-
sion profile of cells under different conditions, and we could eluci-
date that distinct genes, including several novel genes, were
differentially expressed in RA-SF during proliferation. Moreover, the
expression of these genes could be found in RA synovium, espe-
cially at sites of invasion, suggesting that these molecules are
involved in synovial activation in RA. It needs to be stressed, that
the expression of certain genes in RA-SF depends on the stage of
proliferation, and as such this stage needs to be considered in all
analysis of differential gene expression in SF. 
Acknowledgement: KM is supported by Japan Rheumatism Foun-
dation, RM by Uehara Memorial Foundation and all others by their
institutions.
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An approach to the analysis of gene expression in
chronically activated T Lymphocytes
AP Cope*, JM Clark*, M Panesar*, P Vagenas*, T Freeman†,
PA Lyons‡
*Kennedy Institute of Rheumatology, London, United Kingdom
†Human Genome Mapping Project, Hinxton, United Kingdom
‡Institute for Medical Research, Cambridge, United Kingdom
We have been studying the intracellular signaling pathways in
chronically activated T cells involved in effector responses and pro-
moting the inflammatory process, and have been struck by the
extent to which T cells stimulated with TNF for prolonged periods
in vitro resemble RA synovial T cells. For example, TNF upregulates
expression of the activation antigen CD69, induces non-deletional
and reversible hyporesponsiveness to TCR ligation by uncoupling
proximal TCR signalling pathways, and represses CD28 gene
expression. We have explored the possibility that systematic
expression profiling of murine T cell hybridomas stimulated with pM
concentrations of TNF under controlled conditions might provide
further insight into the phenotype and function of cytokine acti-
vated T cells, as well as the mechanisms through which TNF
uncouples TCR signal transduction pathways. Expression profiling
has been performed using medium density spotted arrays based
on the Compugen™ gene set. This comprises 9,215 oligonu-
cleotide 50-mer elements including housekeeping genes and
“landing lights”, and covers 7,524 known mouse genes (represent-
ing 17K RNAs and 303K ESTs). Genes whose expression are
altered by TNF treatment have been identified by measuring the flu-
orescence ratio of Cy5- and Cy3-labeled target cDNA bound to
each probe following hybridization of differentially labeled cDNA
pools, prepared from TNF stimulated (Cy5) or control (Cy3) T cells.
Based on this simplistic analysis, clusters of genes that appear to
be differentially regulated in chronic TNF treated T cells have been
identified and were found to include genes whose products may
function to potentiate the inflammatory response. We report that
the expression signature for chronic TNF stimulation suggests a
phenotype which promotes cell survival, while enhancing Th1 dif-
ferentiation, recruitment to sites of inflammation and effector
responses. We are now analysing data from experiments designed
to explore the possibility that this particular gene expression signa-
ture is distinct from the programme of gene transcription arising
from short term TNF stimulation. We anticipate that this approach
may provide further insight into the molecular mechanisms which
promote chronic, as opposed to acute inflammatory responses.
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Efficacy of retroviral gene transfer into synovial
fibroblasts is reduced by co-transduction with
adenoviral vectors
U Müller-Ladner*, O Distler†, S Gay†, E Neumann*, M Judex*,
J Grifka*, CH Evans‡, PD Robbins§
*University of Regensburg, Regensburg, Germany
†Univ. Zurich, Zurich, Switzerland
‡Harvard University, Boston, USA
§Univ. Pittsburgh, Pittsburgh, USA
Objective: Virus-based gene transfer is an elegant method to over-
express molecules of choice and to analyze their effects on carti-
lage destruction in arthritis models. As combinations of different
vector systems for delivery of two cartilage-protective genes may
result in higher transduction efficacy, we compared double gene
transfer, using adenoviral or retroviral vectors alone, to the combi-
nation of these two vectors.
Available online  http://arthritis-research.com/supplements/4/S1Methods: RA synovial fibroblasts were transduced using IL-10- or
IL-1ra-encoding MFG retrovirus (multiplicity of infection (MOI) of
50–200) and/or Ad5 adenovirus (MOI of 10–50). Double gene
transduction was performed in vitro in a co-culture approach with
(a) retroviral IL-10 and IL-1ra, (b) adenoviral IL-10 and IL-1ra, (c)
adenoviral IL-10 and retroviral IL-1ra, (d) retroviral IL-10 and aden-
oviral IL-1ra. Cytokine production was measured by ELISA. Expres-
sion of proto-oncogenes and cytokines before and after gene
transfer was analyzed using a combination of RNA arbitrarily
primed PCR (RAP-PCR) and cDNA expression array to determine
virus-mediated molecular effects.
Results: IL-1ra and IL-10 overexpression performed either with
retroviral or with adenoviral vectors resulted in an enhanced syn-
thesis of these cytokines. Cytokine expression was substantially
higher in adenovirally transduced than in retrovirally transduced
fibroblasts (IL-1ra 317 vs. 39pg/ml; IL-10 221 vs. 44pg/ml).
Double gene transfer of a combination of retrovirus- and aden-
ovirus-encoded genes resulted in a predominant expression of the
gene encoded by the adenovirus even when the retroviral trans-
duction was performed first. Virus-related effects on gene expres-
sion using LacZ or EGFP were higher in adenovirus- (4% of the
proto-oncogenes and cytokines) than in retrovirus transduced
fibroblasts (2%).
Conclusions: The results of the study demonstrate that combina-
tion of retro- and adenovirus-based vector systems for double gene
transfer into RA synovial fibroblasts does not result in enhanced
synthesis of the respective gene products but in suppression of
the retroviral gene transfer. In addition, the experiments reveal that
for human gene therapy the higher efficacy of adenovirus-based
vectors needs to be outweighed against the lower effects on
general alteration of gene expression when retrovirus-based vector
systems are used.
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Family collections for the analysis of common
autoimmune disease genes in systemic rheumatic
and inflammatory diseases
I Melchers, U Buchegger-Podbielski, A Feldmeyer, P Lodemann
University Medical Center Freiburg, Freiburg, Germany
At present, little is known about the influence of genetic factors on
the appearance and development of human autoimmune diseases,
including rheumatic and inflammatory diseases. Our aims are i) to
provide the scientific community with the material required to study
the genetics of these diseases, individually and in their relation to
each other and ii) to contribute to these investigations. We there-
fore collected caucasian families with i) one index patient suffering
from rheumatoid arthritis (RA), systemic scleroderma (SSc), relaps-
ing polychondritis (rPC), Wegener’s granulomatosis (WG) or Sys-
temic Lupus Erythematosus (SLE), ii) at least one first degree
relative suffering from the same or another rheumatic or autoim-
mune disease, iii) healthy first degree relatives. Blood samples from
all family members were used to prepare and store plasma (or
serum), DNA, and Epstein-Barr-Virus (EBV) transformed B cell lines.
Clinical, immunological and genetic information of interest was doc-
umented in a database. Families of healthy people were collected
for comparison. Up to now we have collected more than 100 fami-
lies, mainly in Southwest Germany. According to the patient index
there are now 59 with RA, 12 with SSc, 3 with rPC, 4 with WG and
24 with SLE. In addition we collected information and material from
more than 200 patients with healthy relatives or unavailable families.
In parallel we started to compare patients with “familiar” or “non-
familiar” diseases and have already observed interesting differ-
ences. In patients with RA these differences concern sex
distribution, the presence of rheumatoid factors and the age at
disease onset. At present typing of HLA-DRB1 alleles is being per-
formed.
Acknowledgement: Funded by the Federal Ministry of Education
and Research (Kompetenznetz Rheuma) and the German Sclero-
derma Foundation.
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A polymorphism within the Transforming Growth
Factor β β1 gene is associated with ankylosing
spondylitis (AS)
F McGarry, L Cousins, RD Sturrock, M Field
Centre for Rheumatic Diseases, Glasgow, United Kingdom
Introduction: Genetic factors that predispose individuals to anky-
losing spondylitis (AS) are not fully understood. Axial and sacro-
iliac joint fibrosis are characteristic of AS and the presence of
TGFβ1 mRNA in AS sacroiliac joints raised the possibility that this
cytokine might be implicated in this fibrosis. We have therefore
examined a group of HLA B27 positive AS patients to investigate
whether they could be prone to fibrosis based on overproduction
of TGFβ1.
Methods: DNA from 132 AS patients, 113 healthy controls from
the West of Scotland were compared. DNA covering the G/C
polymorphic site at position +915 in the TGFβ1 gene was
expanded by PCR and examined using sequence specific primers.
Levels of mRNA from stimulated PBMC’s from AS patients and
controls were analysed using Taqman PCR. Serum TGFβ1 was
measured by ELISA on acidified serum.
Results: Although no significant differences in allele frequency was
seen between these two populations examination of genotype fre-
quencies showed that the AS patients were more likely to have the
GG genotype associated with high TGFβ1 production (78% versus
64%; P<0.01, OR=2.0. 95% CI 1.2–3.5). In keeping with this pre-
disposition, the median level of TGFβ1 in serum from AS patients was
6359pg/ml (range 3266–9587pg/ml) which was higher (P<0.02)
than the controls (median 4903pg/ml: range 136–7488pg/ml). The
levels of mRNA from AS patients were higher than controls.
Conclusion: This is the first report of a link with a polymorphic site
within the TGFβ1 gene in AS. An increased predisposition to high
TGFβ1 production could provide insights into the aetiology to AS.
Our data confirm that genes other than B27 may be involved in AS
pathogenesis.
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The association of HLA-DR/DQ coding and QBP
promoter allelic polymorphism with
antiphospholipid antibody response in SLE
D Logar*, B Vidan-Jeras†, A Ambrozic*, V Dolzan‡,
M Hojnik*, B Bozic*, B Rozman*
*University Medical Centre, Ljubljana, Slovenia
†Blood Trasfusion Centre, TTC, Ljubljana, Slovenia
‡Faculty of Medicine, Ljubljana, Slovenia
To ascertain if the polymorphism of HLA-DR, DQA and DQB
alleles and QAP and QBP promoters influences the production of
aCL and anti-β2-GP1 in SLE. While the role of HLA-antigens in
directing various autoantibody responses is relatively well known,
the effect of promoters is less established. Sixty-five consecutive
unrelated Slovenian SLE patients (all female, mean age±SD
36±8.3 years, mean follow-up 93 months) and 74 unrelated
healthy adults were investigated. aCL and anti-β2-GP1 were deter-
mined by ELISA. The patients and controls were typed for DRB1,
DQB1, QAP and QBP alleles by PCR-SSO, using the 12th IHW
primers, probes and protocols. The subtyping of DQB1 alleles as
Arthritis Research    Vol 4 Suppl 1 Abstracts of the 22nd European Workshop for Rheumatology Researchwell as DQA1 typing was carried out with selected Dynal SSP
primers. Allelic and deduced haplotypic frequencies in patients and
controls were compared using Fisher’s exact test. 32 (49%) and
16 (25%) of 65 SLE patients were positive for IgG, IgM and/or IgA
aCL and anti-β2-GP1, respectively. The frequency of the
DQB1*0202 allele was significantly higher in the aCL (P=0.001)
and anti-β2-GP1 (P=0.001) negative patients than in controls.
Conversely, the DQB1*0301 allele and its promoter QBP3.1 were
underestimated in the aCL (P=0.06) and anti-β2-GP1
(P=0.001) negative patients compared with controls. The
DQB1*0202 allele may have a preventive role in provoking auto-
immune response against both tested aPL. While the DQB1*0301
allele and its promoter QBP3.1 were underestimated in anti-β2-
GP1 negative patients, they did not seem to protect from β2-GP1
specific autoimmune response in SLE patients. In contrast, we
have already observed positive correlation of anti-Ro antibody
response with the DQB1*0202 allele and the significantly underes-
timated DQB1*0301 allele and its promoter QBP3.1 in the same
group of anti-Ro positive SLE patients.
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Expression of PAD enzymes and occurrence of
citrulline-containing proteins in human blood and
synovial fluid cells
ER Vossenaar, WAM van Mansum, A van der Heijden,
S Nijenhuis, MAM van Boekel, WJ van Venrooij
University of Nijmegen, Nijmegen, The Netherlands
Antibodies directed against citrulline-containing antigens are
extremely specific for RA. The amino acid citrulline is not incorpo-
rated into proteins during protein synthesis. It is generated by post-
translational modification of arginine residues by PAD
(peptidylarginine deiminase) enzymes. We investigated the expres-
sion of PAD enzymes and the occurrence of citrullinated proteins
in peripheral blood (PB) and synovial fluid (SF) cells. PAD types 1
and 3 were absent from the investigated cells, while PAD types 2
and 4 (also known as type 5) were present. In monocyte-derived
macrophages PAD type 2 mRNA expression was at a similiar level
as in monocytes, while PAD type 2 protein was increased. PAD
type 4 mRNA expression was significant in monocytes and almost
absent in monocyte-derived macrophages, while PAD type 4
protein levels were similar. In monocytes no citrullinated protein
could be detected, while in monocyte-derived macrophages citrulli-
nated vimentin, which is (part of) the Sa-antigen, was present. A
similar pattern of mRNA and protein expression was observed in
mononuclear cells in paired PB and SF samples of RA patients.
These results suggest that PAD type 2 is involved in the citrullina-
tion of SF proteins during inflammation.
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Two promoters for the CD5 gene: one operating in
T cells and activated B cells and another restricted
to resting B cells
Y Renaudineau, N Haget, P Youinou
Laboratory of Immunology, Brest, France
The CD5 T cell marker is present on a minute fraction of B cells.
These B lymphocytes produce multispecific autoantibodies and
generate most of the B chronic lymphocytic leukemias (CLL).
However, very little is known regarding the regulation of the gene
activity in B cells, compared with T cells.
Material and methods: B cells were isolated from tonsils, CLL
blood and the control Daudi cell line cells, while T cells were
obtained from normal peripheral blood (PB) and the control Jurkat
cell line. Conventional and quantitative RT-PCR, 5’ rapid amplifica-
tion of cDNA ends (RACE), sequencing, Southern blot and in situ
hybridization were required in this study.
Results: CD5 transcripts were identified in tonsil and CLL B cells,
as well as PB and Jurkat T cells. Using the RACE technique, the 5’
region of CD5 cDNA was amplified through an adaptor-ligated 5’
primer coupled with a 3’ end-specific primer. In these conditions,
the conventional exon 1 was not identified in the mRNA from
resting B cells. An alternative exon 1 was identified and its tran-
scription confirmed using RT-PCR with appropriate primers and
Southern blot. Importantly, the CD5 5’-flanking region contains
TATA and CAAT boxes, and recognition sites for Ikaros in the
B cells, but not in T cells. Furthermore, after a 48-hour stimulation
with PMA, the conventional exon 1 was used in activated B- as in
the T-cells.
Conclusions: Alternative exon 1 structures may initiate transcrip-
tion of CD5 using two different promoters, one being operative in
the resting B cells and the other in any T cells and B cells only
when activated. Such a finding substantiates our hypothesis of
innate (resting ?) and acquired (activated ?) CD5+ B cells, which
might be relevant to the pathogenesis of nonorgan-specific autoim-
mune disorders.
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Reshaping the shared epitope hypothesis: 
HLA-associated risk for rheumatoid arthritis is
encoded by amino acid substitutions at position 67
to 74 of the HLA-DRB1 molecule
N de Vries*, H Tijssen†, PLCM van Riel†, LBA van de Putte†
*Academic Medical Center Amsterdam, Amsterdam, The Netherlands
†UMC St.Radboud, Nijmegen, The Netherlands
Objective and methods: To further analyze the association of
HLA-DRB1 alleles with disease susceptibility in recent onset
rheumatoid arthritis (RA), 167 caucasian RA patients and 166
healthy controls were typed for HLA-DRB1.
Results: The association of susceptibility to RA with the group of
alleles encoding the shared epitope susceptibility sequences
(SESS) was confirmed in recent onset RA. Among non-SESS
alleles DRB1*07, *1201, *1301 and *1501 showed significant
protective effects. Even after correction for the influence of SESS
alleles, significant independent protective effects of DRB1 alleles
were observed. Protective alleles share a third hypervariable region
motif. Independent homozygosity effects were observed both for
susceptibility and protective alleles.
Conclusion: Non-susceptibility alleles differ significantly regarding
RA risk. Protective alleles show clear homology at positions
67–74, often encoding Isoleucine at position 67 or Aspartic acid
at position 70. Both susceptibility and protective alleles show
homozygosity effects. Based on these results and literature data, in
order to incorporate differential risks among non-susceptibility
alleles, we propose to reshape the shared epitope hypothesis to,
“HLA-associated risk for rheumatoid arthritis is encoded by amino
acid substitutions at position 67 to 74 of the HLA-DRB1 mole-
cule”.
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Genome-wide gene expression in experimental
arthritis: defining new targets of
chronic/destructive rheumatoid arthritis (RA)
N Takahashi*, T Boenafaes†, B Ostendorf‡, ASK de Hooge*,
E Lubberts*, PLEM van Lent*, P Rottiers†, FAJ van de Loo*,
LAB Joosten*, J Grooten†, WB van den Berg*
*UMC St. Radboud/NCMLS, Nijmegen, The Netherlands
†VIB, Gent, Belgium
‡University of Dusseldorf, Dusseldorf, Germany
Genome-wide expression analysis using microarrays enables us to
visualize activation of complex signaling pathways in the total
genome of an organism upon biological, pharmacological and toxi-
cological stimulus or during pathological conditions. Rheumatoid
Arthritis (RA) is a complex multigenic disease with yet unknown
ethiology, and consequently, suitable target for genomics
approach. We have used a high density DNA filter array, containing
25,142 DNA sequences, that represents a condensed mouse
genome to analyze gene expression in animal models of RA. Well-
defined animal models were chosen in order to investigate clear
relationships between disease activity and gene expression. We
have identified a number of genes whose targeted deletion or
insertion results in modification of disease progression. Gene dele-
tion of, e.g. IL-6 prevents development of sub-chronic inflammation
without modifying the acute inflammation in zymosan-induced-
arthritis (ZIA). Similarly, gene deletion of FcγR prevents some
aspects of chronic inflammation in antigen-induced arthritis (AIA).
On the other hand, adenoviral mediated gene transfer of IL-4 com-
pletely inhibits progression into the destructive phase in collagen-
induced arthritis (CIA). Therefore we have analyzed
gene-expression profiles in the following conditions: A) IL-6–/– vs.
WT/ZIA, B) FcγR –/– vs. WT/AIA, C) AdIL-4 vs. AdC/CIA. Possi-
ble candidate genes for (sub)chronic inflammation or destructive
arthritis were defined by two-parameter and cluster analysis of the
expression profile. Seventy-seven common candidates, possibly
involved in sub-chronic or destructive arthritis, were defined. Many
of these are genes not yet inferred to be involved in inflammation.
Selected ESTs were further analyzed and one candidate was
cloned as a full length gene. Investigation into gene function is in
progress. This approach, combining DNA array technology with
cloning and functional characterization of candidate genes, proves
highly effective in defining novel targets in inflammatory/autoim-
mune diseases such as RA.
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Discovery of distinctive gene expression profiles in
human arthritides by cDNA micro-array analysis
TCTM van der Pouw Kraan*†‡, FA van Gaalen†, P Kasperkovitz*,
N Verbeet*, AA Alizadeh‡, M Fero§, TWJ Huizinga†,
E Pieterman†, FC Breedveld†, LM Staudt^, D Botstein¶, 
PO Brown‡¶, CL Verweij*†‡
*Dept. of Molecular Cell Biology, VUMC, Amsterdam
†Dept. of Rheumatology, LUMC, The Netherlands
Depts of ‡Biochemistry, §Genetics and ¶Howard Hughes Medical
Institute, Stanford University, USA
^Division of Clinical Sciences, NIH, Bethesda, USA
A potentially powerful way to gain insight in the complex pathogen-
esis of rheumatoid arthritis (RA) and to classify arthritides has
arisen from cDNA microarray technology, which provides the
opportunity to determine differences in gene expression of a large
portion of the genome in search of genes that are differently
expressed between clinically diagnosed arthritides. Therefore, we
studied the gene expression profile of synovial tissues from
affected joints of patients with diagnosed RA (n=21) in compari-
son to those of patients with osteoarthritis (OA) (n=9), a degenera-
tive joint disease. Cy-5 labeled mRNAs from these samples were
hybridized together with a Cy-3 labeled common reference mRNA
preparation to arrays containing 18,000 genes of importance in
immunology. The results revealed 1066 genes with a twofold dif-
ference in expression in at least 4 samples, relative to the median
Cy-5 to Cy-3 ratio. Hierarchical cluster analysis revealed a remark-
ably ordered variation in gene expression profiles in the affected
joint tissues of patients with RA and OA. These data revealed bio-
logical pathways and novel genes involved in disease. Based on
the molecular signatures at least two distinct subsets of RA tissues
could be identified. One class revealed abundant expression of
gene clusters indicative of the presence and activation of the adap-
tive immune response, and the other group resembled the expres-
sion pattern of the OA tissues, which is characterized by a low
inflammatory gene expression signature and increased tissue
remodeling. The differences in the gene expression profiles reflect
important aspects of biological variation within the clinically diag-
nosed arthritides that may help to understand the molecular pathol-
ogy of and (sub-)classify rheumatic diseases.
Inflammation
29
TNF-α α blockade in early rheumatoid significantly
reduces serum VEGF and ultrasonographic
measures of synovitis and joint vascularity by 
18 weeks
PC Taylor*, A Steuer*, P Charles*, J Gruber*, D Cosgrove†,
C Blomley†, C Wagner‡, RN Maini*
*The Kennedy Institute of Rheumatology, London, United Kingdom
†Imperial College (ICSTM), London, United Kingdom
‡Centocor Inc, Malvern, PA, USA
This study compared the ability of ultrasonographic methods and
serological measurement of vascular endothelial growth factor
(VEGF) to discriminate between early rheumatoid arthritis (RA)
patients receiving infliximab or placebo infusions added to pre-
existing methotrexate (MTX) treatment over the first 18 weeks of
therapy. Twenty-four patients with early RA (<3 years duration) on
stable doses of methotrexate were randomised in a double-blinded
study to receive infusions of infliximab (5mg/kg) or placebo at entry
then weeks 2, 6, and 14. At baseline and 18 weeks blood was
taken and serum stored. At the same time points, metacarpopha-
langeal joints were imaged over the dorsal surface in longitudinal
and transverse planes by high resolution ultrasound (HRUS) and
power Doppler to assess synovial thickness, the presence of syn-
ovial vascularity and the number of vascularised erosions. At
18 weeks, there was a median reduction in DAS28 of 1.21 from
baseline in the infliximab group and 0.39 in the placebo group
(P=0.157). In the infliximab group 54% achieved ACR20
responses versus 18% in the placebo group (P=0.08). In con-
trast, median reduction in synovial thickness as assessed by HRUS
was 50% in the infliximab group as compared with an increase of
1.2% in the placebo group (P=0.014). Median colour Doppler
area diminished by 98.4% in the infliximab group as compared with
a reduction of only 30.7% in the placebo group (P=0.017). The
total number of vascularised erosions decreased by a median of
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placebo group (P=0.001). Median serum VEGF was reduced by
31.5% in the infliximab group and 3.1% in the placebo group
(P=0.007). In this cohort, changes in serum VEGF and sono-
graphic measures of synovial thickening and joint vascularity
showed a marked reduction in the infliximab treated group com-
pared with the placebo and methotrexate treated group. These
findings indicate that reversal of inflammatory and joint destructive
mechanisms are already apparent at an early stage of treatment
with infliximab.
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Expression of galectin-3 in rheumatoid arthritis
synovium
M Neidhart, S Kuchen, C Seemayer, RE Gay, BA Michel, S Gay
University Hospital, Zurich, Switzerland
Background: Galectins are involved in cell-cell interactions, cell
adhesion to extracellular matrix, tissue remodelling, cell growth and
regulation of apoptosis. Particularly, galectin-3 has antiapoptotic
properties, proinflammatory and chemotactic activities. An altered
expression has been associated with tumor progression. The aim
of this study was to investigate the expression pattern of galectin-3
in rheumatoid arthritis (RA) synovial tissues.
Material and methods: Synovial tissues were obtained after joint
replacement from patients with RA (n=7) or osteoarthritis (OA,
n=3). Specific sequences of galectin-3 cDNA were amplified by
RT-PCR and used for the generation of digoxigenin-labeled ribo-
probes. In situ hybridisation was performed on paraffin sections.
Immunohistochemistry was applied on paraffin and snap frozen
sections using mouse monoclonal anti-galectin-3 antibodies. For
comparison, the macrophage marker CD68 was used.
Results: In RA, galectin-3 was found at sites of joint destruction,
as well as in the lining and sublining layers. The percentage of pos-
itive cells, however, was lower in the lining than in the sublining
layer. A predominant expression of galectin-3 was found in cells
with follicle-like structures and in perivascular infiltrates, whereas
vessels remained negative. Synovial fibroblasts also stained posi-
tive and, at least in the sublining, the expressions of galectin-3 and
CD68 appeared mutually exclusive. In contrast, in OA synovial
tissues, only a few cells in the lining layer were positive for galectin-
3. Similar results were obtained by in situ hybridisation and
immunohistochemistry.
Conclusion: Taken together, theses observations suggest that
galectin-3 is involved in cell-cell and cell-matrix interactions in the
RA synovium and therefore may contribute to both the inflamma-
tory and the destructive processes.
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Bacterial peptidoglycan stimulates integrin
expression and MMP production of synovial
fibroblasts
DK Kyburz*, J Rethage*, R Seibl*, BA Michel*, RE Gay*,
DA Carson†, S Gay*
*University of Zurich, Zurich, Switzerland
†Dept of Medicine, UCSD, La Jolla, USA
Bacterial products such as peptidoglycan (PGN) have been found
in joints of patients with rheumatoid arthritis. Recently, it has been
shown that intra-articular injection of bacterial PGN can induce a
transient arthritis in mice, indicating a possible role of bacterial
products in the pathogenesis of arthritis. Whereas the activation of
macrophages by PGN is established, it is not known whether syn-
ovial fibroblasts are also able to respond. We studied the activation
marker expression of human synovial fibroblasts in culture after
incubation with or without PGN in vitro. Cultured human synovial
fibroblasts derived from RA patients were incubated in presence or
absence of PGN. After culture periods of 24 to 48 hours the
surface expression of integrins was measured by FACS using
directly labeled antibodies. Expression of various matrix metallopro-
teinases (MMP) was determined by real time PCR (TaqMan).
PGN resulted in an upregulation of the surface expression of
CD54 (ICAM-1) as compared to untreated cultures. In the tested
cultured RA synovial fibroblasts the upregulation in responders
ranged between 20% and 100%. PGN also upregulated the
expression of MMP-3 and MMP-1 mRNA. These results suggest
that the presence of bacterial PGN can activate synovial fibro-
blasts, to express ICAM-1 and MMPs. This activation might repre-
sent an important early step in the development of inflammatory
arthritis.
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Stromal cell derived factor-1 (CXCL12) induces cell
migration into lymph nodes transplanted into SCID
MICE. An investigation of lymphocyte migration to
secondary lymphoid organs
MC Blades*, A Manzo*, F Ingegnoli*, P Taylor†, H Irjala‡,
S Jalkanen‡, DO Haskard§, M Perretti¶, GS Panayi*, C Pitzalis
*GKT, London, United Kingdom
†Guy’s & St Thomas’ Hospital Tr, London, United Kingdom
‡MediCity Research Laboratory, Turku, Finland
§Imperial College, London, United Kingdom
¶William Harvey Institute, London, United Kingdom
SDF-1 (CXCL12), a CXC chemokine, has a primary role in sig-
nalling the recruitment of haematopoietic stem-cell precursors to
the bone marrow during embryonic development. In post-natal life,
SDF-1 is widely expressed and is induced in chronically inflamed
tissues such as psoriatic skin and the rheumatoid synovium, but
has also been implicated in the migration of lymphocytes to lym-
phoid organs. To investigate the role of SDF-1 in recirculation and
homing in vivo we have developed a model in which human periph-
eral lymph nodes (huPLN) are transplanted into SCID mice. We
have shown that huPLN transplants are viable and are vascularised
by the murine circulation, forming functional anastomoses with
transplant vessels. In addition grafts retain some of the histological
features of the pretransplantation tissue, such as follicular dendritic
cell-associated B-cell aggregates, lymphatic and HEV markers. We
also show that SDF-1 is capable of inducing the migration of an
SDF-1 responsive cell-line (U-937) and human PBL’s from the
murine circulation into the grafts in a dose dependant manner
which is inhibitable by CXCR4 blockade. The mechanism of action
of SDF-1 in this model is independent from that of TNF-α and does
not rely on the upregulation of adhesion molecules (such as
ICAM-1) on the graft vascular endothelium. This is the first descrip-
tion of huPLN transplantation into SCID mice, and of the functional
effects of SDF-1 regarding the migration of human cells into
huPLN in vivo. This model provides a powerful tool to investigate
the pathways involved in cell-migration into lymphoid organs and
potentially to target them for therapeutic purposes.
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Identification of homing peptides specific for
synovial microvascular endothelium using in vivo
phage display selection
L Lee*, C Buckley†, MC Blades*, G Panayi*, AJT George‡,
C Pitzalis*
*GKT, London, United Kingdom
†University of Birmingham, Birmingham, United Kingdom
‡Imperial College, London, United Kingdom
The microvascular endothelium (MVE) plays a major role in inflam-
mation as well as tumour growth. Thus, the MVE represents an
important therapeutic target. Peptide phage technology has been
used in vivo to discover peptide sequences with binding capacity
to organ specific MVE determinants in animals. The application of
such powerful technology to humans has been limited by the
obvious difficulties of performing phage-screening studies in vivo.
By grafting human tissues into severe combined immunodeficient
(SCID) mice, it is possible to target specifically human MVE deter-
minants. Here we report for the first time the identification of syn-
ovial specific homing peptides by in vivo phage display selection in
SCID mice transplanted with human synovium. Selected synovial
homing peptide-phages were found to bind to human synovial graft
MVE and retain their tissue homing specificity in vivo indepen-
dently from phage component, disease origin of transplants and
degree of human/murine graft vascularisation. In addition, the
selected phages demonstrate tissue and species specificity in
comparison to cotransplanted human skin grafts or mouse vascula-
ture. Sequence analysis of the peptide inserts from synovial
homing phages identified recurrent consensus motifs. One such
motif maintains synovial MVE specificity both when expressed by a
single phage-clone and as a free biotinylated synthetic peptide.
Furthermore, the free peptide competes and inhibits, in vivo, the
binding of the original peptide-phage to the cognate synovial MVE
ligand. The identification of synovial homing peptides, with tissue
and species specificity, may allow the construction of targeting
devices capable of concentrating therapeutic/diagnostic materials
to human joints.
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Inmunohistologic analysis of synovial tissue from
early and late osteoarthritic patients.
A potential role for COX-2 and NF-κ κB1 (p50)
regulation in early disease
MJ Benito, O FitzGerald, B Bresnihan
St Vincent’s Hospital, Dublin, Ireland
Osteoarthritis (OA) is an erosive inflammatory disease originated
by a biomechanical alteration that, in some patients, shows a
strong component of inflammatory infiltrates in the synovial mem-
brane resembling rheumatoid arthritis. T cells and macrophages ini-
tiate, amplify and perpetuate the inflammatory response. In
stimulated cells, NF-κB, commonly formed by homodimers of
NF-κB1 (p50), or heterodimers with RelA (p65) or c-Rel, bind to
promoters and enhance, or occasionally inhibit, gene transcription
through direct interaction with DNA. The activation of NF-κB may
be a key step in the pathogenesis of OA. Inducible cyclooxygenase
(COX-2) may also play a role in the inflamed profile, since it has a
κB motive in its promoter. The aim of this study is to evaluate the
differences in OA tissue, focusing on whether the pattern of NF-κB
activation is quantitatively different in early and late stages, and its
effect in COX-2 expression. Additional in vitro experiments, using
OA cultured cells, were performed to evaluate the role of IL-6 and
PGE2 in NF-κB activation and COX-2 induction. A significant
increase in inflammatory cell infiltrate and hyperplasia of synovium
was a feature found in early OA tissue. NF-κB1 and RelA were
detected in all the OA samples studied, with significant increases
observed in early OA tissue (P=0.006 and P=0.012). In concor-
dance with NF-κB1/RelA, COX-2 expression was increased in
early OA. Activation of p50 and p65 subunits of NF-κB showed a
positive correlation with COX-2 (r=0.6169 and r=0.6620, respec-
tively) and inverse correlation with COX-1 (r=–0.627 and
r=–0.858) in early OA tissue, while only a positive correlation was
observed between p50 and COX-2 in late OA (r=0.4129). In vitro
synoviocytes cell cultures the activation of NF-κB in cells was
observed together with an increase in COX-2 production. This acti-
vation was inhibited by parthenolide, an inhibitor of IκB degrada-
tion, and a concomitant decrease in COX-2 protein was observed
as a result of the NF-κB inhibition. These findings support the con-
clusion that NF-κB and COX-2 play an important role in the early
stages of OA, and specific inhibition could be a strategic approach
in early OA.
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Comparison of knee joints with small joints:
implications for pathogenesis and evaluation of
treatment in rheumatoid arthritis
MC Kraan*, RJ Reece†, TJM Smeets*, DJ Veale†, P Emery†,
PP Tak*
*Academic Medical Center, Amsterdam, The Netherlands
†University of Leeds, Leeds, United Kingdom
Objective: Serial synovial biopsy samples are increasingly used for
the evaluation of novel therapies for rheumatoid arthritis (RA). Most
studies have used knee biopsies, but technical improvements have
made serial small joint arthroscopy feasible as well. Theoretically,
there could be differences in the features of synovial inflammation
between various joints as a result of mechanical factors, differences
in innervation, and other factors. Therefore, we compared the cell
infiltrate in paired synovial biopsies from inflamed knee joints with
inflamed small joints obtained simultaneously in RA patients.
Materials and methods: Nine RA patients with both an inflamed
knee joint and an inflamed small joint (wrist or metacarpopha-
langeal) were subjected to an arthroscopic synovial biopsy of both
joints on the same day. Multiple biopsy specimens were collected
and stained for macrophages, T cells, plasma cells, fibroblast-like
synoviocytes, and interleukin(IL)-6 by immunohistochemistry. Sec-
tions were analyzed by digital image analysis.
Results: The mean cell numbers for all investigated markers were
equivalent in the samples from knee joints compared with the
paired small joint samples. Statistical analysis by nonparametric
tests identified no significant differences. Using Spearman Rank
tests, we found significant correlations for the number of sublining
macrophages (rho 0.817, P<0.01), the number of T cells (rho
0.683,  P<0.05), and the number of plasma cells (rho 0.766,
P<0.02) when knee joints were compared with small joints. There
was, however, no significant correlation for lining macrophages
and fibroblast-like synoviocyte hyperplasia when large and small
joints were compared.
Conclusion: The results presented in this study show that inflam-
mation in one inflamed joint is generally representative for the
process in other joints. Therefore, it is possible to use serial
samples from the same joint selecting either large or small joints for
evaluation of antirheumatic therapies. Hyperplasia of the intimal
lining layer due to accumulation of intimal macrophages and fibro-
blast-like synoviocytes appears to depend in part on local factors.
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Expression of the EGF-TM7 family members 
EMR-2 and CD97 in rheumatoid synovial tissue
EN Kop, J Hamann, GJ Teske, M Kwakkenbos, TJM Smeets,
MC Kraan, PP Tak, RAW van Lier
Academic Medical Center, Amsterdam, The Netherlands
Background: Fibroblast-like synoviocytes (FLS) express decay-
accelerating factor (CD55) at high levels. One of its ligands,
CD97, is a member of the EGF-TM7 family, a group of class B
seven-span transmembrane receptors, which are prominently
expressed by activated immune cells. Previous work has sug-
gested a close association between CD55+ FLS and CD97+
intimal macrophages in rheumatoid arthritis (RA) synovium. These
previous studies were performed with an antibody that binds both
CD97 and EMR2, which is another member of the EGF-TM7
family. Recently, monospecific antibodies against EMR2 and CD97
were developed.
Objective: To determine the expression of CD97 and EMR2 using
novel, monospecific antibodies to provide more insight into the
factors that might be involved in leukocyte activation in rheumatoid
synovial tissue.
Methods: Synovial tissue samples were obtained by arthroscopy
from 19 RA patients, 17 inflammatory osteoarthritis (OA) patients,
and 11 reactive arthritis (ReA) patients. Immunohistologic analysis
was performed using the following antibodies: CLB-CD97/1
(which recognizes both CD97 and EMR2), CLB-CD97/3 (specific
for CD97), and 2A1 (specific for EMR2). Bound antibody was
detected according to a 3-step immunoperoxidase method. In
addition, double immunofluorescence was performed. Stained sec-
tions were analyzed by digital image analysis using a standardized
program and compared by nonparametric statistical analysis.
Results: CD97 was shown to be expressed on activated leuko-
cytes in the intimal lining layer and in the synovial sublining in all
forms of arthritis. Of interest, we observed a specific increase in
the expression of EMR2 positive cells of myeloid lineage in RA
compared with ReA and OA synovium, even after correction for
cell numbers. These differences were statistically significant (RA
versus ReA and OA for both lining and sublining: all P values
< 0.03). Double immunofluorescence revealed that 40–60% of the
macrophages in RA synovium expressed EMR2.
Conclusion: The increased expression of various members of the
EGF-TM7 family in inflamed synovial tissue suggests a role in the
formation of the architecture of the intimal lining layer as well as in
the maintenance and amplification of synovial inflammation. EMR-2
might be involved in the specific activation of macrophages in RA.
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IgG-mediated activation of leukocytes is
independent of Fc-γ γ receptor polymorphism
HM Dijstelbloem*, AA Rarok*, MG Huitema*, JGJ van de Winkel†,
PC Limburg*, CGM Kallenberg*
*University Hospital Groningen, Groningen, The Netherlands
†University Medical Center, Utrecht, The Netherlands
Introduction: Ligation of Fc-γ receptors for IgG (FcγR) can trigger
potent effector cell responses. Genetic polymorphisms of these
receptors modify IgG binding, and influence internalization of
immune complexes. In patients with infectious or autoimmune dis-
eases, skewing towards low-binding FcγR alleles has been demon-
strated. The objective of this study was to investigate the influence
of FcγR polymorphism on leukocyte activation.
Methods: We analyzed activation of neutrophils and monocytes
stimulated by aggregated or solid phase-coated IgG1, IgG2, and
total IgG. Neutrophil donors were selected based on their FcγR
genotype and homozygous for either FcγRIIa-H131/FcγRIIIb-
NA1/1(HH-NA1/1) or FcγRIIa-R131/FcγRIIIb-NA2 (RR-NA2/2).
Monocyte donors were homozygous for either FcγRIIa-H131/FcγRI-
IIa-V158 (HH-VV) or FcγRIIa-R131/FcγRIIIa-F158 (RR-FF). Binding
of immunoglobulins to lymphocytes was determined by flow cyto-
metry. Activation of neutrophils was measured as the production of
reactive oxygen intermediates (ferricytochrome c reduction), de-
granulation (lactoferrin release), and cytokine production (IL-8).
TNF-α secretion was used as a measure of monocyte activation.
Results: IgG1 aggregates firmly bound to neutrophils of both
types of donors, albeit more avidly to donors expressing
HH-NA1/1 alleles. In contrast, IgG2 aggregates firmly bound to
HH-NA1/1 FcγR neutrophils only. This binding could be blocked
by preincubation of neutrophils with FcγRIIa and FcγRIIIb blocking
antibodies. Despite the differences in binding of IgG subclasses to
HH-NA1/1 and RR-NA2/2 neutrophils, we observed no differences
in their activation. Activation of both types of neutrophils with IgG1
or IgG2 aggregates could be at least partially blocked by the addi-
tion of FcγR blocking antibodies. Similar to neutrophils, HH-VV and
RR-FF monocytes were not distinguishable in their response to
IgG, IgG1, and IgG2 as measured by TNF-α release, although
RR-FF monocytes did not bind IgG2 complexes.
Conclusion: Although IgG-mediated activation of leukocytes is
dependent on FcγR, it does not appear to be influenced by FcγR
polymorphisms. These results are in favour of a new mechanism for
IgG-mediated leukocyte activation, in which a short interaction
between IgG and FcγR is sufficient to generate an appropriate
inflammatory response. This may have important implications for
inflammatory responses in infectious and autoimmune diseases.
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Overexpression of the autoantigen hnRNP-A2
(RA33), the tumour suppressor p53 and activated
MAP-Kinase p38 in inflamed synovial tissue
S Hayer*, M Tohidast-Akrad†, G Schett†, H El Gabalawy‡,
J Smolen†, G Steiner†
*University Hospital of Vienna, Vienna, Austria
†University of Vienna, Vienna, Austria
‡University of Manitoba, Winnipeg, Canada
Objective: Overexpression of the nuclear autoantigen hnRNP-A2
(RA33) has recently been observed in synovial tissue of RA
patients and TNF transgenic mice. To further investigate this issue
expression of hnRNP-A2 was compared with that of two other
hnRNP proteins, the closely related hnRNP-A1 (a rare autoantigen
in RA) and the structurally different hnRNP-C (which is not an
autoantigen). In addition, expression of the tumour suppressor p53
and the MAP-kinase p38 was studied.
Methods: Synovial tissue of patiens with RA or osteoarthitis and
specimen from patients with early arthritis of <1 year duration were
analyzed by immunohistochemistry
Results: HnRNP-A2 was highly overexpressed in RA synovial
tissue as compared to tissue of osteoarthritis patients, and most
abundantly found in CD68-positive cells of the lining layer. The
antigen was not only localized in the nucleus but also in the cyto-
plasm confirming previous observations. Nuclear overexpression
was also observed for hnRNP-C, whereas expression of
hnRNP-A1 appeared normal. Remarkably, in the majority of
hnRNP-A2 expressing cells also the p53 tumor suppressor was
overexpressed and aberrantly localized in the cytoplasm. Further-
more, the MAP-kinase p38 was acitvated in these cells as revealed
by a monoclonal antibody specifically recognizing the phosphory-
lated (activated) form of this kinase. This indicated that cells over-
expressing hnRNP-A2 and p53 had been activated by
Available online  http://arthritis-research.com/supplements/4/S1proinflammatory cytokines such as TNF or IL-1. A comparable
result was obtained with tissue from patients with early arthritis,
irrespectively of their diagnosis (RA or reactive arthritis). So far, the
conditions that lead to aberrant expression of these proteins have
not been clearly defined since even prolonged exposure of
macrophages or synovial fibroblasts to TNF or IL-1 did not cause
any changes in hnRNP-A2 expression or induce its cytoplasmic
accumulation. This was only achieved by treatment with the RNA
polymerase II inhibitor actinomycin D which subsequently led to
apoptosis and accumulation of hnRNP-A2 in apoptotic bodies.
Conclusion: The state of chronic inflammation in the rheumatoid
synovium seems to cause aberrant expression and/or modification
of (some) proteins which may lead to loss of tolerance and induc-
tion of patholocigal autoimmune reactions in genetically suscepti-
ble individuals.
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HMGB1 is a potent proinflammatory mediator
expressed abundantly in chronic synovitis
UG Andersson, H Erlandsson Harris, R Kokkola, E Sundberg,
A-K Ulfgren, K Palmblad
Karolinska Institutet, Stockholm, Sweden
Aim: To dissect the role of the endogenous, cytokine-like protein
high mobility group 1 protein (HMGB1) in arthritis, we set out to
investigate the presence of HMGB1 in synovial biopsies from rats
with adjuvant arthritis and in synovial biopsies and synovial fluid
samples from patients with active RA.
Background: HMGB1 is a DNA-binding, non-histone, nuclear
protein present in all nucleated cells. Previous results have demon-
strated that HMGB1 is released from the cytoplasm of activated
monocytes and macrophages and that extracellular HMGB1 is a
potent inducer of production of proinflammatory cytokines in mono-
cytes and macrophages. Furthermore, anti-HMGB1 treatment
inhibits LPS-induced lethality in sepsis in mice.
Methods: Presence of released HMGB1 in synovial membranes
from arthritic rats and synovial membrane biopsies from RA
patients, were detected by immunohistochemistry. Analysis of
HMGB1 in synovial fluid was performed by western blotting.
Results: In rat ankle joint specimens obtained at the onset of arthri-
tis, as well as in the chronic stage of the disease, we detected cyto-
plasmic HMGB1 in macrophage/monocyte-like cells in the synovial
membrane as well as in synovial fluid. The levels of cytoplasmic
expression was higher at later stages of disease. A similar picture
was obtained when immunohistochemical stainings were performed
on synovial biopsies from RA patients. Analysis of synovial fluid
samples from RA patients revealed high levels of released HMGB1.
Intra-articular rHMGB1 injections in rats caused erosive synovitis.
Conclusion: HMGB1 is a newly identified proinflammatory mole-
cule, now shown to be present in arthritic joints of both RA
patients and rats with adjuvant arthritis. With reference to the previ-
ously demonstrated capacity of HMGB1 to stimulate the produc-
tion of TNF and IL-1β, we speculate that HMGB1 could be of
importance in the pathogenesis of arthritis.
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Expression of protease-activated receptors in
arthritic synovial tissues
AK So, V Chobas-Péclat, C Morard, N Busso
Service de Rhumatologie, Lausanne, Switzerland
Clinical and experimental evidence suggests that synovial thrombin
formation in arthritic joints is prominent and deleterious, leading to
exacerbation of rheumatoid arthritis (RA). In this context, cellular
effects of thrombin mediated by the protease-activated receptors
(PARs) in arthritic joints may be of paramount significance. Four
PARs have now been identified. PAR1, PAR3, and PAR4 can all
be activated by thrombin whereas PAR2 is activated by trypsin and
few other proteases.
We first explored PARs expression in RA synovial tissues. Synovial
membranes from 11 RA patients were analyzed for PARs expres-
sion by RT-PCR and by immunohistology. PAR4 was found in all the
biopsies, whereas the expression of PAR1, PAR 2 and PAR3 was
more restricted (8/11, 5/11 and 3/11 respectively). In the arthritic
synovial membrane of murine antigen-induced arthritis (AIA) we
found coexpression of the four different PARs. Next, we explored
the functional importance of PAR1 during AIA in vivo using PAR-1
deficient mice. The phenotype of PAR1-deficient mice (n=22),
based on the analysis of arthritis severity (as measured by 99m tec-
netium uptake, histological scoring and intra-articular fibrin measure-
ments) was similar to that of wild-type mice (n=24). In addition, the
in vivo production of antibodies against mBSA was also similar. By
contrast, the mBSA-induced in vitro lymph node cell proliferation
was significantly decreased in PAR1-deficient mice as compared
with controls. Accordingly, mBSA-induced production of
interferon-γ by lymph node cells in culture was significantly
decreased in PAR1-deficient mice as compared with controls,
whereas opposite results were observed for production of IL-10.
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IFN-β β-induced IL-1Ra synthesis in human monocytes
involves PI 3-kinase-STAT1 signaling pathway
J-M Dayer, N Hyka, M-T Kaufmann, R Chicheportiche, D Burger
*University Hospital, Geneva, Switzerland
IFN-β displays an anti-inflammatory property by inducing IL-1Ra
without triggering synthesis of IL-1β in human monocytes (Mo). IFN-β
initiates JAK-STAT pathway that may cross-talk with components of
MAP- and PI 3-kinase pathways. Since maximal activation of tran-
scription by several STATs requires both Tyr and Ser phosphorylation,
we investigated the role of MAP- (ERK1/2) and PI 3-kinases in IFN-β-
induced IL-1Ra production in Mo. The PI 3-kinase inhibitor Ly294002
but not the MAP kinase inhibitor PD98052 suppresses, in a dose-
dependent way, IL-1Ra production in Mo at a protein level correlating
with the reduction of steady state levels of IL-1Ra mRNA. IFN-β treat-
ment of Mo leads to rapid Ser-phosphorylation and nuclear transloca-
tion of STAT1 that is inhibited by Ly294002. Interestingly,
suppression of PI 3-kinase activity in Mo stimulated by IFN-β and anti-
CD11b mAb results in inhibition of IL-1Ra and upregulation of IL-1β
production, suggesting that PI 3-kinase might be a check-point signal-
ing molecule favoring IL-1Ra synthesis. Involvement of PI 3-kinase
pathway in IL-1Ra synthesis seems to be independent of the differen-
tiation state of Mo: M-CSF differentiated Mo requires activation of PI
3-kinase to synthesize IL-1Ra following IFN-β treatment. Thus, IFN-β
induced IL-1Ra production in Mo by simultaneously activating compo-
nents of JAK-STAT and PI 3-kinase signaling pathways.
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Activating Fcγ γRIII determines cartilage destruction
during immune complex arthritis but not in the
presence of T-cell immunity
PLEM van Lent*, K Nabbe*, AB Blom*, AEM Holthuysen*,
JS Verbeek†, WB van den Berg*
*UMC Nijmegen, Nijmegen, The Netherlands
†Human and Clinical Genetics, Leiden, The Netherlands
Introduction:  We have recently shown that activating Fcγ
receptors determine metalloproteinase (MMP)-induced cartilage
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immune complexes (IC). In the mouse, two activating FcγR (FcγRI
and FcγRIII) which bind IC have been described. In this study, we
investigated the role of activating FcγRIII in MMP-mediated carti-
lage destruction in two different models of experimental arthritis,
one induced only by ICs and the second by ICs and T cells.
Methods: Mice made deficient for FcγRIII and their wildtype con-
trols(C57BL/6) were used. Immune complex arthritis (ICA) was
induced by injecting lysozyme directly into the knee joint of mice,
which had previously been given antilysozyme intravenously. T cell-
mediated IC-mediated IC-arthritis (AIA) was induced by immunizing
mice with mBSA in CFA and injection of the antigen directly into
the knee joint, 3 weeks after immunization. Cartilage destruction
was studied by immunolocalisation of MMP-mediated neoepitopes
(VDIPEN) and matrix erosion in total knee joint sections. Adaptive
cellular cells (T cells) and humoral immunity (anti-mBSA antibod-
ies) were investigated using lymphocyte stimulation assay and
ELISA.
Results: ICA induced in naive C57BL/6 knee joints showed florid
inflammation at day 1 and 3. MMP-mediated cartilage destruction
and matrix erosion was moderate at day 3. When ICA was induced
in knee joints of FcγRIII deficient mice, joint inflammation, MMP-
mediated cartilage destruction and erosion was significantly lower
(respectively 95, 100 and 80%). In addition, AIA was induced in
FcγRIII–/–. Immunisation of FcγRIII–/– did not alter adaptive cellu-
lar immunity or humoral immunity against mBSA if compared to
wildtype controls. Induction of AIA showed similar swelling at
day 1, 3 and 7. At day 7, histology showed severe chronic joint
inflammation not different from controls. MMP-mediated cartilage
destruction and erosion was also similar to wildtype controls. In
contrast, AIA induction in knee joints of Fcg chain–/– (which lack
both functional FcγRI and III), MMP-mediated cartilage destruction
and erosion was completely prevented.
Conclusion: FcγRIII is the dominant activating receptor in MMP-
mediated cartilage destruction and erosion during arthritis merely
induced by immune complexes. In T cell driven immune complex
arthritis, however, FcγRIII is not important or redundant.
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Sustained high expression of Fcγ γ receptor II
(CD32) on dendritic cells (DCs) in patients with
rheumatoid arthritis (RA)
TRDJ Radstake*, A Blom*, E van Gorselen*, L Engelen†,
G Adema†, P van Lent*, P Barrera*, C Figdor†, W van den Berg
*University Medical Center Nijmegen, Nijmegen, The Netherlands
†Tumor Immunology Laboratory, Nijmegen, The Netherlands
Introduction: DCs are proffesional antigen presenting cells. For
antigen internalisation, DCs use the Fcγ receptor II (CD32) which
recognises anti-IgG-complexes and therefore might be involved
in regulation of autoimmunity. Normally, CD32 is abundantly
expressed on immature DCs and down-regulated after full matu-
ration.
Objective: Evaluation of CD32 expression on DCs from RA
patients.
Methods: Peripheral blood mononuclear cells obtained from RA
patients and healthy donors were cultured with GM-CSF and IL-4
for 6 days to obtain immature DCs. Stimulation with LPS from
day 6 yielded mature DCs at day 8. The expression of surface
markers involved in T cell-DC interaction (DC-SIGN, CD83)
antigen uptake (FcγRI, II and III) and presentation (CD80, CD86,
MHC-I and MHC-II) were studied using FACS analysis. In addition,
RT-PCR and in vivo colocalisation studies using DC-specific
markers in synovium were used to confirm these findings.
Results: In both RA patients and controls DCs expressed
expected levels of CD80, CD86, CD83, MHC-I, MHC-II and
DC-SIGN. Interestingly, immature DCs showed a threefold
increase in expression of CD32 when compared with controls
(mean fluorescence 185.8 vs. 63.0 P<0.01). Moreover, this
increased expression of CD32 is sustained in fully mature DCs
from RA patients (mean fluorescence 452.3 vs. 187.8 P=0.005),
whereas CD32 expression is strongly down-regulated upon matu-
ration of DCs from controls. The sustained high expression of
CD32 was further confirmed by RT-PCR. Both FcγRIIa and FcγRIIb
were increased in immature DCs as well as mature DC from RA
patients but not in DCs from healthy controls. In RA both immature
and mature DCs showed a balance towards FcγRIIb. Colocalisa-
tion between FcγRII and DC-LAMP and DC-CK1 was clearly
observed in RA synovial tissue.
Conclusion: Both immature and mature DCs from RA patients
showed a significant increased expression of the FcγRII suggestive
for an aberrant maturation pathway. In vivo, mature DCs with a
high FcγRII expression are clearly present in the synovium in RA.
These findings are suggestive for a crucial role of high FcγRII
expression on DCs in synovial tissue in promoting and sustaining
the local immune response in RA.
Cell signalling
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Signaling pathways involved in IL-18 induced
VCAM-1 expression in RA synovial fibroblasts
J Morel*, B Combe*, P Kumar†, JH Ruth†, CC Park†, AE Koch†
*Rhumatologie, Montpellier, France
†Northwestern University, Chicago, USA
In a recent report, we suggested the implication of a phosphoinosi-
tide-3 kinase (PI3 kinase) pathway in IL-18-induced VCAM-1
expression in rheumatoid arthritis (RA) synovial fibroblasts. Here,
we demonstrated for the first time that IL-18 rapidly activates PI3
kinase and its downstream effector Akt. In our investigation to elu-
cidate the signaling events downstream and upstream of PI3-
kinase, we found that IL-18 induces a parallel pathway involving
extracellular regulated kinases (ERK) 1/2. Using specific kinases
inhibitors LY294002 and PP2, we showed that ERK1/2 activation
was independent of PI3 kinase but dependent of Src kinase with
an approximately 63% (P<0.05) decrease of phosphorylated
ERK. IL-18 also showed a time dependent activation of both c-Src,
Ras and Raf-1suggesting the implication of this signaling cascade
in ERK activation. Electrophorectic mobility shift assay demon-
strate that activator protein-1 (AP-1) is activated by IL-18 through
ERK and Src but not through PI3 kinase. Finally, the Src kinase,
which is known to activate PI-3 kinase may represent the early
event in IL-18-activated PI3 kinase because the specific inhibitors
of these two kinases both affect IL-18 induced VCAM-1 expression
in RA synovial fibroblasts by 50% (P<0.05). In contrast,
PD98059 and pertussis toxin had no impact on VCAM-1 expres-
sion excluding the participation of ERK and Go/i proteins in the
IL-18-mediated VCAM-1 production. These data demonstrate the
activation of two novel pathways in IL-18-stimulated RA synovial
fibroblasts and they indicate that it is possible to selectively inhibit
the expression of VCAM-1. Targeting PI3 kinase may represent an
interesting approach to the development of selective drugs in
inflammation and RA.
Available online  http://arthritis-research.com/supplements/4/S145
Effect of P38 mapkinase inhibitor RWJ-67657 on
proinflammatory mediators produced by IL-1β β-
and/or TNFα α-stimulated rheumatoid synovial
fibroblasts
J Westra, MC Harmsen, MH van Rijswijk, PC Limburg
Academic Hospital Groningen, Groningen, The Netherlands
Introduction: The p38-mitogen activated protein kinase (p38
MAPK) inhibitor RWJ-67657 has been shown to effectively sup-
press clinical and cytokine response to endotoxin in healthy human
volunteers (Fijen JW: JCI 2001, 124:16). In patients with rheuma-
toid arthritis (RA) p38-MAPK activity is observed in the synovial
lining layer (Schett G, Arthritis Rheum 2000, 43:2501). To further
characterise the role of p38-MAPK in RA the effect of RWJ-67657
on IL-1β and/or TNFα induced mRNA expression and production
of cytokines (IL-6 and IL-8) and matrixmetalloproteinases (MMP-1,
MMP-3 and TIMP-1) as well as on mRNA expression of
ADAMTS-4 (aggrecanase) and COX-2 was studied in cultured
synovial fibroblasts.
Methods: Rheumatoid synovial fibroblasts were isolated from
patients who underwent a total joint replacement. Cells at passage
3–8 were stimulated with 1ng/ml IL-1β and/or TNFα with or
without preincubation with 0.001–30µM RWJ-67657. RNA isola-
tion and RT-PCR was performed after 6 hour stimulation and
protein levels in supernatants were measured by ELISA after
48 hour stimulation.
Results: RWJ-67657 induced a dose-related decrease in IL-6, IL-8
and MMP-3 production, both after IL-1β and TNF-α stimulation.
Inhibition of MMP-1 was seen only at high levels of RWJ-67657.
TIMP-1 was produced constitutively and was not affected by stim-
ulation or inhibition. These findings were all confirmed by mRNA
expression studies. COX-2 mRNA expression was induced both by
IL-1β and TNFα and could be inhibited by RWJ-67657.
ADAMTS-4 mRNA expression was only seen after IL-1β stimula-
tion, which could be inhibited by RWJ-67657.
Conclusion: RWJ-67657 is a potent inhibitor of cytokine and
MMP production, as well as of their mRNA expression in stimulated
RA synovial fibroblasts. Also COX-2 and aggrecanase mRNA
expression was inhibited by RWJ-67657. Thus, inhibition of the
p38 MAPK pathway by RWJ-67657 effectively leads to inhibition
of different inflammatory mediators produced by rheumatoid syn-
ovial fibroblasts. Therefore, RWJ-67657 could be of therapeutic
significance in RA.
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Fibroblast-like synoviocytes from rheumatoid
arthritis patients express less flice-inhibitory
protein than FLS from osteoarthritis, trauma and
prosthesis loosening patie
TCA Tolboom, JP Medema, EJ Pieterman, FC Breedveld,
TWJ Huizinga, REM Toes
Leiden University Medical Center, Leiden, The Netherlands
Rheumatoid arthritis (RA) is characterized by hyperplasia of the
synovium and degradation of cartilage by fibroblast-like synovio-
cytes (FLS). The hyperplasia is thought to be a result of an imbal-
ance between proliferation and apoptosis. Proliferation and
apoptosis can be regulated by death receptors like TNF receptor
and Fas. TNF is abundantly expressed in the rheumatoid synovium
and could contribute to the hyperplasia by promoting proliferation
and/or inhibition of apoptosis. In this study it was investigated
whether overexpression of flice inhibitory protein (FLIP), a protein
that inhibits death receptor mediated apoptosis, could potentially
be involved in the hyperplasia of FLS. Epression of FLIP was inves-
tigated using a western blot and was seen in all samples tested,
but most expression was seen in two trauma patients (n=3), one
OA patient (n=2) and two patients with prosthesis loosening
(n=3). RA patients (n=3) showed the least expression of FLIP (see
figure 1). Thus, in RA FLS no overexpression of FLIP was
observed, therefore it is unlikely that FLIP contributes to resistance
to apoptosis of FLS and hyperplasia in the rheumatoid synovium.
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Chronic exposure to TNF activates distinct TNF-R
signaling pathways favouring cell survival in
T lymphocytes
AP Cope, P Vagenas, M Panesar, JM Clark
Kennedy Institute of Rheumatology, London, United Kingdom
Tumour necrosis factor α (TNF) is a multipotent cytokine. Its role in
the pathogenesis of rheumatoid arthritis (RA) is now well estab-
lished. However, the signaling pathways activated by TNF in the
context of chronic inflammation are less well understood. We have
previously reported that chronic as opposed to acute TNF expo-
sure induces non-deletional and reversible T cell hyporesponsive-
ness to T cell receptor ligation. To explore this further, we set out
to explore more precisely how TNF signals in T lymphocytes, and in
particular to determine whether chronic exposure to TNF activates
a cascade of signaling pathways which are qualitatively or quantita-
tively distinct from those activated following short term stimulation.
Initial experiments revealed that the p55 TNF-R is necessary and
sufficient to induce T cell hyporesponsiveness. Accordingly, we
focussed subsequent studies on p55 TNF-R signaling in a murine
T cell hybridoma model. Over 8 days, repeated stimulation of
T cells with pM doses of TNF leads to chronic, stable cytokine
exposure throughout the culture period. At this low dose NF-κB is
activated, while activation of other p55 TNF-R signaling pathways
is much less pronounced. Within minutes of TNF-R ligation, high
dose (nM) TNF induces strong activation of NF-κB and JNK in
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Figure 1
Western blot showing expression of human FLIP in several patients. 
#, Trauma patients; RA, rheumatoid arthritis; PL, prosthesis lossening
patients.control T cells. In contrast, TNF-R ligation of T cells chronically
exposed to low dose TNF leads to attenuation of JNK activation,
while activation of NF-κB and ERK are spared. Preliminary data
indicate that translocation of RelA to the nucleus is enhanced and
sustained in TNF treated T cells. Together, the data indicate that
the signaling pathways in T cells exposed to inflammatory cytokines
for prolonged periods may be distinct from those activated by
cytokines over much shorter periods. We speculate that in dis-
eases such as RA, T cell effector responses may be promoted by
selective activation of the ERK and NF-κB pathways, which
promote T cell survival. The data also predict that the gene expres-
sion signature arising from chronic TNF stimulation should be dis-
tinct from the programme of gene transcription arising from short
term TNF-R engagement.
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Prolonged stimulation by TNF uncouples T cell
receptor (TCR) signalling pathways at many levels
JM Clark*, P Isomaki*, M Panesar*, A Annenkov†,
Y Chernajovsky†, AP Cope*
*Kennedy Institute of Rheumatology, London, United Kingdom
†SBH and RLH School of Medicine, London, United Kingdom
CD4+ cells at sites of inflammation such as the rheumatoid joint
exhibit profound proliferative hyporesponsiveness. We recently
demonstrated that expression of the zeta chain of the TCR (TCR
zeta) was down-regulated in TNF-treated T cells. Reduced expres-
sion of TCR zeta, together with impaired assembly and stability of
the cell surface TCR/CD3 complex, may uncouple proximal signal
transduction pathways from the TCR. We have proposed that sig-
nalling pathways downstream of the TCR may be attenuated as a
result, and that this may contribute to the hyporesponsive pheno-
type. A T cell hybridoma cell line was generated which expressed a
single-chain Fv/TCR zeta chimaeric receptor (C2-zeta) under
control of retroviral LTR: TNF was not expected to affect expres-
sion of C2-zeta. We now report that the receptor-proximal tyrosine
phosphorylation responses of these cells were reduced after pro-
longed TNF-treatment, even though C2-zeta expression was
unchanged. Furthermore, while the amplitude and duration of
calcium release from intracellular stores were slightly lower in TNF-
treated T cells, there was a marked attenuation of capacitative
calcium entry in these cells. In addition, PMA- and ionomycin-stimu-
lated IL-2 production was also suppressed in cells that had under-
gone prolonged culture in TNF. These data indicate that chronic
exposure to TNF attenuates a number of signal transduction events
downstream of the TCR, independently of TNF-induced suppres-
sion of TCR zeta expression. Such changes may account, in part,
for the profound hyporesponsiveness of T cells at sites of inflam-
mation.
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Constitutively activated N-Ras stimulates LFA-1-
dependent adhesion in rheumatoid arthritis
synovial fluid T lymphocytes
KA Reedquist*, PHJ Remans†, SI Gringhuis†, KMT de Bruyn‡,
S Rangarajan‡, JL Bos‡, PP Tak*
*Academic Medical Center, Amsterdam, The Netherlands
†Leiden University Medical Cent, Leiden, The Netherlands
‡Utrecht Univ Medical Center, Utrecht, The Netherlands
Synovial fluid (SF) T lymphocytes isolated from rheumatoid arthritis
(RA) patients display constitutive activation of the integrin LFA-1.
LFA-1-dependent T cell interactions with ICAM-bearing fibroblast-
like synoviocytes and macrophages contribute to the inflammatory
state of the joint via retention of T lymphocytes in the synovium and
induction of inflammatory cytokines. SF components, notably
TGF-β, are sufficient and required to sustain activation of LFA-1 in
SF T lymphocytes, but little is known about the intracellular sig-
nalling pathways regulating LFA-1-dependent adhesion in SF
T lymphocytes. We have recently found that deregulated signalling
via the small GTPases Ras and Rap1 is responsible for chronic
oxidative stress in SF T lymphocytes. Although activated Rap1 is a
critical mediator of T cell receptor and CD31 -stimulated LFA-1
adhesion, SF T lymphocytes adhere via LFA-1 in the complete
absence of Rap1 signalling. We find that both N-Ras and K-Ras
isoforms of Ras are constitutively activated in SF T cells, and that
transient expression of activated N-Ras, but not K-Ras or H-Ras,
stimulates LFA-1-dependent adhesion in Jurkat T lymphocytes.
Adhesion induced by N-Ras is insensitive to overexpression of the
Rap1 negative regulatory protein RapGAP, consistent with the
observation that SF T cells are highly adherant despite unde-
tectable levels of activated Rap1. We provide pharmacological evi-
dence indicating that N-Ras and Rap1 induce adhesion by distinct
signalling mechanisms. Identification of N-Ras as a key intracellular
signalling protein mediating lymphocyte retention in RA joints pro-
vides potential targets for new therapeutic strategies for RA.
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Potassium calcium-dependant BK channel: a
potential membrane target of estrogens in human
osteoblasts
VB Breuil*, G Romey†, L Euller-Ziegler*, B Rossi*, H Schmid-
Antomarchi*
*INSERM U 364 Faculté de Médecine-Pasteur, Nice, France
†CNRS U145, Valbonne, France
Estrogens have been recognized for many years for their positive
effects on bone. However, their mechanisms of action are still only
partially resolved. Although it is generally accepted that estrogens
act at genomic level by binding to intracellular estrogen receptor,
they trigger nongenomic effects mediated by plasma membrane
receptor. One of these is to increase activity of the BK channel in
many cells types (smooth muscle and vascular endothelium), but
this has never been reported in bone. BK channels are composed
of alpha (encoded by Slo gene) and beta subunits. The alpha
subunit forms the K+/–selective pore, while beta subunits influ-
ence the pharmacology, kinetics, and voltage/calcium sensitivity of
the BK channel. β1 and β4 subunits have been reported to
mediate estrogen effects on the BK channel. In this study, we have
shown that primary human osteoblasts, and 3 cell lines of human
osteosarcoma (MG63, SaOs2, CAL72) express the Slo protein
(western blot). Using RT-PCR, we observed in all these cells the
expression of the 4 beta subunits (β1, β2, β3, β4). In electrophysi-
ology analysis, we observed a calcium-induced potassium current
of high conductance. As expected, β1 subunit expression induced
Charybdotoxine and Iberiotoxine (classical inhibitors of the BK
channel) resistance of the BK channel. We investigated whether
17β estradiol increased the probability of the BK channel opening
(NP0). Our data indicate that 17β estradiol (5nM) increase BK
channel activity, shedding a new light on the nongenomic effects of
estrogens and opening new ways for therapeutic development.
Available online  http://arthritis-research.com/supplements/4/S151
Molecular mechanisms of resistance to disease
modifying antirheumatic drugs (DMARDs)
G Jansen, J van der Heijden, RJ Scheper, BAC Dijkmans
Vrije Universiteit Medical Center, Amsterdam, The Netherlands
Background: Drug resistance is a common cause of treatment
failure in infectious and neoplastic diseases. Relatively little is
known about the molecular mechanisms of resistance to DMARDs.
Objective: To obtain insight into the onset and molecular mecha-
nism(s) of resistance to 2 DMARDs: 1) the antimmalarial chloro-
quine (CHQ) and 2) sulfasalazine (SSZ), an inhibitor of the
activation of NF-κB.
Methods: Human CEM (T) cells were used as an in vitro model
system of a target cell in rheumatoid arthritis (RA). Resistance to
CHQ and SSZ was provoked by growing CEM (T) cells in step-
wise increasing concentrations of either of these DMARDs.
Results: Over a period of 5 months, CEM (T) cells developed a
level of 4–5-fold resistance to CHQ and SSZ. The molecular basis
of CHQ resistance appeared to be due to a 5-fold overexpression
of one of the ATP-Binding Cassette (ABC) drug efflux proteins; the
multidrug resistance-associated protein 1 (MRP1). Consistently,
blockers of MRP1 (MK571 and probenecid) reversed CHQ resis-
tance in CEM/CHQ cells. The molecular basis of SSZ resistance
appeared to be due to a marked overexpression of another ABC
protein; the breast cancer resistance protein (BCRP). A blocker of
BCRP reversed resistance for SSZ in CEM/SSZ cells by more
than 50%. Beyond this, CEM/SSZ revealed a diminished basal
level of expression of cytoplasmic phosphorylated IκB-α and
nuclear NF-κB(p65).
Conclusions: Members of the ABC family of drug efflux pumps
(i.e. MRP1 and BCRP) can confer resistance to DMARDs (CHQ
and SSZ, respectively). This result warrants further investigations
into the contribution of drug efflux pumps in treatment failure of RA
patients with DMARDs.
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Deregulated Ras and Rap1 signaling in
rheumatoid arthritis T cells leads to persistent
production of free radicals
PHJ Remans*, KA Reedquist†, JL Bos†, CL Verweij*,
FC Breedveld*, JM van Laar*, SI Gringhuis*
*LUMC, Leiden, The Netherlands
†UMC, Utrecht, The Netherlands
Background: We have previously found that key Ras family signal-
ing molecules, H-Ras and Rap1, are deregulated in SF T lympho-
cytes: Ras is constitutively active, whereas Rap1 can not be
activated. Here we report that similar signaling events in Jurkat
cells lead to the persistent production of intracellular reactive
oxygen species (ROS), mimicking the hyporesponsiveness of syn-
ovial T lymphocytes.
Methods:  Jurkat cells were cotransfected with pCMV-CD20
expression plasmid to differentiate between transfected and
untransfected cells and 20 µg expression plasmid encoding for
RasV12, RasN17; RasV12/G37, RasV12/E38, RasV12/C40, Rlf-
CAAX, RalV23, RalN; RapV12, RapGAP, RapN17 RasV12/G37,
RasV12/E38, RasV12/C40. For ROS determination, cells were
first stained with CyCr CD 20 for detection of positive transfected
cells. CD20-pos cells were analysed on a FACScan for the mean
fluorescence intensity of oxidated DCF (di-chlorofluorescin), as a
measurement for the presence of intracellular ROS.
Results: 1) Treatment of either PB T lymphocytes or Jurkat cells
with either anti-CD3 antibodies or PMA/I leads to a rapid and tran-
sient generation of intracellular ROS which was maximal
2–5 minutes poststimulation. 2) In Jurkat, expression of Ras is suffi-
cient to induce the generation of ROS, in a Ral dependent manner
and Ras is required for TCR and PMA/ionomycine induced ROS3.
Consitutively active Rap1 suppressed TCR, TPA and Ras-induced
ROS production in a PI3-kinase dependent manner, while inactiva-
tion of the Rap signalling pathway sensitized T cells to agonist-
induced ROS generation.
Conclusions: 1) Rap1 GTPase plays a critical role in the termina-
tion of transient ROS production in T lymphocytes following
agonist stimulation. This is unlikely due to competitive sequestra-
tion of Ras effectors by Rap1 as Rap1-dependent inhibition of
ROS is PI 3-kinase-dependent, while Ras-induced ROS generation
is Ral-dependent. 2) As the chronic oxidative stress observed in SF
T cells can be mimicked by transient transfection of Jurkat cells
with interfering Rap1 proteins, we hypothesize that deregulation of
Rap and Ras are the critical events leading to the disturbed intra-
cellular redox balance that underlies the hyporesponsiveness of
Synovial T cells in rheumatoid arthritis.
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Induction of apoptosis by polyamine metabolites
in immunocompetent cells and different tumor cell
lines
H-M Lorenz, M Schiller, C Gabler, N Blank, M Kriegel, S Winkler,
JR Kalden
University of Erlangen-Nuremberg, Erlangen, Germany
Polyamines (PAs) are involved in regulation of cell growth and cel-
lular survival by interacting with processes like translation, tran-
scription or ion transport. It is described that polyamines can
induce apoptosis in mesenchymal cell lines. The aim of our study
was to analyze whether the physiological PAs (putrescine, spermi-
dine or spermine) or the PA-derivate deoxyspergualin (DSG), a
novel immunosuppressant, induce apoptosis in immunocompetent
cells. Furthermore, we wanted to investigate which molecular
mechanisms are involved in the execution of the cell death
program. By means of flow cytometric analysis we found an induc-
tion of apoptosis by spermine (Spm) and DSG in quiescent and
activated PBMCs, PHA generated lymphoblasts, and various tumor
cell lines (Jurkat, SKW-3, U937). Moreover, DSG and Spm trig-
gered apoptosis in human Fas-deficient cells and in cell lines
MV 4.11. and RS 4.11., which are described to be resistant to
apoptosis induction by many conventional chemotherapeutic
agents. Apoptosis induction after Spm or DSG treatment was
dependent on caspase activity and associated with a decrease in
mitochondrial membrane potential and Bcl-2 expression. In order
to test whether PAs mediate their proapoptotic effects through
metabolites resulting from PA catabolism, we tested different
antagonists of PA degrading enzymes or PA metabolites. We show
that aminoguanidine (inhibition of PA oxidase), aldehyd-dehydroge-
nase (degradation of PA-aldehydes) or N-acetyl-cystein (prevention
of PA-induced glutathion depletion) prevented PA-mediated apop-
tosis. Acrolein, and PA-related aldehyde, could induce pro-
grammed cell death in our system. We conclude that PA
aldehydes and PA-triggered glutathion depletion cause apoptosis
in immunocompetent cells and apoptosis-resistant tumor cell lines.
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TRAIL-mediated enhancement of collagen
production by human lung fibroblasts
VV Yurovsky
University of Maryland, Baltimore, Baltimore, MD, USA
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is
a member of the TNF family that induces apoptosis in a variety of
transformed cell lines and in normal human hepatocytes in vitro.
The expression of TRAIL was found in CD8 T cells that had under-
gone oligoclonal expansion in the lungs of patients with systemic
sclerosis (scleroderma) and were able to stimulate collagen pro-
duction in lung fibroblasts in vitro. Among the family members,
TRAIL displays highest homology to CD95 ligand, a receptor of
which may not only mediate apoptosis of T cells, but also mediate
the proliferation of normal human fibroblasts. Considering struc-
tural and functional similarities between TRAIL and CD95 ligand,
we examined the effects of soluble TRAIL on normal human lung
fibroblasts. Collagen α2(I) mRNA expression was assessed by
real-time RT-PCR, with ribosomal protein S9 as an internal stan-
dard. Total soluble collagen was measured in culture supernatants
using the Sircol Biocolor Assay. Both normalized α2(I) collagen
mRNA expression and total soluble collagen secretion were
increased upon TRAIL stimulation, with peak response (>5-fold
increase) at 10ng/ml TRAIL. DNA microarray hybridization
revealed 78 genes involved in signal transduction, DNA transcrip-
tion, and tissue remodeling, whose expression level increased, and
8 genes whose expression level decreased >2.5-fold in compari-
son with quiescent fibroblasts. Augmented expression of a number
of genes involved in the TGFβ pathway suggested that TRAIL
might induce TGFβ-mediated autocrine and/or paracrine stimula-
tion of fibroblasts. This was confirmed by the ability of anti-TGFβ
antibody to inhibit the effects of TRAIL on collagen production by
fibroblasts. DNA mobility shift assay also revealed TRAIL-induced
increase in protein binding to the collagen promoter that was sub-
stantially inhibited by consensus oligonucleotide for Smad3/4,
mediators of TGFβ signaling. These data suggest that TRAIL can
enhance extracellular matrix synthesis in fibroblasts by triggering
TGFβ production, which acts in autocrine manner.
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Anatomic localization of dendritic cells subsets
and plasmacytoid-like Th1 T lymphocytes in
rheumatoid synovium: correlation with selective
chemokine expression
M Page*, S Lebecque†, P Miossec‡
*INSERM U403, Lyon, France
†Schering-Plough Laboratory, Dardilly, France
‡Hôpital Edouard Herriot, Lyon, France
Rheumatoid arthritis (RA) can be considered as an ectopic lym-
phoid organ. This suggests a role for chemokines in the migration of
T lymphocytes and dendritic cells (DCs) leading to the local organi-
zation that is characteristic of the follicular structure of RA synovium.
To clarify whether DCs reach the synovium as mature cells or
undergo local maturation, we characterized, by immunohistochem-
istry, the different DC subsets and their association with IL-17 and
IFN-γ-producing T cells. The study was done in 12 RA synovium
using tonsils as positive control. Immature and mature DCs were
defined by expression of CD1a and DC-LAMP/CD83 respectively.
Immature CD1a+ DCs were mainly detected in the lining layer
whereas mature DCs were exclusively detected in the perivascular
or lymphocytic infiltrates. The lack of coexpression of DC-LAMP and
CD1a indicated the presence of independent immature and mature
DC subsets. IL-17 and IFN-γ-producing T cells were detected at the
periphery of the lymphocytic infiltrates. They had a plasmacytoid-like
appearance but staining for immunoglobulin light chains was nega-
tive. A similar morphotype was also observed in stimulted PBMC.
To define the DC and Th1 lymphocytes migration pattern, we
focused on the expression of chemokines and their associated
receptors CCL20/CCR6 controlling the migration of immature DCs
and activated T lymphocytes, and CCL21/CCR7, CCL19/CCR7
involved in mature DC and T lymphocyte homing. CCL20 was
expressed in the lining layer and to a lower extent in the lymphocytic
aggregates. CCL20 colocalized with its receptor CCR6. CCL20-
producing cells were associated with CD1a+ immature DCs or
IL-17-producing T cells, suggesting the contribution of CCL20 to
the homing of CCR6+DC and CCR6+Th1 cells to RA synovium.
CCL21 and CCL19 were only detected in the perivascular aggre-
gates as observed for their receptor CCR7. Close association
between CCL19, 21, CCR7, and mature DCs or IL-17-producing
T cells argues for a role for these chemokines in the homing of
CCR7+ DCs and CCR7+IL-17-producing T cells in perivascular
infiltrates. The role of DCs and T lymphocytes in disease initiation
and perpetuation makes the chemokines, controlling their migration,
a potential therapeutic target.
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IL-18 correlates positively with CRP and Il-1Ra but
not with DAS28 or bone erosion in patients with
rheumatoid arthritis
H Nielsen*, P Roux-Lombard†, J-M Dayer†
*Division of Rheumatology and Endocrinology, Herlev Hospital,
University of Copenhagen, Denmark
†Division of Immunology and Allergy Division, University Hospital of
Geneva, Switzerland
We conducted a study testing the hypothesis that IL-18 predicts
disease activity in patients with rheumatoid arthritis (RA), as mea-
sured by the number of swollen joints (40 joint counts), DAS28,
the sedimentation rate and bone erosion. The study consisted of
57 patients with RA and 20 control subjects. The mean age of the
patients was 51 years (range 29 to 75 years). The duration of the
disease averaged 7.3 years (range 0 to 30 years). The numbers
(means) of swollen and tender joints were 5.2 and 5.5 respectively.
The mean activity disease score (DAS28) averaged 4.9 (range
0.6 to 11). Methotrexate and systemic glucocorticoids were admin-
istered to 40% and 30% of the patients, respectively. IL-18 was
significantly increased in RA patients as compared to controls. The
plasma concentration of IL-18 averaged 231 and 144pg/ml in RA
patients and controls (P<0.001). DAS28, CRP, sedimentation
rate and IL-18 positively correlated with the plasma IL-1Ra concen-
tration (P<0.001, P<0.001, P<0.001 and P<0.002), respec-
tively. Stepwise backward and multiple regression analyses
demonstrated that the plasma concentration of IL-1Ra correlated
positively with sedimentation rate, serum triglycerides and bone
erosion (r=0.74; P<0.001). Plasma IL-18 correlated positively
with CRP (r=0.36; P<0.007) and IL-1Ra (r=0.42; P<0.002) but
not with the overall disease activity (DAS 28) or bone erosions. S-
triglycerides correlated positively with IL-1Ra and IL-18 (P<0.002,
P<0.05), respectively. Although IL-18 correlated positively with
CRP and IL-1Ra in RA, we were unable to demonstrate any signifi-
cant correlation with clinical disease score in terms of DAS28,
disease duration or bone erosion.
Acknowledgement: Supported by the Danish Rheumatism
Association.
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Adenoviral transfer of murine Oncostatin M
induces inflammation and bone apposition in
joints of IL-1, IL-6 and TNF-α α deficient mice
ASK de Hooge*, FAJ van de Loo*, M Bennink*, CD Richards†,
OJ Arntz*, WB van den Berg*
*Rheumatology Research Laboratory, Nijmegen, The Netherlands
†McMaster University, Hamilton, Canada
The IL-6 family member Oncostatin M (OSM) is expressed in the
joints of rheumatoid arthritis patients. Murine OSM was expressed
in the joints of naive wild-type mice by an adenoviral vector
(AdmuOSM). This induced inflammation. Gene expression for IL-1,
IL-6 and TNF-α were greatly enhanced in the inflamed synovium.
To determine the role of these cytokines in the AdmuOSM induced
inflammation, we injected this vector in IL-1, IL-6 or TNF-α knock-
out (ko) mice. Both IL-1 and TNF-α ko mice showed reduced acute
inflammation. Inflammation at day 14, however, was not reduced
compared to wild-type mice. AdmuOSM induced inflammation in
IL-6 ko mice did not differ from wild-type inflammation. In all the
mice examined, cartilage proteoglycan depletion occurred. Deple-
tion of proteoglycans not only occurred in the articular, but also in
the epiphyseal cartilage. Early during the inflammation, the perios-
teum became activated and new bone apposition took place along
the femur and tibia. These results suggest an important and inde-
pendent role for OSM in joint pathology. Furthermore, they show
that overexpression leads to damage to the epiphysis and bone
apposition.
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Effect of IL-18 on synovial cell subsets and its
regulation by IL-18BP
M Kawashima, P Missec
INSERM U403, Lyon, France
IL-18 has multiple biological activities that are important in generat-
ing Th1 responses and inflammatory tissue damage. IL-18 has mol-
ecular similarity with IL-1, and IL-18 receptor (IL-18R) belongs to
the superfamily of IL-1 receptor. In our previous studies, IL-18 was
detected in both synovial fluid and serum samples from patients
with rheumatoid arthritis (RA) and serum IL-18 levels correlated
with disease activity as assessed by levels of serum CRP and ery-
throcyte sedimentation rate. We then examined the synovial
expression of IL-18 in RA. Isolated RA tissue cells could sponta-
neously produce high amounts of IL-18 in culture. In RA synovium,
IL-18-positive cells were frequently located in both the lining and
sublining layer, but not in lymphocyte aggregates. Both CD14+
macrophages and synoviocytes isolated from RA synovium
expressed detectable levels of IL-18 mRNA. Using IL-1 as a posi-
tive control, we next examined the effect of IL-18 on IL-6 produc-
tion in RA synoviocyte culture. In contrast to IL-1, IL-18 has no
effect on IL-6 production from RA synoviocyte at both mRNA and
protein levels. This lack of response appears to be related to
defective receptor expression. Isolated RA tissue cells as well as
nonstimulated RA synoviocytes expressed detectable levels of
mRNA of IL-18R alpha chain, but IL-18R beta chain, which is criti-
cal for IL-18 signal transduction, was detected in RA tissue cells
but not in purified synoviocytes, even if these cells were stimulated
with IL-1β, TNF-α, or supernatant of RA synovium culture. RA syn-
ovial cells responded to IL-18. IFN-γ production by IL-12-stimu-
lated RA synovial tissue cells was synergistically enhanced by
IL-18, and it was partially inhibited by addition of IL-18 binding
protein (IL-18BP). Upregulation of IL-18R beta mRNA levels in RA
synovial tissue cells with IL-12 stimulation could explain this
synergy. These results indicate a complex effect of IL-18 on various
cell subsets found in RA synovium. IL-18 appears to further
enhance the Th1 promoting activity of IL-12, an effect which is reg-
ulated by IL-18BP.
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The expression of IFN-β β in synovial tissue from
rheumatoid arthritis patients compared to
osteoarthritis and reactive arthritis patients
J van Holten, TJM Smeets, MC Kraan, PP Tak
Academic Medical Center, Amsterdam, The Netherlands
Objective: IFN-β may have anti-inflammatory effects in rheumatoid
arthritis (RA) patients through inhibition of the production of proin-
flammatory cytokines like TNF-α. Increased IFN-β production in RA
synovium could represent a reactive attempt to inhibit the inflam-
matory cascade. The aim of this study was to determine the
expression of IFN-β in synovial tissue of patients with RA,
osteoarthritis (OA), and reactive arthritis (ReA).
Methods:  Synovial biopsy specimens were obtained by needle
arthroscopy from 15 RA patients, 10 patients with inflammatory
osteoarthritis (OA), and 5 patients with reactive arthritis (ReA).
Immunohistologic analysis was performed using a monoclonal anti-
body specific for IFN-β (PBL). Bound antibody was detected
according to a 3-step immunoperoxidase method. Stained sections
were evaluated by computer-assisted image analysis.
Results: IFN-β was abundantly expressed in the synovial tissue of
RA patients, especially by fibroblast-like synoviocytes. Digital
image analysis using a standardized program revealed a statisti-
cally significant increase in the mean integrated optical density for
IFN-β expression in RA synovial tissue compared with controls (RA
1900±514 vs. OA 447±171, and ReA 358±195) (P<0.04). The
specific upregulation of IFN-β expression was also observed when
the results were controlled for cell numbers (P<0.02).
Conclusions: The increased expression of IFN-β in RA synovium
suggests activation of an immunomodulatory mechanism that could
inhibit synovial inflammation.
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BiP may have an immunoregulatory function
mediated through IL-10 production
VM Corrigall, MD Bodman-Smith, GS Panayi
GKT School of Medicine, London, United Kingdom
Aim: We have recently described BiP, a ubiquitous chaperone
protein and member of the heat shock protein 70 family, as an
autoantigen in rheumatoid arthritis (RA). Animal studies showed
that pretreatment with BiP conferred protection from adjuvant
arthritis in rats and collagen induced arthritis in mice.
Methods: Peripheral blood mononuclear cells (PBMC) were stimu-
lated with recombinant human (rhu) BiP, rhu β-galactosidase
(β-gal) and lipopolysaccharide (LPS) in the presence or absence of
polymyxin B (polyB). Supernatants were collected after 24 hours
and IL-10, TNF-α, IL-1β were measured by ELISA. Proliferation
was measured by uptake of tritiated thymidine following stimulation
of PBMC by tuberculin PPD in the presence and absence of BiP at
5 days.
Results: BiP induced production of IL-10 was significantly higher
than that induced by β-gal (P=0.008) and LPS (P=0.033).
Polymyxin B caused no inhibition of cytokine release following rhu
BiP stimulation (-polyB: 4.8±1.5ng/ml vs. +polyB: 4.6±1.6ng/ml)
although IL-10 secretion by rhu β-gal (-polyB: 4.3±1.1ng/ml vs.
+polyB: 1.7±0.4ng/ml) and LPS (-poly B: 3.2±0.8ng/ml vs.
+polyB: 1.6±0.7ng/ml) was significantly reduced. BiP stimulation
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none was detectable 96 hours post-stimulation. The proliferative
response of PBMC to tuberculin PPD was significantly reduced by
the presence of BiP (P=0.0128).
Conclusions: The increased production of IL-10 induced by rhu
BiP stimulation was not due to LPS contamination of the recombi-
nant protein. BiP may have an immunoregulatory role mediated
through the production of IL-10.
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The human chaperone BiP stimulates
interleukin(IL)-10 producing CD8 T cells:
implications for rheumatoid arthritis
MD Bodman-Smith, VM Corrigall, DM Kemeny, GS Panayi
GKT School of Medicine, London, United Kingdom
Introduction: Rheumatoid Arthritis (RA) is the most common, crip-
pling autoimmune disease, affecting between 0.3 and 3% of the
population. Our laboratory has implicated the human chaperone,
BiP, in the disease process.
Aims: This study was aimed at dissecting the T cell response to
BiP.
Methods: T cell clones from normal individuals shown to respond
to BiP were generated. The specificity of the clones was deter-
mined and the clonality determined by staining for the Vβ region of
the T cell receptor. Supernatants were taken from the clones and
control cells after stimulation with phytohaemagglutinin and
cytokine production determined by ELISA. Additional phenotypic
investigation was performed by flow cytometry.
Results: Out of the 6 clones isolated, which responded to BiP, 5
expressed CD8 and 1 CD4. Three clones, all CD8+, grew strongly
and were investigated further. T cell receptor usage was deter-
mined in two clones (Vβ 7.1 and Vβ 12) with the Vβ element of the
remaining clone not being recognised by the panel of antibodies
used. All three clones produced IL-10 (80–380pg/ml), with two
producing IL-4 (10–80pg/ml) and IL-5 (>5000pg/ml). One clone
produced both IL-10 and IFNγ (>5000pg/ml). Additional pheno-
typing of these clones showed them to express CD25, CD28,
CD80 and 86 but not CD56 or 57. One clone constitutively
expressed CTLA-4 cytoplasmically.
Conclusions: This study shows that a population of CD8+ T cells,
with the cytokine profile of Tc2 cells, can be stimulated by the
chaperone BiP. These cells may perform a regulatory role in the
normal response to inflammation. The increase in response to this
antigen in the synovial joint in RA may indicate an attempt to regu-
late the ongoing inflammation.
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The effects of interferon-β β (IFN-β β) treatment on
synovial cytokine expression in collagen induced
arthritis in DBA/1 mice
J van Holten*, P Sattonnet-Roche†, C Plater-Zyberk†, PP Tak*,
TJM Smeets*
*Academic Medical Center, Amsterdam, The Netherlands
†Serono Pharmaceutical Research, Geneva, Switzerland
Objective: IFN-β is believed to have immunomodulatory properties
which might have a beneficial effect in rheumatoid arthritis (RA) by
inhibition of TNF-α and enhancement of IL-10 and IL-1RA produc-
tion, as has been shown in vitro. The aim of this study was to evalu-
ate the effect of IFN-β treatment on cytokine expression in vivo in
an animal model of RA.
Methods: DBA/1 male mice with collagen induced arthritis (CIA)
were treated with daily intraperitoneal injections of IFN-β
(2.5mg/day, 1.25mg/day, 0.25mg/day), or NaCL for 7 days
(n=8–10). Treatment started on day 1, which represents the first
day that clinical arthritis was detected in that mouse. The mice
were sacrificed on day 8. Immunohistologic staining was per-
formed on decalcified wax-embedded paw sections with polyclonal
antibodies specific for TNF-α, IL-1β, IL-6, IL-10, and IL-18. The
sections were evaluated by semiquantative analysis on a 5-point
scale (0–4).
Results: There was a statistically significant decrease in the mean
scores for expression of TNF-α and IL-6 in animals treated with the
highest dose of IFN-β (2.5mg/day) compared with the NaCL
control group (TNF-α: NaCL: 2.9±0.3 vs. IFN-β 1.4±0.2) (IL-6:
NaCL: 2.3±0.3 vs. IFN-β 0.9±0.3) (TNF-α:  P<0.05, IL-6:
P<0.05). IL-18 and IL-1β expression tended to be lower in IFN-β
treated animals, but this difference did not reach statistical signifi-
cance. Interestingly, IL-10 production was increased in the IFN-β
treated animals (NaCL: 0.5±0.3 vs. IFN-β: 1.6±0.5), although not
statistically significant.
Conclusion:  The reduced expression of TNF-α, IL-6, IL-1β, and
IL-18 and the increased expression of IL-10 in mice with CIA
treated with IFN-β extends previous in vitro observations. Because
of its immunomodulatory effects, IFN-β is a potential therapy for RA.
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Production of interleukin (IL)-1 receptor antagonist
by human articular chondrocytes
G Palmer*, PA Guerne*, F Mezin*, M Maret*, J Guicheux†,
MB Goldring‡, C Gabay*
*University Hospital Geneva, Geneva 14, Switzerland
†INSERM EM 9903, Nantes, France
‡Harvard Institutes of Medicine, Boston, USA
IL-1 receptor antagonist (IL-1Ra) is a member of the IL-1 family,
which acts as a natural IL-1 inhibitor. The balance between IL-1
and IL-1Ra plays an important role in the course of various inflam-
matory diseases, such as arthritis. IL-1Ra is produced as different
isoforms, one secreted (sIL-1Ra) and three intracellular (icIL-1Ra1,
2, 3), derived from the same gene. We examined the production of
IL-1Ra isoforms by cultured human articular chondrocytes in
response to various cytokines. The concentrations of IL-1Ra were
measured by ELISA in conditioned media and cell lysates. The
levels of IL-1Ra were undetectable in culture supernatants of
untreated cells, but were significantly increased by IL-1β (IL-1).
IL-1Ra secretion was first detectable after 24 hours and increased
progressively thereafter, for at least 72 hours. In contrast, the cell
lysates contained very low levels of IL-1Ra, even in response to
IL-1 stimulation, suggesting that articular chondrocytes produce
essentially the sIL-1Ra isoform. IL-6, which had no effect on its
own, enhanced the effect of IL-1, while dexamethasone (dex) pre-
vented the response. By RT-PCR, we observed that IL-1 and IL-6
induced mainly the production of sIL-1Ra mRNA. Furthermore, IL-1
alone or combined with IL-6 increased the levels of nascent
unspliced sIL-1Ra mRNA, suggesting that sIL-1Ra expression is
regulated at the transcriptional level. Consistently, reporter gene
assays performed in immortalized human chondrocytes, C20/A4,
showed increased sIL-1Ra promoter activity in response to IL-1
and IL-6. In conclusion, human articular chondrocytes produce
sIL-1Ra in response to IL-1. This effect, which is enhanced by IL-6
and inhibited by dex, reflects increased transcription from the
sIL-1Ra promoter. The production of sIL-1Ra by chondrocytes may
have a protective effect against articular inflammatory and cata-
bolic responses.
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Loss of surface CXCR3 expression in the RA
synovial CD3 cells as a result of ligand binding
suggests the mechanism for increased Th1 cell
infiltration
OK Krystufkova*, J Niederlova*, S Ruzickova*, J Sinkora†,
Z Rehakova†, O Horvath‡, J Vencovsky*
*Institute of Rheumatology, Praha 2, Czech Republic
†Institute of Microbiology CAS, Novy Hradek, Czech Republic
‡Institute of Microbiology, CAS, Prague, Czech Republic
Introduction: Inflammatory cell infiltration in synovium is a charac-
teristic feature of rheumatoid arthritis (RA). Chemotactic gradients
of various chemokines are responsible for cell attraction and possi-
bly for their activation. Th1 cells are the predominant T cells in the
synovium and have been shown to express high levels of
chemokine receptors CXCR3 and CCR5.
Aim: To examine a role of CXCR3 and its respective ligands (IP-10
and MIG) in the migration of Th1 cells into the synovial tissue.
Methods:  Synovial tissue samples were obtained from 12 RA
patients undergoing either synovectomy or a total joint replacement.
Cells were released by digestion with collagenase, DNAse and
briefly with hyaluronidase. A three-colour fluorescence analysis was
performed with FITC conjugated anti-CXCR3 MAb (R&D) and with
PE conjugated anti-CD3. Live cells were identified by propidium
iodide. PBCs were stained using the same protocol. Cells were per-
meabilized with IntraPrep for intracellular staining. Cryostat tissue
sections were stained for CXCR3 ligands IP-10 and MIG.
Results:  In the investigated RA patients 18–70% of PB CD3+
cells expressed surface CXCR3. CD3+ population of cells in the
synovium expressed 0–5% of surface CXCR3. The intracellular
CXCR3 was found in 97–100% of synovial CD3+ cells. IP-10 and
MIG were expressed in all tissue samples. This staining was partic-
ularly enhanced in tissues with strong vascularity. Endothelial cells
were strongly positive for IP-10 and weakly positive for MIG.
Conclusions: The intracellular presence of CXCR3 and simultane-
ous loss of surface expression in the synovial CD3+ cells is the
result of internalization of this molecule upon ligand binding. The
presence of IP-10 and MIG in the synovium suggests the possible
method of Th1 cell migration and their further activation.
Acknowledgement: This work was supported by a grant NI/6459
from IGA MZ CR.
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Differential influence of IL-1-β β, TNF-α α, and 
PDGF-BB on the expression of matrix-
metalloproteinases (MMPs) and ‘total’-MMP
activity in early-passage RA- and OA-synovial
fibroblasts (SFB)
RW Kinne*, E Kunisch*, R Winter†, A Roth†
*Experimental Rheumatology Unit, Jena, Germany
†Department of Orthopedics, Jena, Germany
Objectives: To characterize the influence of stimulation with IL-1-β,
TNF-α or PDGF-BB on the mRNA expression of MMP-1 to MMP-19
in rheumatoid arthritis (RA)-SFB and osteoarthritis (OA)-SFB, and to
assess the ‘total’ MMP activity in the supernatants of the cells.
Methods: RNA was isolated from 2nd passage RA- and OA-SFB
(enrichment 98%; with/without stimulation by IL-1-β, TNF-α or
PDGF-BB for 24 hours). The expression of MMP-1 to MMP-19
was analyzed by semiquantitative RT-PCR with gene-specific
primers. ‘Total’ MMP-activity was assessed in the supernatant of
stimulated RA- and OA-SFB using the nonspecific fluorogenic
MMP-substrate Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2.
Results:  No significant differences were observed between
unstimulated 2nd passage RA- and OA-SFB for the expression of
any MMP. Following IL-1-β stimulation, MMP-1, MMP-2, MMP-3,
MMP-9, MMP-10, MMP-13, and MMP-19 were upregulated in RA-
SFB, but only MMP-3, MMP-9, MMP-10, and MMP-12 in OA-SFB.
In addition, MMP-11 and MMP-14 were downregulated in
OA-SFB. TNF-α upregulated MMP-1, MMP-9, and MMP-13, but
downregulated MMP-8, MMP-12, MMP-14, and MMP-19 in RA-
SFB. In OA-SFB, TNF-α upregulated MMP-3, MMP-7, and MMP-9,
but downregulated MMP-8 and MMP-16. Following PDGF-BB
stimulation, MMP-8 was upregulated, but MMP-3, MMP-10, and
MMP-13 were downregulated in RA-SFB. Strikingly, stimulation of
OA-SFB with PDGF-BB led to significant downregulation of 8
MMPs (MMP-1, MMP-2, MMP-3, MMP-8, MMP-11, MMP-12,
MMP-13, and MMP-14). IL-1-β and TNF-α significantly downregu-
lated ‘total’ MMP-activity in the supernatants of OA-SFB, but not in
the supernatants of RA-SFB. In contrast, PDGF-BB downregulated
‘total’ MMP-activity in the supernatants of both RA-SFB and
OA-SFB.
Conclusion:  IL-1-β and TNF-α may contribute to prodestructive
features of RA-SFB by upregulating MMP expression and by failing
to downregulate ‘total’ MMP activity. More extensive downregula-
tion of MMP expression in OA-SFB than in RA-SFB suggests a dif-
ferential, tissue-protective role of PDGF-BB in different
inflammatory joint diseases.
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Heterogeneity in cytokine profile after 
intra-articular steroid treatment
ENG AfKlint, A-K Ulfgren, U Andersson, L Klareskog
Karolinska Institute, Stockholm, Sweden
Introduction: It is well known that intra-articular steroids are effi-
cient and fast in reducing arthritis symptoms. However, treatment
does not exclude long-term morbidity. Earlier studies have shown
individual patterns in cytokine expression both inherently and in
response to treatment. In this study we investigated the effect of ia
steroids on the synovial tissue before and 10 days after treatment.
Patients and methods: Serial arthroscopical synovial biopsies
were taken from patients with knee arthritis, before and ten days
after ia triamcinolone injection. Biopsies were stained for histology,
cytokines, cellmarkers and adhesion molecules using monoclonal
antibodies, and measured by digital analysis or conventional count-
ing of cells. Statistics were performed by Wilcoxon paired t-test.
Results: Almost all patients (10/11) improved clinically and macro-
scopically by arthroscopy. Only ICAM-1 and CD3 were signifi-
cantly reduced. Very small amounts of TNF-producing cells were
observed with a clear trend of reduction, but individual patterns
were observed. No overall changes were observed for CD68/163,
IL-1α or IL-1β.
Conclusion: This is the first study where the cytokine pattern has
been analysed after intra-articular steroid injection and almost all
patients improved clinically. However, there was no reduction in
synovial macrophages, but T-cells as well as ICAM-1 diminished.
No change in IL-1 was detected. TNFα producing cells were
remarkably few with a trend to diminish, but individual patterns
were seen. In this study, steroid treatment did effect the inflamma-
tion but it did not disappear completely microscopically as well as
macroscopically. The therapeutic effects have mostly been short-
lived and this study may provide an explanation for this.
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Local inhibition of endogenous IL-18 through
adenoviral overexpression of IL-18BPc results in
reduced incidence and severity of collagen
induced arthritis in mice
RL Smeets, AAJ van de Loo, LAB Joosten, AJ Arntz,
MB Bennink, WB van den Berg
UMC Nijmegen, Nijmegen, The Netherlands
IL-18 is a member of the interleukin-1 family and plays an important
role in innate and acquired immunity. Previous experiments
focused on IL-18 in experimental arthritis showed that neutraliza-
tion through systemic treatment with either antibodies or IL-18
binding protein (IL-18BP) ameliorated the disease. To study the
local role of IL-18 in arthritis we developed a replication deficient
adenoviral vector containing the murine IL-18BP isoform c gene
(Ad5CMV.IL-18BPc). The neutralizing ability of adenoviral overex-
pressed IL-18BPc on IL-18 response was tested in vitro. Super-
natants of IL-18BP transfected cells significantly inhibited IL-18
induced luciferase production in IL-18 sensitive NFkB luciferase
reporter fibroblasts. Next we injected 1×107 PFU of
Ad5CMV.IL-18BPc or the control vector Ad5CMV.Luc into the
murine knee joint cavity of DBA/1 mice before onset of collagen-
induced arthritis (CIA). IL-18BPc overexpression significantly
reduced local knee joint swelling in CIA with 66% (P<0.001) and
distal paw swelling with approx. 50% (P<0.01) compared to the
control vector. Furthermore, local IL-18BPc resulted in lower serum
levels of IL-6 compared to the control (respectively 5.0 pg/ml and
12.7pg/ml, P<0.001). Serum titers of specific IgG1, IgG2a and
total IgG antibodies directed towards collagen type II showed no
significant differences between control and IL-18BPc treatment,
indicating that the effect seen on arthritis by overexpression of
IL-18BPc in the joint was not caused by an IL-18BPc effect on
humoral immunity. These results clearly show that IL-18 present in
the arthritic joint plays an important proinflammatory role and
demonstrate that adenoviral overexpression of IL-18BPc in the syn-
ovium is an efficacious local treatment in experimental arthritis.
68
The bias for Th1 cell differentiation of rheumatoid
arthritis T cells is characteristic of memory but not
of naive T cells
A Skapenko, J Wendler, PE Lipsky, JR Kalden, H Schulze-Koops
Nikolaus Fiebiger Center for Molecular Medicine, Clinical Research
Group III, and Department of Internal Medicine III, University Erlangen,
Germany and NIAMS, Bethesda, USA
An impaired ability of CD4 memory T cells to differentiate into
immunomodulatory Th2 cells has been documented in patients
with rheumatoid arthritis (RA) and has been implicated in the initia-
tion and perpetuation of the characteristic Th1 dominated rheuma-
toid inflammation. To determine the stage of T-cell maturation at
which the bias for Th1 cell differentiation becomes manifest, we
investigated Th cell differentiation from resting CD4 CD45RA
(naive) and CD45RO (memory) T cells in patients with untreated
early RA (mean disease duration <8 months) and in age- and sex-
matched healthy controls in vitro. No differences in the cytokine
secretion profile, as assessed by flow cytometry, between patients
and control subjects were detected in freshly isolated naive or in
freshly isolated memory T cells. Th2 cells could be induced from
naive T cells in all healthy donors and in all RA patients by priming
with monoclonal antibodies (mAbs) to CD3 and CD28. Exogenous
IL-4 was not required for Th2 differentiation from naive cells and
did not consistently increase Th2 priming efficacy. In contrast to
naive cells, Th2 effectors were effectively generated from memory
T cells by stimulation with anti-CD28 without ligation of the T-cell
recceptor. This mode of stimulation generated Th2 cells from
memory T cells of all healthy controls but in only one third of the RA
patients. The data suggest that CD4 memory T cells from the
majority of patients with early RA manifest a deficiency in their
capacity to differentiate into Th2 effectors. In contrast, naive T cells
are capabale of differentiating into Th2 cells with appropriate stim-
ulation suggesting that the bias in Th1 differentiation of most RA
patients may be acquired during T-cell maturation presumably in
response to antigenic stimulation.
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Induction of Th2 cell differentiation by cognate
interaction of CD4 memory T cells
A Skapenko, PE Lipsky, JR Kalden, H Schulze-Koops
Department of Internal Medicine III, University of Erlangen, Germany
and NIAMS, Bethesda, USA
Th2 cell differentiation can be induced from human CD4 memory
T cells by priming with anti-CD28 without engagement of the TCR.
To test whether CD28 mediated Th2 differentiation from memory
T cells was an effect of a particular anti-CD28 mAb, Th2 differenti-
ation was assessed after priming of purified CD4 memory T cells
with transfected myeloma cells expressing human CD80 and/or
CD86. Whereas the mock control did not induce Th2 differentia-
tion, priming in the presence of myeloma cells expressing CD80,
CD86 or CD80 and CD86 significantly increased Th2 frequencies.
Thus, Th2 differentiation from memory T cells can be induced by
engaging CD28 with its natural ligands, CD80 and/or CD86. We
next evaluated the possibility that activated T cells might prime
bystander T cells for Th2 differentiation. CD4 memory T cells were
activated with mAbs to CD3 and CD28 for five days. Flow cyto-
metric analysis revealed that in contrast to resting T cells, activated
T cells expressed CD80, however, at a low level. CD80 expressing
T cells were fixed and cocultured with freshly isolated, syngeneic,
CD4 memory T cells for five days in the presence or absence of
exogenous IL-4, but without additional stimulatory signals. For
control, priming was performed with fixed syngeneic T cells that
were freshly isolated and, thus, negative for CD80. Priming with
fixed, non-activated syngeneic T cells did not induce Th2 differenti-
ation, even in the presence of exogenous IL-4. In marked contrast,
priming with fixed activated T cells induced significant Th2 differen-
tiation. This effect was dependent on exogenous IL-4, suggesting
that the low levels of CD80 expressed on activated T cells were
not sufficient to induce IL-4 transcription. However, the data indi-
cate, that Th2 differentiation might be induced from bystander
T cells by recently activated T cells through cognate T–T-cell inter-
action involving CD28. TCR independent generation of Th2 effec-
tors might provide a way to control Th1 dominated cellular
inflammation.
Autoantigens and autoantibodies
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Comparison of different immunoassays detecting
anti-chromatin autoantibodies in systemic lupus
erythematosus (SLE)
P Roux-Lombard, S Mormile, JM Dayer
Division of Immunology and Allergy, Geneva, Switzerland
Introduction: Anti-double-strand DNA (dsDNA) autoantibodies are
considered a hallmark of SLE and many assays have been devel-
Available online  http://arthritis-research.com/supplements/4/S1oped to improve the determination of these antibodies. Recently,
autoantibodies to nucleosome, the fundamental unit of chromatin,
have been shown to constitute a new and very specific marker of
SLE.
Methods: To evaluate the diagnostic value of (A) Crithidia lucillae
indirect immunofluorescence (CLIFT), anti-dsDNA immunoassays
using (B) purified dsDNA (Quanta LiteTM dsDNA ELISA INOVA,
San Diego, CA), (C) recombinant plasmid dsDNA (EliATM, Phar-
macia, Freiburg, Germany) and (D) anti-nucleosome immunoassay
(Quanta Lite Chromatin ELISATM, INOVA, San Diego, CA), we
investigated in a prospective study all the sera sent to our labora-
tory for anti-dsDNA detection during 2 months. 122 sera were
enrolled in this study of which 16 appear to be from SLE patients
and we assessed the sensitivity and specificity of the assays. We
also compared a group of 30 SLE patients with other autoimmune
diseases (19 cutaneous lupus, 22 Sjögren’s syndrome, 14 sys-
temic scleroderma) in a retrospective study.
Results: In the prospective study, the sensitivity for SLE was 13%,
53%, 47% and 60% for test A, B, C and D, respectively; the speci-
ficity was 99%, 94%, 94% and 99% for test A, B, C and, respec-
tively. Results were similar in the retrospective study.
Conclusion: Anti-nucleosome autoantibodies are sensitive and
specific markers for SLE. However, other studies are necessary to
evaluate if they are also useful in monitoring disease activity.
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Anti-keratin and anti-cyclic citrullinated peptide
autoantibodies in patients with juvenile idiopathic
arthritis
J Vavrinec*, I Hromadnikova*, K Stechova*, P Vavrincova*,
D Hridelova*, H Nekvasilova†, H Reitzova*
*2nd Medical School, Charles University, Prague 5, Czech Republic
†Immunological Lab Budejovicka, Prague 4, Czech Republic
Objective:  We discuss the presence of anti-keratin antibodies
(AKA) and anti-cyclic citrullinated peptide (anti-CCP) antibodies of
the IgG class in sera of patients with defined juvenile idiopathic
arthritis (JIA) of various subgroups with more than one year dura-
tion of the disease.
Methods: An indirect immunofluorescence test on rat oesophagus
substrate (ImmuGloTM, Immco Diagnostics, Buffalo, USA) and
enzyme-linked immunosorbent assay (Immunoscan RA, Eurodiag-
nostica, The Netherlands) were used for the detection and quantifi-
cation of AKA and anti-CCP antibodies in 140 patients with JIA
(64 male and 76 female) aged 2–47 years (median 16.5 years).
Results:  Overall, AKA were found in 40/140 patients (28.6%,
P=0.04) including 2/11 systemic arthritis (18.2%), 2/32
oligoarthritis (6.3%), 18/52 RF negative polyarthritis (34.6%,
P=0.01), 14/18 RF positive polyarthritis (77.8%, P=0.000002),
2/15 enthesitis related arthritis (13.3%) and 2/3 psoriatic arthritis
patients. AKA were not found in a very small cohort of patients with
extended oligoarthritis (n=4) and unclassifiable arthritis (n=5). Only
7/122 (5.7%) patients were positive for anti-CCP. The correlation
between AKA and anti-CCP was 77.1% (P=0.05).
Conclusion:  We conclude that while AKA antibodies measured
using IIF on rat oesophagus can be detected in patients with definite
JIA with more than 1 year duration of the disease, only rare occur-
rence of anti-CCP was observed. We conclude that AKA occurred
in any JIA patient category, however when statistically compared with
healthy controls significantly higher frequencies were found only in a
cohort of RF positive and RF negative polyarthritis.
Acknowledgement: This research was supported by a grant of
2nd Medical Faculty, Charles University Prague, VZ
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The effect of infliximab on rheumatoid factor and
anti-citrullinated cyclic peptide antibodies
N van Damme, L de Rycke, E Kruithof, IEA Hoffman, EM Veys,
F de Keyser
Ghent University Hospital, Ghent, Belgium
Background: Rheumatoid arthritis (RA) patients are successfully
treated with infliximab (anti-TNF-α therapy). This therapy may
induce autoantibodies like anti-dsDNA antibodies.
Objectives: To investigate the effect of infliximab on rheumatoid
factor (RF) and anti-citrullinated cyclic peptide antibodies (anti-
CCP antibodies).
Patients and methods: 62 patients with refractory RA were
treated with infliximab in an early access program. They received
3mg/kg infliximab IV at week 0, 2, 6 and every 8 weeks thereafter
in combination with MTX. Serum samples were obtained at base-
line and week 30. Samples were tested for RF Waaler-Rose
(SERODIA-RA, Fujirebio inc), RF Latex Fixation (DifcoLaboratories)
and anti-CCP antibodies ELISA (Euro-Diagnostica).
Results:  At baseline, 41/62 RA patients were positive for RF
Waaler-Rose, 39/62 RA patients were positive for RF Latex Fixa-
tion and 41/62 RA patients had a positive testresult for anti-CCP
antibodies ELISA. After infliximab treatment, 33/62 RA patients
were positive for RF Waaler-Rose, 31/62 RA patients were posi-
tive for RF Latex Fixation and we observed a positive test result for
anti-CCP antibodies in the same 41/62 RA patients. McNemar test
revealed a significant paired difference for RF Waaler-Rose
(P=0.039) and for RF Latex Fixation (P=0.021), but not for anti-
CCP antibodies (P=1.0). Wilcoxon Signed Rank Test showed a
significant decrease for RF Waaler-Rose (P<0.001) and for RF
Latex Fixation (P=0.035). No significant difference was observed
for anti-CCP antibodies (P=0.744).
Conclusion:  In RA patients, infliximab treatment results in a
decrease of RF Waaler-Rose and RF Latex Fixation. No difference
considering the anti-CCP antibodies is seen.
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Infliximab induced anti-dsDNA: characteristics of
autoantibody response
PJ Charles*, L Aarden†, RN Maini*
*Kennedy Institute Of Rheumatology, London, United Kingdom
†CLB, Amsterdam, The Netherlands
We have previously been reported that 7–12% of patients with
rheumatoid arthritis develop IgM anti-dsDNA following treatment
with infliximab and that lupus was observed in 1 of 156 patients and
was associated with and IgG and an IgM anti-dsDNA response
(Charles et al. Arthritis Rheum 2000, 43:2883-2900). In this study
we examine the characteristics of the autoantibody response to find
evidence for the involvement of potential mechanisms including up-
regulated synthesis of natural autoantibodies, polyclonal IgM activa-
tion, the production of cross reactive rheumatoid factors, or a
response to apoptotic release of nucleosomal material.
Methods: IgM antibodies to IgG (rheumatoid factor), mitochondr-
ial, microsomal, measles antigens and circulating nucleosome
levels were measured prior to and following infliximab therapy. Sera
containing induced anti-dsDNA antibodies were studied by
immunofluorescent inhibition to examine cross reactivity.
Results:
• IgM antibodies to mitochondrial, microsomal and measles anti-
gens were unchanged following infliximab therapy (pretreat-
ment vs. post-8 weeks=ns).
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human IgG, or histones.
• Levels of circulating nucleosomes fell following infliximab
therapy (pre-treatment vs. post-2 weeks P ≤ 0.02; vs.
post-4 weeks P ≤ 0.05).
Conclusion: We were unable to find any evidence to support a
role for upregulation of IgM natural autoantibodies, a polyclonal
increase in IgM antibodies, cross reactive rheumatoid factors, or
nucleosome release and consequent antigen drive. The induction
of anti-dsDNA antibodies appears to be dependent on an, as yet, ill
understood mechanism.
74
Specificity of rheumatoid synovial B-cell
hybridoma with germline configurated IGVH genes
against human nuclear protein histone
LM Morawietz*, JM Möller*, GF Fernahl*, EC Müller†,
RM Magalhaes*, VK Krenn*
*Universitätsklinikum Charité, Berlin, Germany
†Max-Delbrnck-Zentrum, Berlin, Germany
B cells (plasma cells and B-lymphocytes) belong to the dominant
part of the inflammatory infiltrate in RA synovitis. To disclosure the
nature of antigens involved in the triggering and the perpetuation of
the disease we carried out the study of IgG, a monoclonal B-cell
hybridoma, belonging to the VH3 family (DP 43), from rheumatoid
synovial membrane, produced by electrofusion and without prior in
vitro stimulation. The subject of the study was an RA patient with
definite and active RA, featuring dense inflammatory infiltration with
the occurrence of secondary lymphatic follicles in the affected
joint. This hybridoma was analysed by PCR, immunohistology,
immunoprecipitation and western blot, and the results were corre-
lated with pathological data and parameters of local disease activ-
ity. By PCR we found out that this hybridoma had germline
configuration IgVH genes with R/S ratio=1; it revealed specific
binding (20kDa) to nuclear extract of fibroblasts cell line (Hep2),
later identified by mass spectrometry as the nuclear protein human
histone (1B, 1C, 1D). Being this protein an exclusive nuclear
protein involved in the chromatin condensation, it can be assumed
that its implication in RA will be related to the perpetuation of the
disease and inflammation after massive cell death, due to destruc-
tion of the joint tissues.
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Immunomic analysis of syovial fluid exosomes of
rheumatic diseases patients
A Sternjak*, S Bläß*, S Metzkow*, P Jungblut†, G Burmester*, 
SK Skriner*
*Institute of Rheumatology and Clinical Immunology, Charité Humbolt
University, Berlin, Germany
†Max-Planck-Institute for Infection Biology, Berlin, Germany
In addition to soluble proteins and mediators, cells also release
membrane vesicles in the extracellular environment, exosomes and
apototic blebs. Apoptotic blebs have been studied and contain
multiple autoantigens. Exosomal protein content and its functions
are starting to be unraveled. During an immune response the
40nm particles are formed, on the surface they have Class I and II
antigens as well as viral proteins or other proteins like heatshock
proteins Hsp 70 and 90, or B7 a costimmulatory molecule. Recent
studies showed that exosomes can stimulate T cells directly or
bind to dendritic cells, suggesting a general function for exosomes
in immune response. The mechanism of action in vivo is poorly
understood. Exosomes seem to stimulate T cells and have been
shown to induce tumor rejection when loaded with tumor peptide.
The composition of synovial exosomes has so far not been studied
or compared to other diseases and normals. Autoimmune diseases
like rheumatoid arthitis (RA) are characterized by autoantibodies to
different proteins like BiP, hnRNPs and p205 which has not been
charaterized in its nature. Different synovial exosomes from RA
patients, reactive arthritis, and osteoarthritis patients and controls
have been purified and anlysed for specific autoantigenic content
by immunoblotting. P205 was found in all exosomal preperations in
contrast to Bip and hnRNP A2, which could not be detected in the
synovial exosomes fractions so far. Synovial Exosomal proteins
haved been analysed by immunoblotting after 2D electrophoresis
and immuneprecipitation. Based on that methods the specific
autoantigenic protein content can be analysed now. After revealing
the primary structure and molecular identity of the autoantigens,
recombinant autoantigens will be produced and used for diagnos-
tic as well as immunemodulatory purposes. In summary, the
autoantigenic analysis of synovial exosomes revealed that p205 is
associated with exosomal particles. The investigation of the syn-
ovial exosome protein content as well as the analysis of B and T-
cell sitmulation potential, may thereby possibly lead to novel
diagnostic and therapeutic strategies in rheumatic diseases.
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Protein microarray characterization of
autoantibody responses in rheumatoid arthritis
and systemic lupus erythematosus
W Robinson*, W Huber*, WI van Venrooij†, S Muller‡,
GS Panayi§, C Verweij¶, JS Smolen^, L Steinman*, PJ Utz*
*Stanford University School of Medicine, Stanford, CA, USA
†Katholieke Universiteit, Nijmegen, The Netherlands
‡Institut de Biologie, Strasbourg, France
§King’s College, London, United Kingdom
¶Vrije Universiteit, Amsterdam, The Netherlands
^University of Vienna, Vienna, Austria
In rheumatoid arthritis (RA), systemic lupus erythematosus (SLE),
and other autoimmune rheumatic diseases, our understanding of
the specificity of the autoantibody response and the role of autoan-
tibodies in pathogenesis are limited. We developed antigen
microarray technology to perform multiplex characterization of
autoantibody responses. Antigen microarrays are produced by
attaching thousands of proteins and peptides to addressable loca-
tions on the surface of solid supports using a robotic arrayer.
Arrays are probed with serum from disease and control patients,
followed by anti-human secondary antibodies covalently-conju-
gated to spectrally-resolvable fluorochromes. We initially devel-
oped a ‘connective tissue disease’ array containing structurally
diverse autoantigens including nucleic acids, histones, hnRNPs,
snRNPs, collagens, Ro, La, SCL-70, CENP-B, Jo-1, pyruvate dehy-
drogenase, and post-translationally-modified antigens. Array analy-
sis of serum derived from patients with SLE, rheumatoid arthritis,
Sjögren’s syndrome, mixed connective tissue diseases, sclero-
derma, myositidies, and primary biliary cirrhosis identified autoanti-
body response patterns characteristic of these diseases (Fig. 1).
We are now developing ‘synovial proteome’ arrays to study the
autoantibody responses in RA, and have produced first-generation
arrays containing 450 distinct protein and peptide candidate anti-
gens derived from synovial joints. These include native and cit-
Available online  http://arthritis-research.com/supplements/4/S1rulline-modified filaggrin peptides, native and deiminated fibrinogen
and vimentin, glucose-6-phosphate isomerase, collagen types I, II,
III, IV and V, hnRNP-A2/RA33, hnRNP-D, immunoglobulins,
HCgp39, BiP, and HSPs 60, 65, 70, and 90. We probe our arrays
with sera and synovial fluid from RA and control patients. We are
using our arrays to examine serial serum samples from patients
with early RA to: (1) identify antigens targeted early in disease, and
(2) examine for evidence of B-cell epitope spreading. ‘Synovial pro-
teome’ arrays represent a powerful tool to study the breadth and
specificity of autoreactive B-cell responses, and to identify candi-
date and define relevant autoantigens in RA.
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Do IgA antiphospholipid antibodies have any
clinical importance?
GN Gaspersic, S Cucnik, T Kveder, B Bozic
University Medical Centre, Ljubljana, Slovenia
Antiphospholipid antibodies (aPL) are strongly associated with clinical
manifestations of the antiphospholipid syndrome (APS) such as
thromboembolic events and/or pregnancy loss. IgG anticardiolipin
(aCL) at moderate/high titre and IgG anti-β2-glycoprotein I (aB2GPI)
are closely related to clinical complications, IgM are commonly tran-
sient, present during infections, while IgA are not routinely tested. The
aim of our study was to evaluate the occurence and possible clinical
significance of the IgA isotype of four different aPL: aCL, aB2GPI,
anti-prothrombin (aPT) and anti-annexin V (aANXV) antibodies. Sera
from 92 patients (87 females and 5 males) with systemic autoimmune
disorders (63 with systemic lupus erythematosus (SLE), 19 with sec-
ondary APS (SLE with APS) and 10 with primary APS (pAPS)) were
assayed with four different in-house ELISA tests. For each of the four
antibodies IgG, IgM and IgA isotypes were determined. In evaluating
the association of isotypes with particular clinical features (arterial and
venous thromboses, CNS disorders, abortuses, thrombocytopenia),
IgA isotype did not improve the clinical sensitivity of any measured
antibody. The IgA aB2GPI were the only aPL occuring alone in a sig-
nificant number of patients. Such patients should be followed-up to
provide insight into the possible clinical significance of IgA aB2GPI.
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Cell-free Fc-γ γ receptors IIIb, autoantibodies and
related immune complexes trigger the production
of G-CSF and GM-CSF in nonorgan-specific
autoimmune diseases
V Durand*, Y Renaudineau†, P Youinou†
*Brest University Medical School, Brest, France
†Laboratory of Immunology, France
The Fcγ IIIb and IIa classes of receptors for the Fc portion of IgG
are constitutively expressed in polymorphonuclear neutrophiles
(PMN). High levels of cell-free (CF) Fcγ RIIIb were detected in
nonorgan-specific autoimmune diseases, as well as related autoan-
tibodies (Ab) present in 56, 58 and 51% of the patients with
primary Sjögren’s syndrome, systemic lupus erythematosus and
rheumatoid arthritis, respectively. These autoAb were categorized,
based on the results of an indirect immunofluorescence (IIF) test
for the detection of anti-membrane-bound Fcγ RIIIb Ab, and an
enzyme-linked immunosorbent assay for that of Abs recognizing
only CF Fcγ RIIIb. Those sera positive in the IIF test were not cyto-
toxic ; rather, they enhanced the survival of PMNs (5 methods). The
autoAb-triggered antiapoptotic signal was transduced from
Fcγ RIIIb, either directly or through Fcγ RIIa and/or CD11b, (the
β-chain of the neighboring complement receptor type 3). CF
Fcγ RIIIb produced similar effects, as well as immune complexes
made up of CF Fcγ RIIIb and anti-CF Fcγ RIIIb auto Abs. Anti-
Fcγ RIIIb autoAb-conditioned supernatant had the capacity to
induce the transcription of messenger RNA for G- and GM-CSF,
resulting in the synthesis of these antiapoptotic factors. Such a
delay in apoptosis was associated with a downregulated expres-
sion of Bax, whereas Bcl-2 was unmodified. Differed apoptosis of
PMNs should occur in patients with anti-Fcγ RIIIb autoAbs, particu-
larly in the rheumatoid synovial fluid. Treatment with anti-G- and/or
anti-GM-CSF might thus be proposed.
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Cerebrovascular insult and antiphospholipid
antibodies in young adults
S Cucnik*, N Gaspersic†, U Rot‡, B Bozic†, T Kveder†
*University Medical Centre, Ljubljana, Slovenia
†Dept of Rheumatology, Ljubljana, Slovenia
‡Dept of Neurology, Ljubljana, Slovenia
Antiphospholipid antibodies (aPL) are strongly associated with arte-
rial and/or venous thrombosis and recurrent foetal loss. The only
neurological manifestation satisfying the diagnostic criteria for the
antiphospholipid syndrome (APS) is ischemic cerebrovascular insult
(CVI). Because of previous contradicting reports on the association
between aPL and CVI, we examined the occurrence of different aPL
in a group of patients with CVI without an evident systemic autoim-
mune disease. 39 patients (26 women, 13 men, all under 40 years)
were included in study. Blood withdrawal was performed twice after
CVI at least 8 weeks apart. Sera were tested by enzyme linked
immunosorbent assays (ELISA) for the presence of IgG, IgM and
IgA anti-cardiolipin (aCL), anti-β2-glycoprotein I (aβ2GPI), anti-pro-
thrombin (aPT) and anti-annexin V (aANXV) antibodies. Increased
levels of IgG aCL were found in 3 (8%) patients and for IgA aβ2GPI
in 1 (3%). In all aCL and aβ2GPI positive CVI patients only low pos-
itive levels of antibodies were detected. aPT were completely
absent while aANXV were detected in 4 (10%) patients (3 had IgG
and one IgM). aPL directed against serum antigens did not appear
with a significant frequency in the studied group of CVI patients.
But aANXV, directed against a tissue protein, might be important as
one of the possible markers in at least some patients with CVI.
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Interference of PR3-ANCA with the enzymatic
activity of PR3
AA Rarok*, YM van der Geld*, ATJ Tool†, M de Haas†,
PC Limburg*, CGM Kallenberg*, D Roos†
*University Hospital Groningen, Groningen, The Netherlands
†CLB, Amsterdam, The Netherlands
Introduction: Anti-neutrophil cytoplasmic antibodies (ANCA)
against proteinase 3 (PR3) are strongly associated with Wegen-
er’s granulomatosis (WG) and are thought to be involved in its
pathogenesis. In vitro functional effects of these antibodies have
been suggested to correspond better to disease activity than
levels of PR3-ANCA.
Methods: To investigate the relation between functional effects of
PR3-ANCA and disease activity, we tested IgG from sera of
43 WG patients and four controls for their capacity to interfere
with the proteolytic activity of PR3. Blood was drawn either during
active disease or during remission of WG. The enzymatic activity of
PR3 was determined using MeSuc-AAPV-pNA, casein, and by
complexation of PR3 with α-1-antitrypsin (α-1-AT).
Results: Most of the IgG samples from WG patients inhibited the
enzymatic activity of PR3 and the complexation of PR3 with α-1-
AT. A difference in the capacity to interfere with proteolysis of
casein and with complexation of PR3 with α-1-AT was observed
between samples taken during active disease and during remission
of WG, but this was not observed for the hydrolysis of MeSuc-
AAPV-pNA. However, PR3-ANCA titers giving fifty percent inhibi-
tion of the PR3/α-1-AT complexation and the proteolytic activity of
PR3 for the hydrolysis of MeSuc-AAPV-pNA were lower for remis-
sion samples compared to samples during active disease, indicat-
ing a relatively higher inhibitory activity in the former samples.
PR3-ANCA titers correlated with the inhibitory activity both for
patients with active disease and for patients during remission.
Conclusion: With a fixed amount of IgG, PR3-ANCA-containing
IgG from patients with active disease had a higher inhibitory
capacity towards the proteolytic activity of PR3 than did PR3-
ANCA-containing IgG from patients during remission of WG.
However, when correcting the results for the PR3-ANCA titer,
PR3-ANCA of patients during remission had a relatively higher
inhibitory capacity towards the proteolytic activity of PR3 than did
PR3-ANCA of patients during an active phase. These results may
indicate that PR3-ANCA of patients with active disease recognize
different epitopes on PR3 than do PR3-ANCA of patients during
remission of WG. These findings may have relevance for the patho-
genicity of the antibodies.
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Anti-Ro/SSA antibodies in systemic sclerosis
(SSc): determination of the fine specificity, clinical
and laboratory correlations
C Antonioli, F Franceschini, I Cavazzana, P Airò, E Danieli,
R Bettoni, R Cattaneo
Spedali Civili, Brescia, Italy
Background: The frequency of anti-Ro/SSA in SSc varies from
3% to 11% with immunoprecipitation assays and from 12% to
37% with ELISA. Significant associations were reported between
anti-Ro/SSA and Sjögren’s syndrome, pulmonary involvement and
myositis in patients with SSc.
Objective:  To evaluate the frequency the association of anti-
Ro/SSA antibodies and their fine specificity with clinical and
immunological features in SSc.
Patients and methods: We studied 193 patients with SSc
(58 diffuse, 129 limited and 6 overlap syndromes) attending our
outpatient clinic. Antibodies to ENA were determined by counter-
immunoelectrophoresis (CIE) using rabbit thymus (Peel-Freeze)
and human spleen extract as substrates. ELISA assay with recom-
binant 52 and 60kD Ro proteins (Pharmacia) was performed on
107 sera, cut-off values were determined testing 75 sera from
routine: 50ANA negative and 25ANA positive-ENA negative.
Results:  Anti-Ro was detected by CIE in 12/193 patients (6%)
and by ELISA in 14/107 (13%). As a whole, CIE and/or ELISA
detected the presence of anti-Ro in 20 patients (Ro+). It was sig-
nificantly associated with photosensitivity (P=0.02), xerophtalmia
(P=0.05), raised ESR (P=0.02), hyperγglobulinemia (P=0.002),
anti-La (P=0.004) and antinucleolar antibodies (P=0.02). Anti-
Scl70 antibodies tended to be specifically associated with anti-
Ro60 as compared with anti-Ro52 antibodies (P=0.06). Anti-Ro+
patients had higher incidence of interstitial lung disease and slight
reduction of DLCO at the moment of first evaluation, as compared
with patients Ro– (P=0.06), particularly with the subset anti-
centromere positive (P=0.001). However, decrease of DLCO
during follow-up was more frequent in patients Ro– (P<0.001).
This observation might be partially related to a longer steroid treat-
ment received by patients Ro+ (P<0.03).
Conclusion: Antibodies to Ro/SSA are not infrequently detected
in SSc. They are associated with a subset of disease characterized
by clinical and serological features commonly associated with anti-
Ro/SSA independently from the underlying disease. Anti-Ro+ SSc
patients tended to have an earlier lung involvement apparently less
evolving as compared to anti-Ro– patients.
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Autoantibodies to the TNF-α α translational
regulators TIA-1 and TIAR occur frequently in sera
of patients with SLE and scleroderma
E Jimenez-Boj*, G Schett†, N Kedersha‡, C Zimmermann§,
E Hoefler§, J Smolen¶, P Anderson‡, G Steiner†
*Division of Rheumatology, Vienna, Austria
†University of Vienna, Vienna, Austria
‡Brigham and Women’s Hospital, Boston, USA
§Lainz Hospital, Vienna, Austria
¶University of Vienna, Vienna, Austria
Objective: The two closely related RNA binding proteins TIA-1 and
TIAR are involved in post-transcriptional regulation of TNF expres-
sion by acting as translational silencers via association with the
TNF mRNA. Given that TNF is upregulated in many inflammatory
and autoimmune conditions it was the aim of this study to investi-
gate the possible occurrence of autoantibodies (aab) against TIA-1
and TIAR in patients with rheumatic diseases.
Methods: Recombinant proteins were employed in immunoblotting
studies involving sera of 40 patients with SLE and 20 sera each of
patients with systemic sclerosis (SCL), poly/dermatomyositis
(PM/DM), Sjögren’s syndrome (SS), rheumatoid arthritis (RA),
reactive arthritis (REA) as well as sera of 20 healthy controls (HC).
Results: IgG aab against TIA-1 and/or TIAR were frequently detected
in sera of patients with SLE or SCL: thus, 67% of SLE sera (anti-
TIA1: 52%, anti-TIAR: 47%) and 50% of the SCL sera (anti-TIA1:
40%, anti-TIAR: 40%) contained either of the two aab. These aab
were detected at lower frequency also in sera of patients with PM/DM
(30%), REA (25%), SS (15%) and RA (10%). However, only PM/DM
patients differed significantly (P<0.05) from healthy controls (5%).
Due to the close structural homology between the two proteins the
majority of sera were reactive with both of them suggesting a high
degree of crossreactivity. Nevertheless, some sera contained auto-
antibodies directed specifically to only one of two antigens.
Available online  http://arthritis-research.com/supplements/4/S1Conclusion: Autoantibodies to TIA-1 and TIAR occurred frequently
in patients with SLE and SCL but, interestingly, were rarely
detectable in patients with RA. Thus, these data suggest that in
susceptible individuals systemic upregulation of TNF may lead to
autoimmune reactions against proteins associated with the TNF
mRNA.
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Molecular cloning of candidate antigens
recognized by anti-endothelial cell antibodies
R Revelen, P Youinou, M Dueymes
Brest University Medical School, Brest, France
Anti-endothelial cell antibodies (AECA) have been reported in such
a vast array of conditions associated with vasculitis that the related
autoantigens have become extremely difficult to identify. We have,
therefore, used a molecular cloning approach to define endothelial
cell (EC) target structures by screening a human umbilical vein EC
(HUVEC) cDNA expression library. Total RNA was extracted from
HUVECs and purified by oligo-dT cellulose chromatography. A
commercial kit was used to synthesize cDNA which was inserted
into the EcoRI/XhoI-digested and dephosphorylated lambda ZAP
Express vector. The construct was incorporated into phages and
transformed with E. coli strain XL1 Blue. After the addition of
AECAs, positive clones were isolated in suspending medium, puri-
fied and incorporated again into the XL1. The insert-containing
phagemids were exised from recombinant phages and introduced
into E. coli XLOLR strain. The restriction fragments, obtained from
the cDNA inserts by EcoRI endonuclease digestion, were
sequenced by the dideoxy-chain termination method with two
primers, T3 (AATTAACCCTCACTAAAGGG) and T7
(CGGGATATCACTCAGCATAATG). The sequences were exam-
ined for analogy in the GenBank and EBML nucleic acid data
banks. Two sera, one from a patient with systemic lupus erythe-
matosus (SLE) and another from a patient with Wegener’s granulo-
matosis (WG), both strongly AECA-positive in our in-house
cell-ELISA, were used to screen the bank. The SLE serum recog-
nized methyltransferase, NADH dehydrogenase and unidentified
components, whereas the WG serum recognized methyltrans-
ferase, GAPDH and unidentified structures. AECAs could thus be
associated with a bulk of autoantibodies targeting various
enzymes, or get inside the ECs to bind to such proteins.
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Sensitivity of ANA indirect immunofluorescence
testing for the detection of anti-ENA antibodies
IEA Hoffman, I Peene, EM Veys, F De Keyser
University Hospital Ghent, Ghent, Belgium
Background: Detection of antinuclear antibodies (ANA) is mostly
performed by indirect immunofluorescence (IIF) on HEp2 cells. The
HEp2000 substrate, consisting of HEp2 cells transfected with
Ro60 cDNA, could be a valuable alternative, with increased sensi-
tivity for detecting anti-SSA antibodies. When IIF is positive, further
determination of the fine specificities is performed. However, some
reactivities can be missed on IIF (anti-SSA, anti-Jo1).
Objectives:  1) To compare the performance of the HEp2 and
HEp2000 substrate for ANA detection. 2) To determine the sensi-
tivity of ANA IIF testing for the detection of anti-ENA antibodies.
Patients and methods: 495 samples consecutively referred for
routine ANA testing by rheumatologists were collected. IIF on
HEp2 and HEp2000 and Line Immunoassay (INNO-LIA ANA, Inno-
genetics, Belgium) was performed on all samples.
Results:  Fluorescence intensities and patterns on HEp2 and
HEp2000 were strongly correlated (Spearman’s Rho=0.838;
P<0.001 and 0.787; P<0.001, respectively). 292 samples were
negative on HEp2 and HEp2000, 18 of these had a positive LIA
result. Reactivities seen are towards one or more RNP antigens
(8 patients); Ro52 and Ro60 (1 patient); mono SSB (4 patients);
Jo1 (1 patient); SmD (1 patient); RNPC, Ro52, Ro60, SSB,
sclero70 (1 patient); RNPC and SSB (1 patient); SmB (1 patient).
Two out of 26 patients, positive on HEp2 but negative on
HEp2000, showed reactivities: one with anti-Jo1 and one with anti-
RNPC. Three out of 23 patients, positive on HEp2000 but nega-
tive on HEp2, showed reactivities: one with Ro52, one with SSB
and one with Ro52, Ro60 and SSB (SSA-fluorescence pattern on
HEp2000). A significant fraction of patients with positive LIA
results who were negative on IIF had classical systemic disease.
Detailed diagnostic and serological validation will be discussed.
The SSA pattern was seen in 9% of the HEp2000 positive
samples, all of them showed Ro52 or Ro60 positivity on LIA. When
considering the total population, 79/495 were positive on LIA, of
whom 73.4% were detected with HEp2 and 74.4% were detected
with HEp2000.
Conclusion: IIF has no optimal sensitivity for detecting anti-ENA
reactivities. In the context of clinical suspicion, anti-ENA testing is
warranted, regardless of the IIF result.
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Induction of ANA, anti-dsDNA and anti-
nucleosome antibodies following infliximab
treatment in rheumatoid arthritis and
spondyloarthropathy patients
LEB de Rycke, N Van Damme, E Kruithof, IEA Hoffman,
EM Veys, F De Keyser
Ghent, University Hospital, Ghent, Belgium
Background: Rheumatoid arthritis (RA) and spondyloarthropathy
(SpA) patients are successfully treated with infliximab. There is
indication that this therapy induces ANA and anti-dsDNA antibod-
ies in RA.
Objectives: To investigate the induction of ANA, anti-dsDNA and
anti-nucleosome antibodies in both RA and SpA after infliximab
treatment.
Patients and methods: Sera from 62 patients with refractory RA
treated with infliximab (3mg/kg infliximab IV at week 0, 2, 6 and
every 8 weeks thereafter) were obtained at baseline and week 30.
Sera from 35 patients with active SpA treated with infliximab
(5mg/kg infliximab IV at week 0, 2 and 6 and 10mg/kg every
14 weeks thereafter) were obtained at baseline and week 34.
Samples were tested for ANA (indirect immunofluorecence [IIF] on
HEp-2 cells), anti-dsDNA antibodies (IIF on Crithidia luciliae and
Varelisa, PharmaciaDiagnostics), anti-nucleosome antibodies
(Medizym anti-Nucleo, Medipan Diagnostica).
Results: At baseline, 32/62 RA and 6/35 SpA patients were pos-
itive for ANA. After infliximab treatment, an increase in ANA inten-
sity of 2 or more steps (on a 0 to 5+ scale) was observed in
28/62 RA and in 26/35 SpA patients. A patient was defined as
having developed anti-dsDNA antibodies when a positive result in
both the IIF on Crithidia luciliae and anti-dsDNA ELISA was
observed. At baseline, none of the RA and SpA patients had anti-
dsDNA antibodies. After treatment, 7/62 RA and 6/35 SpA
patients developed anti-dsDNA antibodies. At baseline, anti-
nucleosome antibodies were observed in 1/62 RA and 3/35 SpA
patients. After treatment, 5/62 RA and 4/35 SpA patients were
positive for anti-nucleosome antibodies.
Arthritis Research    Vol 4 Suppl 1 Abstracts of the 22nd European Workshop for Rheumatology ResearchConclusion: Infliximab treatment induced ANA and anti-dsDNA
antibodies in both RA and SpA patients. After treatment, anti-
dsDNA antibodies were significantly associated with anti-nucleo-
some antibodies.
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Membrane expression of neutrophil proteinase 3
(PR3) is associated with relapse in PR3-ANCA
related vasculitis
AA Rarok, CA Stegeman, PC Limburg, CGM Kallenberg
University Hospital Groningen, Groningen, The Netherlands
Background: The highly specific presence in serum of autoantibod-
ies directed against intracellular neutrophil proteins such as PR3
(PR3-ANCA) suggests a pathophysiological role of these autoanti-
bodies in patients with necrotizing small vessel vasculitis. A stable but
interindividually highly variable membrane expression of PR3 has been
found on resting neutrophils. We hypothesized that, in patients with
PR3-ANCA related vasculitis, a higher expression of PR3 on neu-
trophil membrane would lead to more interaction with PR3-ANCA and
could thereby influence the extent or course of the disease.
Methods: PR3 expression on unstimulated isolated neutrophils
from patients with PR3-ANCA related vasculitis was determined by
FACS analysis using anti-PR3 murine mAb 12.8. Patients were
divided according to the distribution of neutrophil membrane PR3
in 3 groups: low, bimodal, and high. Disease extent at diagnosis
was scored with the Birmingham Vasculitis Activity Score (BVAS).
Actuarial relapse-free survival was calculated from diagnosis to the
first relapse and compared between groups with the logrank test.
Results: 89 patients (age 49±16.6; 47 male/42 female) with PR3-
ANCA related vasculitis followed at our department were included.
At diagnosis, renal involvement was present in 52 (58%) and pul-
monary involvement in 49 (55%) patients, BVAS was 23±10.5.
During follow-up (81±67 months) 50 patients had one or more
relapse. Age at diagnosis, organ involvement and BVAS at diagno-
sis were not different between patients with low (n=32), bimodal
(n=26), and high (n=31) neutrophil membrane PR3 expression.
However, median relapse-free survival was 104.5 months in
patients with low PR3 expression as compared to 36.6 and
30.8 months in patients with bimodal and high PR3 expression,
respectively (P=0.023). Clinical manifestations at first relapse of
vasculitis were not different between these groups.
Conclusion: The level of individual PR3 expression on resting neu-
trophils is significantly associated with risk for relapse in patients
with PR3-ANCA associated vasculitis, but not with disease extent
or manifestations at diagnosis or relapse. These data support the
hypothesis that interaction in vivo of ANCA with PR3 expressed on
neutrophil membrane plays a role in the pathophysiology of PR3-
ANCA related vasculitis.
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Cryoglobulins induce temperature-dependent
TNF-α α production via Fcγ γ-receptor II
J Rönnelid*, L Mathsson*, K Carlsson†, M Höglund†, B Nilsson*,
K Nilsson-Ekdahl*, U Lycken*
*Department of Clinical Immunology, Uppsala, Sweden
†Dept of Internal Medicine, Uppsala, Sweden
Introduction:  Cryoglobulins (CG) are antibodies that reversibly
agglutinate and form immune complexes (IC) when plasma or
serum is cooled below normal body temperature. Precipitation of
CG is also known to depend on pH and ionic strength. We have
previously shown that IC from SLE-patients can induce cytokine
production from peripheral blood mononuclear cells (PBMC). We
have investigated if, and under which circumstances, CG can also
induce cytokine production.
Methods: CG from two patients were purified under sterile condi-
tions. One patient was a 71 years old male with an IgG multiple
myeloma and an IgG CG. The other patient was a 58 years old
female with Waldentröm’s macroglobulinemia and an IgM CG. The
purified CG were added to PBMC cultures. Cytokine production in
the supernatants was measured with ELISA. Fcγ-receptors were
blocked with specific antibodies against FcγRII and FcγRIII. In sep-
arate experiments temperature, ionic strength and pH were varied.
Results: CG, especially IgG CG, induce production of TNF-α and
IL-1β. This cytokine production was partly blocked by anti-FcγRII
antibodies but not by antibodies to FcγRIII. When CG were added
to PBMC at 4°C and 37°C respectively, more TNF-α production
was seen in cultures with CG added at 4°C. The IgG and IgM CG
showed maximal precipitation at different ionic strength, with paral-
lel differences in TNF-α production in cell cultures with varying
ionic strength. Parallel studies on the effects of pH on CG precipi-
tation and cytokine production are underway.
Conclusions: CG-induced cytokine production varies with temper-
ature, ionic strength and pH, and is at least partly mediated via
FcγRII. CG-induced production of proinflammatory cytokines might
be of importance in CG-associated vasculitis/nephritis. Modulation
of CG precipitation and ensuing cytokine production may gain
therapeutic importance.
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Assessment of activity and damage in
ANCA-associated vasculitis in India
M Rajappa
Apollo Hospitals, Chennai, India
Background:  Wegener’s Granulomatosis, once thought to be
uncommon in India, is being recognized with increasing frequency
in Indians. In the present study, the assessment of the primary sys-
temic necrotizing Vasculitis was done using the Birmingham Vas-
culitis Activity Score (BVAS ) and Vasculitis Damage Index (VDI).
Method: Seventy-six patients with ANCA-associated vasculitis
were evaluated using the BVAS and VDI, between January 1990
and June 2001. The diagnosis of Wegener’s granulomatosis and
Churg Strauss disease were made by 1990 ACR criteria and that
of Microscopic Polyangiitis by Chapel Hill Consensus. ANCA, ANA
and anti-DNA were estimated by indirect immunofluorescence and
antibodies to PR3 and MPO by ELISA. All other causes for sec-
ondary vasculitis and infections were excluded.
Results: There were 40 males and 36 females. The mean age at
diagnosis was 43.4. The mean disease duration prior to diagnosis
was 3.4 months. The distribution of vasculitis were: Wegener’s
granulomatosis, 48, microscopic polyangiitis, 10, Churg Strauss, 6
and crescentic glomerulonephritis, 12. cANCA was positive in
48(63.15%) and pANCA in 21( 27.63%). ANA and anti-DNA were
negative in all the patients. The mean BVAS score at baseline was
16.4. The mean VDI system score was 3 and the mean total VDI
score was 4.6. Using the VDI, the following items of damage were
seen: musculoskeletal damage, 12 (15.8%); skin damage,
16 (21%); ENT damage, 28 (36.8%); pulmonary damage,
42 (55.3%); cardiovascular damage, 34 (44.7%); renal damage,
51 (67.1%); peripheral vascular damage, 26 (34.2%); ocular
damage, 21 (27.6%); neuropsychiatric damage, 48 (63.2%); and
other damage & drug toxicity, 14 (18.4%).
Conclusions:  1) ANCA-associated vasculitis were rare in India,
present in only 0.001% of Hospital admissions. 2) Neuropsychi-
atric manifestations were common (63%). 3) The BVAS and VDI
offer a comprehensive and cumulative measure of disease activity
and damage in the serial assessment of vasculitis patients.
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Clinical optimization and multicenter validation of
antigen-specific cut-off values on the INNO-LIAr
ANA Update for the detection of autoantibodies in
connective tissue disorders
K De Bosschere*, A Wiik†, T Gordon‡, P Roberts-Thomson‡,
D Abraham§, C Dobbels*, H Pottel*, F Hulstaert*, L Meheus*
*Innogenetics NV, Zwijnaarde, Belgium
†Statens Seruminstitut, Copenhagen, Denmark
‡Flinders Medical Center, Adelaide, Australia
§Royal Free Hospital, London, United Kingdom
Objectives: Optimization and validation of antigen-specific cut-off
values for SmB, SmD, RNP-70k, RNP-A, RNP-C, SSA/Ro52,
SSA/Ro60, SSB/La, Cenp-B, Topo-I, Jo-1, ribosomal P and his-
tones to achieve 98% specificity for each of the markers.
Patients and methods: The INNO-LIAr ANA Update is a qualita-
tive test detecting antibodies to several different antigens, most of
which are recombinantly made, with the exception of SSA/Ro60
and histones (natural), and SmD and ribosomal P (synthetic). The
LIA-SCAN ANA provides a quantitative read-out of the INNO-LIAr
ANA Update results. The cut-off value of the different antigen lines
was optimized using an in-house set of 955 samples. The assay
specificity was validated at multiple sites using a different set of
330 samples obtained from 158 apparently healthy blood donors,
100 patients with a variety of infections, 20 with Wegener’s granu-
lomatosis, 20 with inflammatory bowel disease, 20 with primary
antiphospholipid syndrome, and 12 with psoriatic arthritis. The
INNO-LIAr ANA Update reactivity using the optimized cut-off was
tested in 147 patients with scleroderma, 93 with Sjögren’s
disease, 40 patients with systemic lupus erythematosus (SLE),
40 with rheumatoid arthritis (RA), 39 with mixed connective tissue
disease, and 19 with myositis. The clinical diagnosis was consid-
ered as the gold standard.
Results and Conclusions: The optimized cut-off values resulted in
an average specificity of over 98% for all LIA markers in the valida-
tion set of 330 samples. The pattern of reactivity for the different
LIA ANAs in the 378 samples from the target patient groups corre-
sponded to the sensitivities reported in the literature. In conclusion,
the INNO-LIAr ANA Update shows uniformly high specificities
combined with sensitivities very similar to those of reference
assays, in a single test format.
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Autoantibodies to deiminated fibrinogen are the
most efficient serological criterion for the
diagnosis of rheumatoid arthritis
NL Nogueira*, M Sebbag*, S Chapuy-Regaud*, C Clavel*,
B Fournie†, A Cantagrel‡, C Vincent*, G Serre*
*Paul Sabatier University, Toulouse Cedex, France
†Purpan Hospital, Toulouse Cedex, France
‡Rangueil Hospital, Toulouse Cedex, France
Background:  Antifilaggrin autoantibodies are recognized as the
most specific serum marker in rheumatoid arthritis (RA). Their high
diagnostic value led in the past few years to the development of
several efficient tests for detection of these autoantibodies
directed against deiminated (‘citrullinated’) peptidic epitopes borne
by profilaggrin. We recently showed that deiminated forms of the α
and β chains of fibrin are the major targets of antifilaggrin autoanti-
bodies in the synovial tissue of RA patients. Consequently, we
developed a new test to assay the serum autoantibodies to deimi-
nated fibrinogen (AhFibA) and evaluated its diagnostic value in RA.
Methods: An enzyme-linked immunosorbent assay (ELISA) using
in vitro deiminated human fibrinogen as immunosorbent was devel-
oped, and 617 sera from patients with well characterized
rheumatic diseases, including 181 RA, were tested. The diagnostic
performance of the AhFibA-ELISA was compared, in the same
cohort of patients, to that of rheumatoid factor (RF) assayed by
nephelometry, and to those of various methods for detection of
antifilaggrin autoantibodies: indirect immunofluorescence (‘antiker-
atin antibodies’), immunoblotting onto human epidermis filaggrin,
CCP-ELISA and an ELISA on deiminated recombinant rat filaggrin
(ArFA-ELISA).
Results:  With a cut-off value allowing 95% of specificity to be
reached, AhFibA were detected in 83% of the RA sera. At 98.5%
specificity, 76% of the RA sera were positive. In contrast, at the
same specificities, RF was detected in only 56% and 6% of the RA
sera, respectively. In addition, the diagnostic performance of the
AhFibA-ELISA was significantly higher than those of all the tests
for antifilaggrin autoantibodies, including CCP-ELISA and ArFA-
ELISA.
Conclusions:  Presence of autoantibodies to deiminated human
fibrinogen appears as the most efficient (specific and sensitive)
serological criterion for the diagnosis of RA. Moreover, these
results confirm that deiminated fibrin is a major B autoantigen in RA
and sustain its probable involvement in the pathophysiology of the
disease.
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Characterization of binding interactions in
solution between β β-2-glycoprotein I and
monoclonal antibodies
NHH Heegaard*, C Schou*, E Kogutowska*, M Anderson†,
L Blomberg†,
*Statens Serum Institut, Copenhagen S, Denmark
†Department of Chemistry, Karlstad University, Sweden
The circulating so-called antiphospholipid antibodies associated
with autoimmune thrombophilia appear in most cases to be
directed against phospholipid-binding proteins, chiefly apolipopro-
tein H (β-2-glycoprotein I, β2gpI) or prothrombin. Accordingly, the
determination of antibodies reacting with β2gpI in solid-phase
immunoassays is useful in the diagnostic workup of thrombophilic
patients. These antibodies are characterized by significant binding
only when β2gpI is immobilized on “high binding”, chemically acti-
vated, or phospholipid-coated surfaces. It is not yet known,
however, if the binding of antibodies is a result of a specific confor-
mation that β2gpI attains when immobilized on a surface or simply
a reflection of a sufficiently high epitope density. We are establish-
ing solution binding assays based on capillary electrophoresis to
measure antibody–β2gpI interactions without immobilizing any of
the interacting molecules. Here we describe the optimization of
analysis conditions in uncoated and coated capillaries for native
and succinylated human β2gpI. Monoclonal anti-β2gpI and the
humanized monoclonal antibodies proposed as standards for solid-
phase assays were used as model ligand systems and we demon-
strate the measurement and quantitation of binding. The influence
of changes in buffer conditions such as ionic strength, pH, and of
buffer additives including heparin - a known β2gpI ligand - is easily
assessed by this approach and minute amounts of biological mate-
rial are consumed (nanoliter injection volumes). The set-up is well
suited for determining weak affinity interactions and will be helpful
in providing answers to the questions about solution affinities of
patient antibodies for native β2gpI and thus for understanding the
molecular pathology behind the thrombophilic effect of anti-β2gpI
autoantibodies.
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Anti-nuclear antibody (ANA) analysis should
include specific analysis of antibodies to SS-A/Ro
C Dahle*, T Skogh†, AK Berg‡, A Jalal§, P Olcén‡
*University Hospital, Linköping, Sweden
†Div of Rheumatology, Linköping, Sweden
‡Div of Clinical Immunology, Rebro, Sweden
§Div of Rheumatology, Rebro, Sweden
Objectives: Evaluation of ELISAs and immunodiffusion (ID) in addi-
tion to IF microscopy for ANA screening.
Methods: 3079 patient sera sent for routine analysis were diluted
1:100 in PBS and examined by IF microscopy (HEp-2 cells) for the
presence of ANA. In addition, all sera were analysed by two differ-
ent commercial ELISAs for screening of ANA specificity. The sera
were also analysed by an in-house ID test for precipitating antibod-
ies to extractable nuclear antigens (ENA). All sera positive in any of
the ELISAs or ID were further analysed by an ‘ANA profile’ ELISA kit
and a commercial ID test for determination of antigenic specificity.
Results: 334 (11%) of the sera were positive by IF microscopy.
102 (31%) of these sera were also positive in at least one addi-
tional test. 214 HEp-2 negative sera (7%) turned out positive in at
least one of the additional ANA tests. In 40 of these 214 sera the
antigenic specificity was confirmed by the commercial ID test,
37 (92%) of which proved to have specificity for SS-A/Ro. The dif-
ferent ELISAs correlated poorly with one another.
Conclusion: In addition to IF-microscopy on HEp-2 cells, an assay
for anti-SS-A antibodies should be included for routine ANA
screening.
Cellular immunity
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Abnormal gene expression in CD8 T cells from the
lungs of scleroderma patients
IG Luzina*, SP Atamas*, R Wise†, FM Wigley†, B White*
*University of Maryland Medical School, Baltimore, USA
†Johns Hopkins University, Baltimore, USA
Activated CD8+ T cells in bronchoalveolar lavage (BAL) samples
are associated with progressive lung fibrosis in scleroderma. The
hypothesis of this work is that CD8+ T cells from a subset of scle-
roderma patients, especially those with lung inflammation, have an
abnormal pattern of gene expression that can promote fibrosis.
Freshly isolated BAL CD8+ T cells from 26 individuals were tested
for expression of cytokines, chemokines, growth factors, and
receptor genes, using DNA microarrays. Hierarchical cluster analy-
ses showed two groups of arrays. Group 1 included all 10 patients
with lung inflammation and two patients without. Arrays from the
other 7 patients without lung inflammation clustered with all
7 arrays from controls in group 2. Differences in gene expression
indicated that CD8+ T cells in group 1, compared to group 2, were
more likely to be activated, express type 2 cytokines, and stimulate
extracellular matrix deposition, and less likely to undergo activation-
induced cell death. T-cell activation was suggested by increased
expression of LIGHT, neurotropin-4, CD100, CD6, integrin b1 and
decreased expression of VIP R1 genes. Type 2 cytokine produc-
tion was suggested by increased expression of CCR4, G-CSF R
and IL-13 Ra and decreased expression of TRANCE and TNF R1
genes. Reduced expression of TNF R1, TNF R11, TRAIL R1,
CD30 L and Fas genes suggested that CD8+ T cells from
Group 1 were less likely to die following activation. Increased gene
expression of oncostatin M, which simulates fibroblast proliferation
and collagen production, integrin b6, which can activate TGF-β,
FGF17, FGF4, and membrane type-1 and -2 matrix metallopro-
teinases was seen. To confirm some of these results, increased
IL-4 mRNA had been reported in our previous work, and increases
in oncostatin M and activated TGF-β proteins in BAL fluids from
patients with lung inflammation were confirmed by ELISA. These
findings suggest that activated CD8+ T cells are part of a pathway
that leads to lung fibrosis in scleroderma.
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CD25 regulatory cells are involved in protection
from collagen-induced arthritis in both susceptible
and non-susceptible mice
ME Morgan, RPM Sutmuller, HJ Witteveen, A Snijders,
R Offringa, EH Zanelli, RRP De Vries, REM Toes
Leiden University Medical Center, Leiden, The Netherlands
CD4+ regulatory T cells expressing the activation marker CD25
have been strongly implicated in the control of autoimmune dis-
eases. For example, immune compromised mice that receive
splenocytes depleted of CD25+ cells develop a variety of organ-
specific autoimmune diseases such as colitis, gastritis, oophoritis,
orchitis, and thyroiditis. Nonetheless, the role of regulatory T cells
in many other autoimmune diseases, particularly systemic autoim-
mune diseases, has not been explored. We have now analyzed the
role of CD25+CD4+ T cells in the control of collagen-induced
arthritis (CIA), a commonly accepted model of rheumatoid arthritis.
Depletion of CD25+ T cells in CIA susceptible DBA/1 mice leads
to an earlier and more aggressive disease as evidenced by the
development of severely swollen limbs following collagen injection.
These mice also showed an increase in collagen specific antibod-
ies. In addition, B6 mice, which are normally not susceptible to
CIA, rapidly develop arthritis when vaccination is performed after
depletion of CD25+ cells. Together, these findings indicate the
importance of CD25+ cells in modulating CIA, establishing them as
significant contributors in the control of chronic and systemic joint-
related inflammation like that found in rheumatoid arthritis.
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The accumulative and maturative type of B-cell
activation in synovitis: a new concept of B-cell
activation in autoimmune diseases
VK Krenn*, LM Morawietz*, H-JK Kim†, JM Möller*, CB Berek†
*Universitàtsklinikum Charité, Berlin, Germany
†Rheumaforschungszentrum, Berlin, Germany
Introduction:  B-cells and plasma cells in chronic synovitis of
osteoarthritis (OA), reactive arthritis (ReA) and rheumatoid arthritis
(RA) show two different histological patterns: lymphoplasmacellu-
lar pattern and germinal centre (GC) pattern. To clarify what
immunological mechanisms stands beyond these histological pat-
terns, IgVh gene analysis from the B and plasma cells present in
those patterns was performed.
Methods:  IgVh gene repertoires were determined from RNA
(OA=5, ReA=2, RA=5), prepared from tissue cryosections and
from isolated B-cells and plasma cells (plc) by micromanipulation.
The B-cell environment was analysed immunohistochemically by
detecting plc (IgM, IgG, IgA), B-lymphocytes (CD20) and Ki-67
positive (proliferating) cells.
Available online  http://arthritis-research.com/supplements/4/S1Results: In the lymphoplasmacellular pattern of OA (n=5), somati-
cally highly mutated IgVh genes (R/S: CDR=R/S=5.3;
Fr=R/S=2.0) could be detected, but no clonal relation could be
established amongst them. The plc of the GC pattern in ReA (n=2)
and RA (n=5) revealed highly somatically mutated IgVh genes:
R/S: CDr=R/S=3.4; Fr=R/S=1.7; and CD20+ B cells in germline
configuration. A clonal relation between low mutated B cells and
highly mutated plc could be established indicating a local clonal
expansion. A proliferation of CD20+ B cells could only be observed
in GC.
Conclusions: Therefore, two different patterns of B-cell activation
may be defined: (1) The accumulative type: already activated B
cells migrate into the synovial tissue and accumulate there without
further IgVh diversification. (2) The maturative type of B-cell prolif-
eration with IgVh diversification occurring in a GC like reaction.
The two different patterns of B-cell activation may reflect that dif-
ferent antigens are involved in autoimmune and degenerative dis-
eases. Since in organ specific autoimmune diseases (RA, Morbus
Sjögren, Morbus Basedow) a local germinal centre reaction takes
place, it is likely that the B cells are expanded by disease specific
antigens. The experimental expression of IgVh genes isolated from
these germinal centre B cells may therefore lead to the identifica-
tion of pathogenic organ specific antigens.
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Regulation of T cell and monocyte activation by
human anergic/suppressive CD4 CD25 T cells
LS Taams, JMR van Amelsfort, KMG Jacobs, JWJ Bijlsma,
FPJG Lafeber
University Medical Center Utrecht, Utrecht, The Netherlands
Regulation of the immune response is important to avoid chronic
inflammation and autoimmunity. Anergic/suppressive CD4+CD25+
T cells have been shown to be major contributors to this regulation.
We have previously shown that the suppressive CD4+CD25+
T cells can suppress mitogenic and antigen-specific CD4+ T-cell
responses in humans (EJI 2001,  31:1122;  Immunology 2001,
104:6). In rheumatoid arthritis (RA), besides CD4+ T cells also
monocytes play an important role in the disease process. Therefore
we investigated whether the suppressive CD4+CD25+ T cells
could affect monocyte activation as well as T-cell activation. CD4+
T cells and monocytes were isolated from peripheral blood
mononuclear cells from healthy donors via MACS isolation tech-
niques. CD4+ T cells were separated into CD4+CD25+ and
CD4+CD25– T cells. T cells and monocytes were cocultured for
two days without or with anti-CD3 mAb, after which proliferation,
cytokine production and phenotypic markers were investigated.
Coculture of monocytes with CD4+CD25– T cells in the presence
of anti-CD3 mAb resulted in strong T-cell proliferation, production
of cytokines (TNF-α, IFN-γ, IL-1β, IL-10), upregulated expression of
HLA II, CD40 and CD80 and remaining high CD86 levels on the
monocyte/macrophage. In contrast, coculture of monocytes with
CD4+CD25+ T cells and anti-CD3 mAb resulted in T-cell anergy,
low levels of cytokine production, reduced upregulation of HLA II,
CD40 and CD80 and downregulation of CD86. We are currently
investigating how this altered activation affects the antigen-pre-
senting and/or cartilage-destructive capacity of the monocytes/
macrophages. In conclusion, we demonstrate that anergic/-
suppressive CD4+CD25+ T cells can suppress — besides T-cell
responses — also the activation of monocytes. Further investigation
into the function of these suppressive CD4+CD25+ T cells in RA
patients as well as understanding their regulatory mechanism
might elucidate their potential role in the pathogenesis of RA.
97
The characterisation and regulation of type 1
immune responses in psoriatic arthritis
JA Gracie, H Wilson, SE Robertson, DJ Kane, IB McInnes
University of Glasgow, Glasgow, United Kingdom
Psoriatic arthritis (PsA) is a disabling inflammatory disease, of as
yet unknown aetiology. A pathogenic role for TNF-α is suggested
by the beneficial effects of anti-TNF therapy. However, upstream
events remain to be elucidated. We propose that elevated levels of
IFN-γ expression in inflamed PsA tissues, reflects a ‘type 1’ immune
response, of pathophysiological significance. This study sought to
identify and phenotype spontaneous IFN-γ secreting cells within
PsA inflammatory lesions. Furthermore, we have elucidated factors,
including costimulatory molecules and innate cytokines that regu-
late IFN-γ expression.
Methods: Matched PsA and rheumatoid peripheral blood (PB) and
synovial fluid (SF) mononuclear cells were isolated on density gra-
dients. Spontaneous IFN-γ secreting cells were identified using a
novel bi-specific antibody capture method. T cells were further
phenotypically characterised by FACS analysis. Following in vitro
stimulation with mitogen/cytokines mononuclear cells were
analysed for cytokine production by ELISA. Immunohistology on
both skin and synovial membrane samples was performed using
standard methods.
Results: We have identified an increase in the percentage of spon-
taneous IFN-γ secreting cells in PsA synovial fluid when compared
to rheumatoids. FACS analysis of PsA SF further identified cells
expressing both CCR5 and IL-18R, characteristic of a Th1 pheno-
type. The presence of IL-12 and IL-18, potential inflammatory medi-
ators, was confirmed in synovial membrane samples by
immunohistochemistry. Furthermore, in vitro cultures of matched
PsA PB/SF cells showed enhanced IFN-γ production by SF cells
following stimulation with recombinant IL-12/IL-15. A threefold
increase of IFN-γ was detected in the presence of
CD3/CD28/IL-12 in SF compared with PBMC and a twelvefold
increase in the presence of CD3/CD28/IL-15.
Conclusions: We have detected the presence and defined func-
tional significance for the candidate regulatory cytokines, IL-12,
IL-15 and IL-18 in sustaining IFN-γ expression. These findings
support the hypothesis that PsA pathogenesis is associated with a
‘type 1’ polarised immune reponse.
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Identification of T-cell specific autoantigens
D Hamann, I Rensink, HGM Geertzen, L Aarden
CLB, Amsterdam, The Netherlands
The mechanisms that lead to the formation of autoantibodies are
not understood. Accumulating data suggest that autoantigens
might be characterized by post-translational modifications that are
part of the natural apoptosis process such as granzyme B cleavage
(i.e. topoisomerase I, LA (SS-B), U1-70kd), caspase cleavage (i.e.
topoisomerase I and II), phosphorylation/dephosphorylation (i.e.
ribosomal P proteins, LA (SS-B), transglutaminase crosslinking (i.e.
histone H2B) and deimination (arginine–citrullin change in fibrin or
fibrinogen). T cells, which have been negatively selected or toler-
ized against native autoantigens, might be primed by modified
autoantigens and deliver help to self-reactive B cells. So far, there
have been only few reports about autoantigen specific T cells.
Since the frequencies of those T cells in the peripheral blood are
very low, autoantigen specific T-cell responses are difficult to
Arthritis Research    Vol 4 Suppl 1 Abstracts of the 22nd European Workshop for Rheumatology Researchdetect. In our study we are combining the use of monocyte derived
dendritic cells (DC) as professional antigen presenting cells with
intracellular cytokine staining for the detection of T-cell responses.
Monocytes and lymphocytes are purified from freshly isolated
PBMC by density gradient centrifugation. Lymphocytes are frozen
in liquid nitrogen until usage. Monocytes are differentiated into
immature dendritic cells in culture medium containing either 1%
FCS or 10% autologous serum and GM-CSF and IL-4. Maturation
is induced by addition of GM-CSF, LPS, TNF-α and IL-1-β in the
presence or absence of a specific antigen. Mature DC expressing
antigen derived peptides are washed and cocultured with thawed
autologous lymphocytes. After 4 hours, brefeldin A is added and
lymphocytes are intracellulary stained with CD3, CD4, CD69 and
TNF-α mAb after o/n culture. We will use this system to identify
possible T-cell specific autoantigens by using granzyme B cleaved
nuclear extracts and purified modified nuclear antigens.
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Tolerance induction in mice by antibodies to T-cell
epitopes
R Laub, R Brecht, F Emmrich
Institute of Clinical Immunology, Leipzig, Germany
CD4/DR3 mice lack murine cd4 but express human CD4 specifi-
cally on helper T cells, and HLA-DR3 as its natural counter ligand
(CD4/DR3 mice). The injection of these mice with anti-human CD4
prior to immunization with tetanus toxoid (TT, day 0) totally blocked
the formation of specific Abs. When these mice were left untreated
for at least 30 days, and were then re-exposed with TT, but in the
absence of anti-human CD4, they consistently failed to induce spe-
cific antibodies (long-term unresponsiveness). Importantly, the con-
current injection of TT and anti-human CD4 at day 0, followed by
another two anti-CD4 treatments also led to tolerant animals indi-
cating that tolerance was inducible as late as the antigen exposure
is provided. We demonstrate a limited ability of spleen cells to
respond to TT in vitro indicating that T cells are essentially involved
in the maintenance of tolerance. These data show for that the
human CD4 coreceptor may mediate tolerance-inducing signals
when triggered by an appropriate ligand in vivo.
Innovative therapies
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Non viral gene therapy in arthritis by in vivo
intramuscular IL-10 DNA electrotranfer
CJ Jorgensen*, F Apparailly*, N Perez†, V Millet*, D Greuet†,
C Minot†, O Danos†, J Sany*
*University Hospital Montpellier, Montpellier, France
†Genethon III, CNRS URA 1923, E, Evry, France
Intramuscular electroporation of DNA is an attractive technique for
nonviral gene transfer of therapeutic genes in inflammatory/autoim-
mune disease such as rheumatoid arthritis (RA). We have devel-
oped in vivo electroporation for efficient cytokine gene transfer in
collagen induced arthritis.
Methods: We co-injected in the tibialis anterior of DBA1 mice a
standard 30ml dose of plasmid DNA encoding the anti-inflamma-
tory cytokine viral interleukin-10 (vIL-10) under the control of a
doxycycline-inducible promoter, and a plasmid expressing the
tetracycline controlled transcriptional silencer (tTS) that binds pro-
moter in absence of doxycycline. Electroporation was performed in
vivo using 8 pulses of 200v during 1ms day 25 postimmunization
of DBA1 mice with collagen type II.
Results: Electroporation resulted in a dose-dependent increase in
the vIL-10 expression in muscle and serum. The transgene was
expressed only by muscle cells during 4 weeks. The doxycycline
treatment showed significant inhibitory effects on DBA1 mice type II
collagen induced arthritis (CIA) as paw swelling was reduced
(1.79±0.22 vs. 2.13±0.84mm on day 32 postimmunization) and
onset of arthritis clinical delayed in the doxycycline-treated group
compared with the control group without doxycycline (32.62±4.50
days, versus 28.38±3.62 days respectively).
Conclusions:  Muscle-targeted vIL10-rtTA plasmid transfer by in
vivo electroporation is a suitable approach for non viral gene
therapy in arthritis.
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Alefacept treatment in psoriatic arthritis: reduction
of the synovial inflammatory infiltrate and
improvement of clinical signs of arthritis
MC Kraan*, HJ Dinant*, AWR van Kuijk†, AY Goedkoop*,
TJM Smeets*, MA de Rie*, BAC Dijkmans†, AK Vaishnaw‡,
PP Tak*
*Academic Medical Center, Amsterdam, The Netherlands
†Acad Hospital Free University, Amsterdam, The Netherlands
‡Biogen Inc., Cambridge, MA, USA
Objective: Psoriasis and psoriatic arthritis (PsA) are thought of as
T-cell mediated diseases. LFA-3/CD2 interaction plays a signifi-
cant role in T-cell activation. Alefacept, an LFA3-IgG1 fusion
protein, blocks LFA3-CD2 interactions resulting in inhibition of T-
cell responses and T-cell apoptosis which could be beneficial in
patients with active PsA.
Methods: Eleven patients with active PsA were treated with ale-
facept for 12 weeks in an open label design. Clinical joint assess-
ment, Psoriasis Area and Severity Index (PASI), and peripheral
blood (PB) assessments were performed at baseline, after 4, 9, 12,
and 16 weeks of treatment. Serial synovial tissue (ST) biopsies of
an index joint (knee, ankle, wrist or MCP joint) were obtained by
arthroscopy at baseline, 4 and 12 weeks.
Results:  At completion of treatment 6 out of 11 (56%) treated
patients fulfilled the DAS response criteria, 9 patients (82%) ful-
filled the DAS response criteria at any point within the study.
Seven of 11 (64%) treated patients showed improvement (mean
50%) of their skin psoriasis. In the ST there was a statistically sig-
nificant reduction in CD4+ lymphocytes (P<0.05), CD8+ lympho-
cytes (P=0.05), and CD68+ macrophages (P<0.02) in the
synovial samples after 12 weeks of treatment compared to base-
line. Patients fulfilling the DAS response criteria demonstrated a
higher baseline ration and significant reduction in
CD4+CD45RO+ cells in both ST and PB where non-responders
demonstrated only reductions in PB.
Conclusion: The improvement in clinical joint score, skin psoriasis,
and changes in synovial tissue after treatment with alefacept sup-
ports the hypothesis that T-cell activation plays an important role in
this chronic inflammatory disease. Furthermore, since alefacept, a
specific T-cell agent, led to decreased macrophage activation, the
data indicate that T cells orchestrate synovial inflammation in psori-
atic arthritis.
Available online  http://arthritis-research.com/supplements/4/S1102
Chemokine blockade in patients with rheumatoid
arthritis: reduction of synovial inflammation
JJ Haringman, MC Kraan, TJM Smeets, PP Tak
Academic Medical Center, Amsterdam, The Netherlands
Objective: Leukocyte migration to the synovial compartment plays
an important role in rheumatoid arthritis (RA). The presence of
macrophages in the synovium is associated with disease activity
(Arthritis Rheum 1997;  40:217-225). Important mediators of
leukocyte migration include chemokines and their receptors. This
study evaluated the effects of blocking the migration of monocytes/
macrophages and T cells into the joint using a chemokine receptor
antagonist.
Methods:  16 patients were included in a 2-week, double-blind,
placebo-controlled randomised phase-Ib-study evaluating the
effects of an oral CCR1 antagonist. Synovial tissue was obtained
by arthroscopy on day 1 and day 15. Immunohistochemistry was
performed to detect CD68, CD3, CD4, CD8, CD55, CD22, and
CD138. Sections were analysed using digital image analysis. The
results before and after treatment were compared by paired, non-
parametric analysis (Wilcoxon signed rank test). A two-sample
t-test was used to compare the changes from baseline in the two
groups (12 patients in the treatment group versus 4 patients in the
placebo group).
Results: After CCR1 blockade, there was a statistically significant
decrease in: overall cellularity (reduction of 2065±256
(median±s.e.m.) to 891±164, P<0.02), intimal lining layer hyper-
plasia (269±95 to 181±49, P<0.02), CD68+ macrophages
(2386±261 to 1445±283, P<0.02), intimal CD68+ macro-
phages (1201±130 to 496±133, P<0.03) and CD4+ T cells
(432±160 to 215±139, P<0.02). There also was a decrease in
CD8+ T cells (131±44 to 35±31), but the difference was not sta-
tistically significant. As expected there was no decrease in the
number of CD22+ B cells, CD138 plasma cells, or CD55+ fibro-
blast-like-synoviocytes, since these cells do not express CCR1.
There was on average no change in the features of synovial biopsy
samples from patients who received placebo.
Conclusion: It is feasible to influence the migration of inflammatory
cells to the joints by using an oral CCR1 antagonist. This could
provide a completely new treatment for RA patients.
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High dose cyclophosphamide followed by
autologous stem cell transplantation for the
treatment of intractable rheumatoid arthritis (RA):
a 2-year clinical and immunological follow-up
RJ Verburg*, JK Sont*, A Kruize†, F van den Hoogen‡,
FC Breedveld*, JM van Laar*
*Leiden University Medical Center, Leiden, The Netherlands
†University MC Utrecht, Utrecht, The Netherlands
‡University of Nijmegen, Nijmegen, The Netherlands
Background: To investigate the effects of high dose chemother-
apy (HDC) and autologous stem cell transplantation (ASCT) both
clinically and on the synovial infiltrate for selected patients with
severe, refractory RA.
Methods:  12 patients with rheumatoid arthritis, were treated.
Mobilization of autologous blood stem cells was accomplished
with cyclophosphamide (4g/m2) and G-CSF. The conditioning
regimen consisted of intravenous administration of high dose
cyclophosphamide (totalling 200mg/kg), with subsequent reinfu-
sion of the positively selected graft. Biopsies of synovial tissue
from a knee were obtained before and three months after HDC and
ASCT. Immunological monitoring and immunohistochemistry on
the synovial infiltrate was performed.
Results:  The procedure appeared feasible in all patients. The
aplastic period lasted less than 4 weeks in all patients. Efficacy
data, with follow-up ranging from 6–24 months showed that the
mean disease activity score (DAS) decreased from 5.4 (n=12) to
3.2 at 6 months (n=12, P=0.003), 3.1 at 12 months (n=11,
P=0.005) and 2.9 at 24 months (n=5, P=0.043). Mean DMARD-
free period was 12.9 months (95% CI: 7.23–18.48). Patients
could be classified in clinical responders (Good response (Eular);
ACR >50%, n=6) and non-responders (Moderate or no response;
ACR  ≤20%, n=6) at three months post-transplantation.
Immunophenotyping of PBMCs showed prolonged (>24 months)
depletion of CD45RA+ T cells after transplantation, whereas levels
of CD8+, CD3-CD16CD56+ and CD19+ cells quickly recovered.
CD4+CD45RO+ cells were not complety depleted after transplan-
tation. High IgG1 in peripheral blood (responders: 9.69g/l; non-
responders 6.24g/l P=0.046) and high baseline synovial CD27
(mean infitration score; 3 vs. 0.33; P=0.036) and CD45RO (mean
infiltration score; 3.4 vs. 0.67; P = 0.036) predicted clinical
response. Furthermore there were trends towards a decrease in T-
cell markers in the synovium before and after transplantation were
compared (CD3-CD4-CD25-CD45RA-RO and CD27), but no sta-
tistical significant differences were found. IL-1 showed significant
higher scores in non-responders than responders after transplanta-
tion: 3.5 vs. 0.6 (P=0.024).
Conclusions:  The results of the present interim-analysis under-
score the feasibility and potential efficacy of HDC followed by
ASCT for the treatment of intractable RA. Clinical effect of HDC
and ASCT correlated with T-cell debulking in synovial tissue.
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Mycophenolate mofetil prevents the development
of a clinical relapse in SLE patients at risk: 
an open pilot study
M Bijl, G Horst, H Bootsma, PC Limburg, CGM Kallenberg
Academic Hospital Groningen, Groningen, The Netherlands
Background:  Systemic lupus erythematosus (SLE) is charac-
terised by the presence of antibodies to double-stranded DNA
(dsDNA). These antibodies are supposedly involved in the patho-
genesis of SLE. Eighty percent of patients develop a clinical
relapse within 10 weeks after a significant rise in anti-dsDNA level.
This can be prevented by the administration of corticosteroids at
the time of rise in anti-dsDNA. We hypothesise that administration
of mofetil mycophenolate (MMF) will have similar effects without
the side effects of corticosteroids.
Methods: SLE patients (n=36) were followed monthly for a rise in
levels of anti-dsDNA, defined as exceeding 125% of the level of the
previous sample, and amounting at least 15 E/ml within a 4-month
period. At the time of a rise patients started with 2000mg MMF daily
for a period of 6 months. Patients were monitored monthly for the
occurrence of a clinical relapse and to assess serological activity and
state of activation of CD4+, CD8+ and CD19+ lymphocyte subsets.
Results: In 10 patients a serological relapse was encountered. All
patients started MMF and completed a 6 months study period
without the occurrence of a clinical relapse. Side effects were
minimal. Antibodies to dsDNA decreased during the study period
(P<0.001) associated with a decrease in activation of CD19+
lymphocytes. No difference in the state of activation of CD4+ or
CD8+ lymphocyte subsets could be demonstrated.
Conclusion: Administration of MMF after a rise of antibodies to
dsDNA prevents the occurrence of clinical relapses of SLE and is
well tolerated.
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Reduction of cartilage destruction in a rapid
progressive arthritis model in SCID mice
U Sack, A Hirth, B Funke, K Wiedeneyer, F Kahlenberg,
U Anderegg, F Krahnert, J Lehmann, F Emmrich
University of Leipzig, Leipzig, Germany
Fibroblasts are considered to be a crucial cell population for
disease progression, as well as joint destruction in rheumatoid
arthritis. Recent data underline the potency of rheumatoid synovial
fibroblast-like cells to induce the destruction of cartilage and bone,
e.g. following intra-articular injection into SCID mice. We have iso-
lated a fibroblastoid cell line by co-cultivation of human rheumatoid
fibroblasts with murine fibroblasts. The generated cell line exhibits
characteristics of rheumatoid fibroblasts and genetic alterations
indicating a transformed phenotype. These cells have been shown
to induce a rapid destruction of articular cartilage following intra-
articular instillation. Fibroblastoid cells (LS48) were examined for
cytogenetic characteristics, morphology, surface molecules,
cytokine secretion, and functional parameters. 500,000 cells were
injected directly into SCID mouse knee joints to induce cartilage
destruction. Mice were monitored for joint swelling, serological
parameters and by radiological methods. Furthermore, the effects
of immunosuppressive drugs such as cyclosporine A, methotrex-
ate, and FK 506 were investigated in this model. In addition, trans-
fection of LS48 was performed with IL-11 as well as IL-15 prior to
arthritis induction to investigate influence on cartilage destruction.
Finally, the histology of cartilage destruction was explored. LS48
shows characteristics of a fibroblast-like cell but is of murine origin.
Secretion of matrix metalloproteinases 3, 9 and 13 as well of inter-
leukine-6 and tumor necrosis factor revealed similarities to human
invasive rheumatoid synovial membrane fibroblasts. Rapid progres-
sive cartilage destruction within 10 days was induced by instillation
into SCID mouse knee joints. Morphology revealed invasion of
fibroblast-like cells into the articular cartilage. Destruction could be
reduced by methotrexate but not by cyclosporine A or FK 506, indi-
cating a fibroblast-directed action of methotrexate connected to
reduction of joint destruction in RA patients. Transfection with
cytokines did not act on cartilage destruction, but IL-11 reduced
apoptosis of chondrocytes. Induction of cartilage destruction by
intra-articular application of murine fibroblast-like cells, in particular
LS48, is a rapid and highly reproducible model for investigating
invasive arthritis and can be modulated by drugs or gene transfer.
This provides the opportunity to check novel therapeutic strategies
for the treatment of arthritis, especially focussing on the reduction
of cartilage erosion.
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Selective elimination of inflammatory
macrophages by Fcγ γ-RI-directed immunotoxins:
a novel concept in the treatment of rheumatoid
arthritis
JAG van Roon, S Wijngaarden, AJ van Vuuren, JWJ Bijlsma,
FPJG Lafeber, JGJ van de Winkel, T Thepen
University Medical Center Utrecht, Utrecht, The Netherlands
Macrophages contribute to joint inflammation in RA by a number of
functions. The type I IgG receptor (FcγRI) has been shown to be
upregulated on inflammatory macrophages and can very efficiently
endocytose FcγRI-targeted antigens. Based on its unique function
and distribution it was tried to selectively eliminate inflammatory
macrophages by a FcγRI-directed humanized antibody (H22) con-
jugated to the toxin Ricin A (anti-FcγRI-RiA).
FcγRI expression (CD64) was determined on RA monocytes/
macrophages (mo/mac’s) and granulocytes from peripheral blood
(PB) and synovial fluid (SF). Anti-FcγRI-RiA was tested on
mo/mac’s from PB and SF of 12 RA patients. Cell death of
mo/mac’s (vs. lymphocytes) was assessed by morphological
changes, changes in CD14 expression and nuclear DNA fragmen-
tation (measuring apoptosis) after 24 hours. The anti-inflammatory
effect in vitro was tested by the effect of anti-FcγRI-RiA on TNFα
production, antigen-induced Th1-mediated proliferation and T-cell
survival in the context of SFMC. In addition the effect on cytokine
production by synovial tissue explants was studied (n=6).
FcγRI was exclusively expressed on mo/mac’s and was higher in
SF than PB (MFI 232 vs. 59, P<0.01). Treatment with anti-FcγRI-
RiA reduced high FcγRI-expressing mo/mac’s and was associated
and was associated by selective cell death of mo/mac’s (death of
lymphocytes was not observed after 24 hours). Immunotoxin-
induced cell death was higher in SF than in PB (15% in PB vs.
61% in SF, P<0.01). High expression of FcγRI correlated with
increased capacity of anti-FcγRI to induce mo/mac cell death.
Induction of macrophage cell death was mediated via apoptosis as
measured by nuclear DNA fragmentation. After prolonged culture
(3–5 days) macrophage death was associated with significant
reductions in TNFα production, Th1-induced lymphocyte prolifera-
tion and T-cell survival in the context of SFMC (42%, 63%, 72%,
respectively). Furthermore, IL-1 production by RA synovial tissue
explants was inhibited (63%, P<0.01). Macrophages from RA
patients can be selectively eliminated by FcγRI-directed immuno-
toxins. Considering the important role of these cells in RA, this type
of elimination may be a novel concept in the treatment of RA.
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Long term immune reconstitution after
immunoablation and autologous CD34 cell therapy
in autoimmune diseases
AT Thiel*, A Thiel*, T Alexander*, O Rosen†, E Gromnica-Ihle‡,
GR Burmester§, R Arnold†, F Hiepe§, A Radbruch*
*DRFZ Berlin, Berlin, Germany
†Haematology, Charité, Berlin, Germany
‡Rheumaklinik, Berlin-Buch, Berlin, Germany
§Rheumatology, Charité, Berlin, Germany
Introduction:  Immunoablation in combination with autologous
stem cell transplantation (ASCT) is used as a therapy for severe
autoimmune diseases. We have analysed reconstitution of the
immune system in patients treated with ASCT.
Results: During a follow-up period of up to 42 months after ASCT,
one polychondritis and two systemic lupus erythematosus (SLE)
patients in clinical remission were analysed for reappearance of
naive, activated and memory B and T lymphocytes, for reactivity
against pathogens and autoantigens, and for presence of autoanti-
bodies. Titers of disease-specific autoantibodies decreased after
ASCT with the half-life of secreted antibodies, and did not reappear.
Naive T and naive B cells reappeared and reached normal levels
within one year after ASCT. T cells activated and expanded by
pathogens were easily detectable, but not T cells reacting to any of
an array of autoantigens tested, in a cytometric cytokine provocation
test. A third SLE patient suffered from a relapse of disease after
Available online  http://arthritis-research.com/supplements/4/S1being free of any clinical and serological symptoms for 17 months.
In this patient, autoantibodies with old (anti-dsDNA antibodies) and
new specificities (anti-Sm and anti-U1RNP antibodies) appeared
upon relapse. A sudden decrease of peripheral naive and increase
of peripheral memory B and Th cells preceeded the relapse.
Conclusion: ASCT for autoimmune diseases can result in longlast-
ing remissions. According to frequencies and phenotypes of naive
lymphocytes, the reconstituted immune system resembles a ‘juve-
nile’ immune system. Our results reveal that autoreactive and
plasma cells do not survive the therapy but protective immune
memory has to be re-established.
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A new non-viral vector for gene-therapy in
rheumatic diseases
MJBM Vervoordeldonk*, J Adriaansen*, S Vanderbyl†,
G de Jong†, PP Tak*
*Amsterdam medical center, Amsterdam, The Netherlands
†Chromos Molecular Systems Inc., Burnaby, BC, Canada
Background and Objective: Treatment of rheumatoid arthritis
(RA) is problematic with current strategies. Relatively high sys-
temic doses are necessary to achieve therapeutic levels of anti-
rheumatic drugs in the joints. Gene therapy might provide a more
efficient system to deliver therapeutic compounds at the site of
inflammation. Artificial Chromosome Expression System (ACes) is
a unique non-integrating, non-viral gene expression system, which
functions like a natural chromosome. This technology offers advan-
tages over current expression systems because it allows stable
and predictable expression of genes producing single or multiple
proteins over long periods of time. We are developing ex vivo gene
therapy using a murine artificial chromosome containing a reporter
gene (LacZ) for local delivery of genes in rats with adjuvant arthri-
tis. The aim of this study was to evaluate the transfection efficiency
of ACes complexed to two commercially available transfection
agents into primary cells, such as, rat skin fibroblasts (RSF).
Methods:  Transfer efficiency and optimal dose of transfection
agents was determined using iododeoxyuridine (IdUrd)-incorpo-
rated ACes complexed to LipofectAMINE PLUS (Life Technolo-
gies) and Superfect (Qiagen) (Cytometry Vol 44:100–105, 2001).
Following transfection, the ACes were antibody labelled and the
cells were analyzed by FACs for FITC-fluorescence and micro-
scopic staining. Using optimised transfection conditions,
hygromycin resistant colonies were expanded and stable, ACes
containing, karyotypes were verified by FISH analysis. In addition,
β-galactosidase expression was determined to monitor the expres-
sion of the reporter gene in the transfected cells.
Results:  The delivery of intact artificial chromosomes was
detected within 24 to 48 hours post transfection. Maximum delivery
rates of 25% were observed. Flow cytometry data correlated well
with microscopic observations. After growing the cells under
hygromycin B selection, clones expressing LacZ were identified.
Stability of the clones is currently under observation.
Conclusion: These data suggest that artificial chromosomes may
have potential in ex vivo gene therapy applications using non-viral
delivery techniques. Primary cells can be efficiently transfected
with ACes and express the transgene. At present we are investi-
gating local delivery of transfected cells to the joints of rats with
adjuvant-induced arthritis.
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Effects of TIMP-1 and TIMP-3 gene transfer on
invasiveness, proliferation and apoptosis of
rheumatoid arthritis (RA) synovial fibroblasts
(RA-SF)
T Pap*, A Drynda*, CA Seemayer†, PHA Quax‡, JH Verheijen‡,
S Drynda*, TWJ Huizinga§, BA Michel¶, RE Gay†, S Gay†,
WH van der Laan^
*Division of Experimental Rheumatology, Magdeburg, Germany
†Center of Exp Rheumatology, Zurich, Switzerland
‡TNO Prevention and Health, Leiden, The Netherlands
§Dept of Rheumatology, Leiden, The Netherlands
¶Dept. Rheumatology, Zurich, Germany
^TNO Prevention and Health, Leiden, Germany
TIMPs play a key role in counter balancing the action of MMPs and
have been associated with cell proliferation, inhibition of angiogenesis
and induction of apoptosis. Here, we investigated the effects of
TIMP-1 and TIMP-3 gene transfer on cartilage invasion, proliferation
and apoptosis of RA-SF. RA-SF were transduced with an adenoviral
vector expressing human TIMP-1 (AdTIMP-1) or TIMP-3 (AdTIMP-3).
Transduction efficacy was assessed by LacZ staining of RA-SF that
were transduced with an adenoviral β-galactosidase construct.
Untransduced and mock transduced RA-SF were used as controls.
TIMP-1 was measured by ELISA in the culture supernatants of
AdTIMP-1 transduced and mock transduced cells every 10 days until
60 days after transduction. Proliferation was assessed by 3H-thymi-
dine incorporation, and the rate of spontaneous apoptosis as well as
FasL induced cell death was determined by a histon fragmentation
assay. AdTIMP-1 and AdTIMP-3 transduced RA-SF and control
RA-SF were co-implanted with human articular cartilage under the
renal capsule of SCID mice for 60 days and their invasiveness was
evaluated on paraffin sections using a semiquantitative score. Trans-
duction efficacy was 67%, and TIMP-1 levels in the supernatants of
AdTIMP-1 transduced cells were 51.5±6.5µg/ml as compared to
8.7±3.4µg/ml in the mock transduced cells. These levels of TIMP
expression were maintained for at least 60 days. AdTIMP-1 and
AdTIMP-3 gene transfer resulted in an inhibition of proliferation (35%
and 40% vs. mock, respectively; P<0.05). Transduction of RA-SF
with AdTIMP-3 but not TIMP-1 increased spontaneous apoptosis
(+24%; vs. mock, P<0.05) as well as susceptibility to FasL-induced
cell death (+23% vs. mock, P<0.05). In the SCID mouse model,
untransduced and mock transduced RA.SF deeply invaded the carti-
lage (scores: 2.5±0.2 and 3.2 respectively). In the AdTIMP-1 and
AdTIMP-3 transduced RA-SF, invasion was inhibited clearly (scores
0.9±0.4 and 1.2±0.2 respectively) Both AdTIMP-1 and AdTIMP-3
gene transfer inhibit proliferation of RA-SF and reduce cartilage inva-
sion. In contrast to TIMP-1, adenoviral gene transfer with TIMP-3. has
a strong pro-apoptotic effect on RA-SF and facilitates Fas mediated
cell death. These results indicate that gene transfer of TIMPs may be
a useful approach to inhibit joint destruction in RA.
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Suppression of in vitro and in vivo parameters of
inflammatory synovitis by simvastatin
JA Gracie*, D McCarey*, BP Leung*, M Prach*, A Crilly*,
SE Robertson*, R Madhok†, JD Young*, FY Liew*, N Sattar*,
IB McInnes*
*University of Glasgow, Glasgow, United Kingdom
†Centre for Rheumatic Diseases, Glasgow, United Kingdom
We have explored in vitro and in vivo the immunomodulatory activi-
ties of simvastatin, an HMG Co-A reductase (HMGR) inhibitor, in
the context of inflammatory arthritis.
Arthritis Research    Vol 4 Suppl 1 Abstracts of the 22nd European Workshop for Rheumatology ResearchMethods:  Lymphocyte/monocyte populations were purified from
peripheral blood (PB) and synovial fluid/tissues (SF/ST) from
rheumatoid arthritis (RA) patients or normal controls as appropri-
ate. Fibroblast-like synoviocytes (FLS) were obtained by serial
culture from RA ST and utilised from passage 3. T cells were
mitogen or cytokine (IL-15) activated then fixed in PFA prior to co-
culture with macrophages. Collagen-induced arthritis (CIA) devel-
oped in male DBA/1 mice on d26 following priming (d0)/ip
challenge (d21) with type II collagen in CFA.
Results: In vitro, simvastatin significantly suppressed macrophage
TNFα release following cell contact with cytokine or mitogen acti-
vated T cells whether derived from normal or RA PB or from RA
SF. Constitutive release of IL-6 by RA FLS was dose dependently
suppressed by simvastatin (P<0.05). In vivo, simvastatin adminis-
tration ( up to 40mg/kg ip, n=12/group) from d21 reduced plasma
cholesterol by 20% and prevented the development of CIA in a
dose dependent manner in comparison with injection of drug
vehicle alone (P<0.01). Ex vivo analysis indicated significant sup-
pression of collagen-specific humoral and cellular immune
responses. Moreover, administration of simvastatin (40mg/kg) sig-
nificantly suppressed established arthritis (n=20/group) compared
with drug vehicle (P<0.01).
Conclusions:  Simvastatin modulated the release of cell-contact
induced proinflammatory cytokines in vitro from cells of RA PB and
synovial origin. Both developing and importantly, established CIA
were significantly suppressed by administration of simvastatin in
vivo. These data demonstrate for the first time the anti-inflamma-
tory, therapeutic potential of HMGR inhibitors in inflammatory
arthritis.
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Electrotransfer of low doses of plasmid encoding
interleukin-10 in gene therapy of collagen-induced
arthritis
Mc Boissier
Hôpital Avicenne, Bobigny, France
Gene therapy is extremely promising in rheumatoid arthritis (RA).
Electrotransfer (ET) is a recent method reported to enhance the in
vivo effects of intra-muscular DNA injection. Interleukin-10 (IL-10)
has anti-inflammatory effects in RA and in collagen-induced arthri-
tis (CIA), a murine model of RA. We used ET to enhance penetra-
tion into skeletal muscle of plasmids encoding IL-10. CIA was
induced in DBA/1 mice by immunization with bovine type II colla-
gen. Injection into the tibial cranial muscle of low-dose (200ng)
pCOR plasmid encoding murine IL-10 (pCOR-CMV-mIL-10) was
immediately followed by application of square-wave electric pulses
(8 pulses of 200V/cm, 20ms duration at 2Hz). Control groups
received empty plasmid or saline before ET. When ET was per-
formed twice on days 10 and 25 post-immunization, CIA was sig-
nificantly delayed (P<0.05) and attenuated (P<0.001) in
pCOR-CMV-mIL-10 ET groups vs. control groups. When pCOR-
CMV-mIL-10 ET was started at disease onset (days 25 and 40),
the clinical severity of CIA was reduced (P<0.05). All groups
treated early or late by pCOR-CMV-mIL-10 ET showed dramatic
suppression of histological signs of arthritis compared to control
groups. Taken together, these data indicate that administration of
an anti-inflammatory gene by ET of naked DNA is effective in vivo
in an arthritis model in preventive and curative protocols, even
when low doses were given.
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A simple system for rapid generation of
recombinant adenoviruses by ligation
J Dudler*, R Salvi*, R Driscoll*, AK So†
*CHUV, Lausanne, Switzerland
†Service de Rhumatologie, Lausanne, Switzerland
Recombinant adenoviruses provide a versatile tool for gene expres-
sion, and both ease of production and ability to infect non dividing
cells have led to their widespread use in arthritis models. Classi-
cally, their construction is time-consuming, requires homologous
recombination in permissive cells, and, despite recent technical
improvements such as homologous recombination in bacteria, their
construction remains often difficult with manipulation of cosmids or
large plasmids containing full-length adenoviral genome. We have
designed and constructed a system where recombinant aden-
oviruses are constructed by a simple ligation. Ad-P-EGFP is a
recombinant first generation E1-deleted adenovirus where a
unique and rare restriction site (PacI) has been engineered at
3.7mu. The shuttle vector (pC5) also contains a PacI site 3 prime
of a CMV-driven expression cassette. pC5 only contains the left
ITR and packaging signal from wild-type adenovirus serotype 5, but
no regions for homologous recombination. This strategy allows for
a much smaller shuttle than usual, making manipulation and sub-
cloning of transgenes easier. Once the gene of interest is cloned in
the expression cassette of pC5, the resulting plasmid is digested
with PacI and SwaI (another rare cutter engineered just in front of
the left ITR) to free a fragment containing all the necessary ele-
ments for the construction of a recombinant adenovirus (left ITR,
packaging signal and expression cassette). Another engineered
PacI site in the backbone of pC5 allows for easier purification. This
fragment is then ligated overnight to unpurified PacI restricted and
dephosphorylated Ad-P-EGFP viral DNA. The mixture is then
directly lipofected without further manipulation in 293 cells. Cells
are covered with an overlay and, after 5 to 10 days, plaques are
screened under a fluorescent microscope and non fluorescent
plaques picked and amplified. Typical ratios for fluorescent to non
fluorescent plaques are between 1:4 to 1:20. This system allows
for rapid generation of recombinant adenoviruses, uses common
techniques such as ligation and lipofection, and doesn’t need
homologous recombination, special bacteria, extraction of large
DNA fragments or manipulation of cosmids. This system has
allowed us to construct more than 15 different viruses lately,
viruses that will be ultimately used in animal models.
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Biopsy-veryfied response of severe lupus nephritis
to rituximab (anti-CD20 monoclonal antibody) plus
cyclophosphamide after biopsy-documented
failure to respond to NIH-protocol
cyclophosphamide
RF van Vollenhoven, I Gunnarsson, E Welin-Henriksson,
S Jacobson, L Klareskog
Karolinska Hospital, Stockholm, Sweden
Background:  The monoclonal anti-CD20 antibody rituximab
(Rituxin, Mabthera) is approved for the treatment of certain B-cell
lymphomas. Because of its ability to deplete B lymphocytes the
drug may be of benefit in antibody-driven diseases. While treat-
ment of proliferative lupus nephritis with cyclophosphamide-based
therapies is succesful in most SLE patients, some have persistently
active disease despite such treatment; we currently employ an
investigational protocol for the use of rituximab in such patients.
Available online  http://arthritis-research.com/supplements/4/S1Case report: A female patient with SLE since age 20 underwent
renal biopsy at age 31 because of urinary abnormalities. Iohexol
clearance at that time was 55ml/min. She was otherwise asympto-
matic. The renal histology showed focal proliferative glomeru-
lonephritis, WHO IIIB, activity index 6/24, chronicity index 6/12.
Immunofluorescence revealed 3+ IgG, IgM, and complement in the
glomeruli. The patient was given cyclosphophamide and corticos-
teroids according to the usual NIH protocol for six months. A
repeat biopsy after these 6 treatments revealed no improvement,
the activity and chronicity scores being largely unchanged. Subse-
quently, the patient enrolled in the rituximab investigational treat-
ment program.
Treatment: The patient was given 4 weekly infusions with
375mg/m2 rituximab as well as cyclophosphamide 500mg/m2×2
plus methylprednisolone 1000mg along with the first and fourth
anti-CD20 infusions. Oral prednisolone was maintained at
5mg/day.
Results: The patient tolerated the treatment well with only minor
infusion-related side effects. Clinically she remained asymptomatic.
Repeat kidney biopsy 3 months after completion of rituximab treat-
ment revealed SLE nephritis WHO class IB with minimal residual
activity (activity index 1/24), and chronicity index 6/12. Immune flu-
orescence revealed only minimal deposits. Iohexol clearance
remains stable at 55ml/min.
Conclusion: This case provides histopathological documentation
of a significant treatment benefit from anti-CD20 plus cyclophos-
phamide in a patient refractory to cyclophosphamide alone.
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Immunodiagnosis and therapeutic
immunosuppression in rheumatoid arthritis with
ior t1 (anti-CD6) monoclonal antibody
E Montero*, G Reyes†, M Guibert‡, O Torres*, N Rodriguez†,
J Estrada†, L Torres§, R Perez*, A Hernandez†, A Lage*
*Center of Molecular Immunology, Havana, Cuba
†Medical-Surgical Res Center, Havana, Cuba
‡Institute of Rheumatology, Havana, Cuba
§Center for Clin Investigations, Havana, Cuba
CD6 antigen is a type I cell membrane glycoprotein belonging to
the scavenger receptor cysteine-rich (SRCR) superfamily group B,
predominantly expressed by T cells and a B-cell subset. CD6 binds
activated leukocyte cell adhesion molecule (ALCAM), a member of
the immunoglobulin superfamily (IgSF). ALCAM is expressed on
activated T cells, B cells, monocytes, skin fibroblasts, keratinocytes
and rheumatoid arthritis synovium, and mediates homophilic and
heterophilic adhesion. CD6-ligand interaction has been implicated
in cell adhesion, T-cell maturation and regulation of activation, con-
stituting an uncommon type of protein–protein superfamilies inter-
action. The ior t1 is a murine IgG2a mAb recognizing a different
epitope compared to other anti-CD6 mAbs. It is in a phase II clini-
cal trial (PIICT) for cutaneous T-cell lymphomas treatment.
Recently, we reported its intravenous therapeutic effect in a Psori-
asis vulgaris patient. A PIICT was performed in 18 rheumatoid
arthritis patients. Technetium-99m-labeled ior t1 mAb (ior
t1-99Tcm) joint uptake and body distribution was assessed by
anterior and posterior whole body scans and specific regional
imaging. Forty-eight hours apart started a therapeutic dose-finding
study based on 7 consecutive daily doses at 0.2mg/kg, 0.4mg/kg
or 0.8mg/kg of ior t1 mAb intravenous infusion. Clinical evaluation
and laboratory analysis were performed weekly. A rapid ior
t1-99Tcm/lymphocytes association and a marked radioactivity
uptake form inflamed and silent joints were obtained. From biodis-
tribution studies was estimated that more than 0.5% of the ior
t1-99Tcm infusion penetrates into hands and feet with inflamed
joints. ior t1 joint-imaging was superior to MDP-99Tcm, used as
standard method. ior t1 mAb intravenous infusion induced a dose-
dependent therapeutic effect. 0.4mg/kg was defined as the
Optimum Biological Dose, with a long-lasting clinical improvement
observed in this group. This treatment reduced the number of
tender and swollen joints starting at day 4 of the infusions. Adverse
events were dose-depending but controlled by medications. It was
not observed deep lymphopenia neither opportunistic infections.
This is the first clinical report supporting the relevance of the
CD6/CD6-ligand model as a potential target for rheumatoid arthri-
tis immunotherapy. A PI-IICT with a humanized version for iort1
mAb is underway.
Arthritis Research    Vol 4 Suppl 1 Abstracts of the 22nd European Workshop for Rheumatology Research